
<html lang="en"     class="pb-page"  data-request-id="1237402d-8d38-4301-92e6-0e27a4af20cb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-12;article:article:10.1021/jm100395q"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant" /></meta><meta name="dc.Creator" content="Wei-Sheng  Huang" /></meta><meta name="dc.Creator" content="Chester A.  Metcalf" /></meta><meta name="dc.Creator" content="Raji  Sundaramoorthi" /></meta><meta name="dc.Creator" content="Yihan  Wang" /></meta><meta name="dc.Creator" content="Dong  Zou" /></meta><meta name="dc.Creator" content="R. Mathew  Thomas" /></meta><meta name="dc.Creator" content="Xiaotian  Zhu" /></meta><meta name="dc.Creator" content="Lisi  Cai" /></meta><meta name="dc.Creator" content="David  Wen" /></meta><meta name="dc.Creator" content="Shuangying  Liu" /></meta><meta name="dc.Creator" content="Jan  Romero" /></meta><meta name="dc.Creator" content="Jiwei  Qi" /></meta><meta name="dc.Creator" content="Ingrid  Chen" /></meta><meta name="dc.Creator" content="Geetha  Banda" /></meta><meta name="dc.Creator" content="Scott P.  Lentini" /></meta><meta name="dc.Creator" content="Sasmita  Das" /></meta><meta name="dc.Creator" content="Qihong  Xu" /></meta><meta name="dc.Creator" content="Jeff  Keats" /></meta><meta name="dc.Creator" content="Frank  Wang" /></meta><meta name="dc.Creator" content="Scott  Wardwell" /></meta><meta name="dc.Creator" content="Yaoyu  Ning" /></meta><meta name="dc.Creator" content="Joseph T.  Snodgrass" /></meta><meta name="dc.Creator" content="Marc I.  Broudy" /></meta><meta name="dc.Creator" content="Karin  Russian" /></meta><meta name="dc.Creator" content="Tianjun  Zhou" /></meta><meta name="dc.Creator" content="Lois  Commodore" /></meta><meta name="dc.Creator" content="Narayana I.  Narasimhan" /></meta><meta name="dc.Creator" content="Qurish K.  Mohemmad" /></meta><meta name="dc.Creator" content="John  Iuliucci" /></meta><meta name="dc.Creator" content="Victor M.  Rivera" /></meta><meta name="dc.Creator" content="David C.  Dalgarno" /></meta><meta name="dc.Creator" content="Tomi K.  Sawyer" /></meta><meta name="dc.Creator" content="Tim  Clackson" /></meta><meta name="dc.Creator" content="William C.  Shakespeare" /></meta><meta name="dc.Description" content="In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the s..." /></meta><meta name="Description" content="In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 1, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm100395q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm100395q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm100395q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm100395q" /></link>
        
    
    

<title>Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm100395q" /></meta><meta property="og:title" content="Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0027.jpeg" /></meta><meta property="og:description" content="In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon−carbon triple bond linker which skirts the increased bulk of Ile315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with BCR-ABLT315I expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CML, including patients refractory to all currently approved therapies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm100395q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm100395q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm100395q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm100395q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm100395q&amp;href=/doi/10.1021/jm100395q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 4701-4719</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm1003073" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm100230k" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Sheng++Huang">Wei-Sheng Huang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chester+A.++Metcalf">Chester A. Metcalf</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Raji++Sundaramoorthi">Raji Sundaramoorthi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihan++Wang">Yihan Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dong++Zou">Dong Zou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Mathew++Thomas">R. Mathew Thomas</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaotian++Zhu">Xiaotian Zhu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisi++Cai">Lisi Cai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Wen">David Wen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuangying++Liu">Shuangying Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan++Romero">Jan Romero</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiwei++Qi">Jiwei Qi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ingrid++Chen">Ingrid Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Geetha++Banda">Geetha Banda</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+P.++Lentini">Scott P. Lentini</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sasmita++Das">Sasmita Das</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qihong++Xu">Qihong Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeff++Keats">Jeff Keats</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Wang">Frank Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Wardwell">Scott Wardwell</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yaoyu++Ning">Yaoyu Ning</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+T.++Snodgrass">Joseph T. Snodgrass</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc+I.++Broudy">Marc I. Broudy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Russian">Karin Russian</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianjun++Zhou">Tianjun Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lois++Commodore">Lois Commodore</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Narayana+I.++Narasimhan">Narayana I. Narasimhan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qurish+K.++Mohemmad">Qurish K. Mohemmad</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Iuliucci">John Iuliucci</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+M.++Rivera">Victor M. Rivera</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Dalgarno">David C. Dalgarno</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomi+K.++Sawyer">Tomi K. Sawyer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tim++Clackson">Tim Clackson</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+C.++Shakespeare">William C. Shakespeare</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: 617-621-2341. Fax: 617-494-8144. E-mail: <a href="/cdn-cgi/l/email-protection#9ee9fbf7b3edf6fbf0f9b0f6ebfff0f9deffecf7fffab0fdf1f3"><span class="__cf_email__" data-cfemail="6710020e4a140f020900490f120609002706150e06034904080a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm100395q&amp;href=/doi/10.1021%2Fjm100395q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 4701–4719</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 1, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 March 2010</li><li><span class="item_label"><b>Published</b> online</span>1 June 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm100395q" title="DOI URL">https://doi.org/10.1021/jm100395q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4701%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei-Sheng%2BHuang%252C%2BChester%2BA.%2BMetcalf%252C%2BRaji%2BSundaramoorthi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D12%26contentID%3Djm100395q%26title%3DDiscovery%2Bof%2B3-%255B2-%2528Imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2B%2528AP24534%2529%252C%2Ba%2BPotent%252C%2BOrally%2BActive%2BPan-Inhibitor%2Bof%2BBreakpoint%2BCluster%2BRegion-Abelson%2B%2528BCR-ABL%2529%2BKinase%2BIncluding%2Bthe%2BT315I%2BGatekeeper%2BMutant%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4719%26publicationDate%3DJune%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm100395q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8570</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">211</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm100395q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei-Sheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Chester&quot;,&quot;last_name&quot;:&quot;A. Metcalf&quot;},{&quot;first_name&quot;:&quot;Raji&quot;,&quot;last_name&quot;:&quot;Sundaramoorthi&quot;},{&quot;first_name&quot;:&quot;Yihan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Mathew Thomas&quot;},{&quot;first_name&quot;:&quot;Xiaotian&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Lisi&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Wen&quot;},{&quot;first_name&quot;:&quot;Shuangying&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Romero&quot;},{&quot;first_name&quot;:&quot;Jiwei&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Ingrid&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Geetha&quot;,&quot;last_name&quot;:&quot;Banda&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;P. Lentini&quot;},{&quot;first_name&quot;:&quot;Sasmita&quot;,&quot;last_name&quot;:&quot;Das&quot;},{&quot;first_name&quot;:&quot;Qihong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;Keats&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Wardwell&quot;},{&quot;first_name&quot;:&quot;Yaoyu&quot;,&quot;last_name&quot;:&quot;Ning&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;T. Snodgrass&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;I. Broudy&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Russian&quot;},{&quot;first_name&quot;:&quot;Tianjun&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Lois&quot;,&quot;last_name&quot;:&quot;Commodore&quot;},{&quot;first_name&quot;:&quot;Narayana&quot;,&quot;last_name&quot;:&quot;I. Narasimhan&quot;},{&quot;first_name&quot;:&quot;Qurish&quot;,&quot;last_name&quot;:&quot;K. Mohemmad&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Iuliucci&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;M. Rivera&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Dalgarno&quot;},{&quot;first_name&quot;:&quot;Tomi&quot;,&quot;last_name&quot;:&quot;K. Sawyer&quot;},{&quot;first_name&quot;:&quot;Tim&quot;,&quot;last_name&quot;:&quot;Clackson&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;C. Shakespeare&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;4701-4719&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm100395q&quot;},&quot;abstract&quot;:&quot;In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon−carbon triple bond linker which skirts the increased bulk of Ile315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with BCR-ABLT315I expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CML, including patients refractory to all currently approved therapies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100395q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100395q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100395q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100395q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100395q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100395q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm100395q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100395q&amp;href=/doi/10.1021/jm100395q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm100395q" /></input><a href="/doi/pdf/10.1021/jm100395q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26pmid%3D20513156%26genre%3Darticle%26aulast%3DHuang%26date%3D2010%26atitle%3DDiscovery%2Bof%2B3-%255B2-%2528Imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2B%2528AP24534%2529%252C%2Ba%2BPotent%252C%2BOrally%2BActive%2BPan-Inhibitor%2Bof%2BBreakpoint%2BCluster%2BRegion-Abelson%2B%2528BCR-ABL%2529%2BKinase%2BIncluding%2Bthe%2BT315I%2BGatekeeper%2BMutant%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon−carbon triple bond linker which skirts the increased bulk of Ile315 side chain. Extensive SAR studies led to the discovery of development candidate <b>20g</b> (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC<sub>50</sub>s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of <b>20g</b> significantly prolonged survival of mice injected intravenously with BCR-ABL<sup>T315I</sup> expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of <b>20g</b> to be an effective treatment for CML, including patients refractory to all currently approved therapies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic myeloid leukemia (CML<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: CML, chronic myeloid leukemia; BCR-ABL, breakpoint cluster region-abelson; ADME, absorption distribution metabolism excretion; Src/Abl, sarcoma/Abelson; DFG, aspartic acid-phenylalanine-glycine; AUC, area under curve; PK, pharmacokinetic; Ph+, Philadelphia chromosome-positive; FLT3, FMS-like tyrosine kinase 3; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; c-Kit, cytokine receptor; PDGF, platelet-derived growth factor; CDK2, cyclic dependent kinase 2; EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; IGF1R, insulin-like growth factor receptor; JAK2, janus kinase 2; WT, wild type.</p></div>), a hematological stem-cell disorder, is characterized by the occurrence of the Philadelphia (Ph) chromosome, a truncated version of chromosome 22 resulting from the reciprocal translocation between chromosomes 9 and 22. This single mutagenic event leads to the juxtaposition of two genes, whose product is the fusion protein BCR-ABL, a constitutively active tyrosine kinase that drives the pathogenesis of CML.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Development of tyrosine kinase inhibitors targeting the BCR-ABL oncogene constitutes an effective approach to treating CML, as demonstrated by the clinical success of imatinib, a potent first generation BCR-ABL inhibitor.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In patients with newly diagnosed CML in the chronic phase, daily oral administration of imatinib has demonstrated 89% major cytogenetic response rates and 82% complete cytogenetic response rates. These response rates translated into impressive event-free survival (81%), freedom from progression (93%), and overall survival (86%) rates.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Despite the clear benefits of imatinib, many patients eventually develop intrinsic or acquired resistance to this first-line therapy. Resistance rates were reported to be 3−4% per year in newly diagnosed chronic phase CML and much higher with CML patients in accelerated and blastic phases, with the percentage being 40−50% and 80%, respectively.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Mutations in the kinase domain of BCR-ABL that impede effective inhibitor binding are the primary mechanism of acquired imatinib resistance;<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> to date, at least 100 different point mutations have been identified in CML patients who are resistant to this drug.</div><div class="NLM_p">To overcome resistance in CML, a number of second generation inhibitors have been developed.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These include imatinib-like inhibitors nilotinib<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and bafetinib,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and dual SRC/ABL inhibitors dasatinib<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and bosutinib.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Both dasatinib and nilotinib have been approved for the treatment of adults in all phases of CML with resistance or intolerance to imatinib whereas bafetinib and bosutinib are in late-stage clinical testing. Despite the effectiveness of these second-generation compounds to inhibit most imatinib resistant BCR-ABL mutants, subsets of mutants remain resistant. In particular, a common characteristic of these agents is their inability to inhibit the BCR-ABL<sup>T315I</sup> mutant at the “gatekeeper” position which represents ∼15−20% of all clinically observed mutants.<a onclick="showRef(event, 'cit10b ref11 ref12'); return false;" href="javascript:void(0);" class="ref cit10b ref11 ref12">(10b, 11, 12)</a></div><div class="NLM_p">To address this unmet need, several programs targeting development of potent BCR-ABL<sup>T315I</sup> inhibitors have been established and a number of reviews have detailed progress in this area.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Briefly, compounds with notable BCR-ABL<sup>T315I</sup> inhibitory activity include (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>): PPY-A,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> TG101113,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and dual ABL/Aurora inhibitors tozasertib (MK-0457, VX-680),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> danusertib (PHA-739358),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> AT-9283,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and KW-2449.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The dual ABL/Aurora agents have advanced to clinical trials in patients with treatment-resistant CML, in general via intravenous administration. While tozasertib has demonstrated some activity as salvage therapy,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> clinical development has been halted due to toxicity concerns. Despite this progress, there are presently no approved pharmaceutical therapies for CML patients harboring the BCR-ABL<sup>T315I</sup> mutation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0019.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BCR-ABL<sup>T315I</sup> kinase inhibitors with disclosed chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is generally believed that next-generation ABL inhibitors capable of exerting a high level of disease control in CML should incorporate potent activity not only against BCR-ABL<sup>T315I</sup> but also the full range of BCR-ABL kinase domain mutations as well as the native enzyme itself. Such a “pan-BCR-ABL” inhibitor would have the potential to treat disease resistant to all current therapies and potentially to suppress the emergence of resistance when deployed at earlier disease stages. Recently, we described the biological characterization of AP24534 (<b>20g</b>), a potent, orally available multitargeted kinase inhibitor.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><b>20g</b> is potently active against BCR-ABL<sup>T315I</sup> and all other tested BCR-ABL variants and suppresses emergence of resistant mutations in a cell-based screen, thereby fulfilling the criteria for a pan-BCR-ABL inhibitor. In this report, we describe the medicinal chemistry and structural design strategy that led to the discovery of this molecule. Key anticipated design aspects included template morphing, exploration of alternate hydrophobic linkers, and considerable SAR around the pendant DFG-out phenyl ring (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0020.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key medicinal chemistry optimization leading to clinical candidate <b>20g</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Inhibitor Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of 9-(ethenyl)purine based inhibitors <b>1a</b>−<b>e</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) has been reported previously.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> The preparation of 9-(ethynyl)purine based inhibitors <b>6a</b> and <b>6b</b> is depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. 9-(Cyclopropylamino)purine <b>2</b>, prepared by S<sub>N</sub>Ar displacement of 6-chloropurine with cyclopropylamine, was deprotonated with sodium hydride then reacted with tetrachloroethene to yield 9-(trichloroethenyl)purine <b>3</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Exhaustive dechlorination of <b>3</b> with <i>n</i>-butyllithium followed by quenching with methanol generated terminal alkyne <b>4</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Subsequent Sonogashira coupling<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> of <b>4</b> with iodobenzamide <b>5</b> furnished inhibitors <b>6</b>, albeit in low yields.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Early Structure−Activity Relationships (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0008.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0009.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Measured in K562 cell line.</p></div></div></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 9-(Ethynyl)purine Based Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) tetrachloroethylene, NaH, HMPA, 60 °C; (b) <i>n</i>-BuLi, THF, −78 °C; (c) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 2.6 mol % CuI, Et<sub>3</sub>N, Tol, 55 °C.</p></p></figure><div class="NLM_p">The syntheses of inhibitors <b>12</b> bearing C−C≡C−C structural motifs were based on a tandem Sonogashira coupling strategy. Initially, two general methods (A and B) were explored employing either the heteroaryl bromides <b>7</b> or the iodobenzamides <b>5</b> as coupling partners in the first Sonogashira reaction (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). In employing method B, the final coupling reaction between ethynylbenzamides <b>11</b> and <b>7</b> often afforded low yields of desired products with dimerization of <b>11</b> being the major competing reaction. Method A therefore was adopted as the standard approach to <b>12</b>. In the second step involving cleavage of the trimethylsilyl group (from <b>8</b> to <b>9</b>, or <b>10</b> to <b>11</b>), deprotection with either tetrabutylammonium fluoride or potassium carbonate/methanol worked equally well.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Methods for the Synthesis of Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> illustrates the synthesis of inhibitors <b>12a</b>−<b>e</b> compiled in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Starting material <i>N</i>-(imidazo[1,2-<i>a</i>]pyridin-8-yl)acetamide <b>13</b> was prepared by condensing 2,3-diaminopyridine and chloroacetaldehyde diethylacetal followed by acetamidation, according to literature methods.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Selective bromination of <b>13</b> furnished <b>7b</b>, which was hydrolyzed under acidic conditions to yield bromide <b>7a</b>. Direct Sonogashira reaction of <b>7a</b> with trimethylsilylacetylene failed to afford the desired coupling product but the <i>N</i>,<i>N</i>-bis-Boc protected derivative <b>7a′</b> underwent smooth coupling. Subsequent desilylation furnished terminal alkyne <b>9a</b>, which was coupled with iodobenzamide <b>5c</b> to yield <b>12a′</b>. Subsequent removal of the Boc protecting groups furnished inhibitor <b>12a</b>. For the synthesis of <b>12d</b>, 2-imidazolecarboxaldehyde was first reacted with dimethylamine under reductive amination conditions to furnish <b>14</b>. Compound <b>14</b> was then converted into iodobenzamide <b>5d</b> similarly to the preparation of <b>5c</b> via a published two-step procedure employing a copper-catalyzed <i>N</i>-arylation with 3-bromo-5-(trifluoromethyl)aniline followed by amide formation with 3-iodobenzoyl chloride.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Subsequent Sonogashira coupling of <b>5d</b> with <b>9c</b> (structure shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) furnished inhibitor <b>12d</b>. Compound <b>12e</b> was obtained via the same route as <b>12d</b> using 4-imidazolecarboxaldehyde and pyrrolidine as starting materials. Inhibitors <b>12b</b> and <b>12c</b> were constructed via the standard three-step protocol outlined in general method A from <b>9b</b> and <b>5c</b>, or <b>9c</b> and <b>5c</b>, respectively.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitors <b>12a</b>−<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Br<sub>2</sub>, EtOH, rt; (b) trimethylsilylacetylene, 5 mol % Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 80 °C; (c) TBAF, THF, rt; (d) conc. HCl, EtOH, reflux; (e) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt; (f) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) aq Me<sub>2</sub>NH, NaBH<sub>4</sub>; (i) 3-bromo-5-trifluoromethylaniline, 15 mol % 8-hydroxyquinoline, 15 mol % CuI, K<sub>2</sub>CO<sub>3</sub>, DMSO, 120 °C; (j) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Based on Imidazo[1,2-<i>a</i>]pyridine Template (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0010.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0011.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div></div><div class="NLM_p">The synthesis of inhibitors <b>19a</b>−<b>j</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) followed general method A via Sonogashira coupling of <b>9c</b> with the appropriate iodobenzamides. The preparation of <b>19a</b> illustrates the general approach (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). Thus, 4-nitro-2-(trifluoromethyl)benzyl bromide, prepared from bromination of 4-nitro-2-(trifluoromethyl)toluene with <i>N</i>-bromosuccinimide, underwent S<sub>N</sub>2 displacement with <i>N</i>-methylpiperazine yielding <b>16a</b>. Reduction of the nitro group followed by amide bond formation provided the requisite iodide <b>18a</b>. Sonogashira coupling of <b>18a</b> with <b>9c</b> furnished <b>19a</b>. Analogues <b>19d</b>−<b>f</b> and <b>19h−j</b> were constructed via similar routes but with the required commercially available secondary amines as the nucleophile in the initial substitution reaction. Inhibitors <b>19b</b>, <b>19c</b>, and <b>19g</b> were prepared similarly from the coupling of <b>9c</b> with <b>18b</b>, <b>18c</b>, and <b>18g</b>, respectively. The requisite benzoic acid precursor<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> to <b>18b</b>, the substituted aniline precursor<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> to <b>18g</b>, and the iodobenzamide <b>18c</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> were all prepared according to published procedures.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. B-Ring SAR around Inhibitor <b>19a</b> (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0012.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0013.gif" alt="" id="fx6" /></img></td></tr></tbody></table></div></div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Inhibitor <b>19a</b> and Chemical Structures of <b>18b</b>, <b>18c</b>, and <b>18g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methylpiperazine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, acetone/water, reflux; (c) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt; (d) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt.</p></p></figure><div class="NLM_p">In the synthesis of <b>19k</b>−<b>m</b>, protection of the terminal piperazine nitrogens was necessary due to increased reactivity toward aroyl chloride relative to the anilino NH in the amide formation step; this is illustrated in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Iodobenzamide <b>18l</b> was prepared similarly to <b>18a</b> using <i>N</i>-Boc-piperazine instead of <i>N</i>-methylpiperazine as the starting nucleophile. Deprotection of <b>18l</b> and subsequent alkylation with 1-bromo-2-fluoroethane furnished <b>18k</b>. In the preparation of <b>18m</b>, a Boc group was first introduced onto <b>16m</b>, which was prepared via regiospecific <i>N</i>-alkylation of the less sterically hindered NH of 2-methylpiperazine with 4-nitro-2-(trifluoromethyl)benzyl bromide. Elaborated <b>16m′</b> was then converted into iodide <b>18m</b> in a manner similar to <b>18a</b>. Sonagashira coupling of Boc-protected iodides <b>18l</b> or <b>18m</b> with <b>9c</b> and subsequent deprotection furnished inhibitors <b>19l</b> and <b>19m</b>, respectively.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Inhibitors <b>19k</b>−<b>m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) 2-bromofluoroethane, NaHCO<sub>3</sub>, DMF, 80 °C; (c) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt; (d) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt; (e) (i) 10% Pd on carbon, 50 psi H<sub>2</sub>, EtOH, rt, (ii) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt.</p></p></figure><div class="NLM_p">Synthesis of inhibitors <b>20a</b>−<b>p</b> (Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) followed the Sonagashira coupling strategy generally outlined in method A. All starting heteroaryl bromides were obtained from commercial sources, and the corresponding iodobenzamides were prepared from the requisite acids and anilines via chemistry discussed previously, with the exception of aniline precursor <b>17o</b> (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). <b>17o</b> was synthesized via S<sub>N</sub>2 substitution of 2-bromo-4-nitrobenzyl bromide with <i>N</i>-methylpiperazine, followed by Suzuki coupling of the corresponding bromide with cyclopropaneboronic acid and subsequent reduction of the nitro group, as shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. The CH<sub>2</sub>CH<sub>2</sub>-linked analogue <b>24a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>) was accessed directly via hydrogenation of <b>20g</b> and the <i>trans</i>-CH═CH-linked inhibitor <b>24b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>) was prepared via Heck coupling of styrene <b>23</b> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>). The latter was obtained from a Stille coupling of <b>18a</b> with tributyl(vinyl)tin as depicted in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of Alternate Hinge Binding Templates (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0014.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0015.gif" alt="" id="fx8" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All data in this study were obtained from in-house assays. In a different enzymatic assay conducted by Reaction Biology Corporation,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> the IC<sub>50</sub>s of <b>20g</b> were determined to be 0.37 nM (ABL) and 2.0 nM (ABL<sup>T315I</sup>), as previously reported.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR around Inhibitor <b>20g</b> (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0016.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0017.gif" alt="" id="fx10" /></img></td></tr></tbody></table></div></div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Aniline <b>17o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methylpiperazine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) cyclopropaneboronic acid, 10 mol % Pd(OAc)<sub>2</sub>, 20 mol % P(c-hexyl)<sub>3</sub>; K<sub>3</sub>PO<sub>4</sub>, Tol/H<sub>2</sub>O, reflux; (c) Fe/HOAc, MeOH, reflux.</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of Inhibitor <b>24b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3 equiv tributyl(vinyl)tin, 2.7 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 20 mol % P(2-furyl)<sub>3</sub>, DMF, rt; (b) 8 mol % Pd(OAc)<sub>2</sub>, 16 mol % P(<i>o</i>-tol)<sub>3</sub>, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 110 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. The Impact of Linker Hybridization on Potency (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0018.gif" alt="" id="fx11" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">a-b</th><th class="colsep0 rowsep0" align="center">ABL kinase</th><th class="colsep0 rowsep0" align="center">T315I kinase</th><th class="colsep0 rowsep0" align="center" char=".">ABL (Ba/F3)</th><th class="colsep0 rowsep0" align="center">T315I (Ba/F3)</th><th class="colsep0 rowsep0" align="center" char=".">parental (Ba/F3)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="left">C≡C</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="char" char=".">1219</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">317</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="left">295</td><td class="colsep0 rowsep0" align="char" char=".">5998</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24b</b></td><td class="colsep0 rowsep0" align="left"><i>trans</i>-CH═CH</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">536</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="left">211</td><td class="colsep0 rowsep0" align="char" char=".">3241</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds were evaluated for their kinase inhibitory activity against both native and mutant (T315I) ABL as previously described.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> Their cellular activity was assessed using Ba/F3 cells transfected with native BCR-ABL or BCR-ABL<sup>T315I</sup> and inhibition of parental, nontransfected Ba/F3 cells was used as a control. Additionally, pharmacokinetic properties for active compounds were evaluated early in rats to help guide series selection.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Early Linker Exploration and Initial Template Morphing</h3><div class="NLM_p">Recently, we described a novel series of potent, orally bioavailable ABL kinase inhibitors based on the 9-[aren(ethenyl)]purine template which target the inactive, DFG-out conformation of the ABL protein.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> One subtype from this series, exemplified by AP24163 (<b>1a</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) and its des-methyl and des-cyclopropyl analogues <b>1b</b> and <b>1c</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), demonstrated modest potency against BCR-ABL<sup>T315I</sup> in both biochemical and cell-based assays (IC<sub>50</sub>s = 300−500 nM) in addition to potently inhibiting native BCR-ABL.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> It is noteworthy that <b>1a</b>−<b>c</b> inhibit ABL<sup>T315I</sup> because the structurally similar nilotinib is completely inactive against this mutant. When nilotinib is docked into the model of ABL<sup>T315I</sup> kinase, there is an obvious steric clash between the amino group on the pyrimidine ring and the larger gatekeeper isoleucine.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This steric repulsion, in combination with a forfeited hydrogen bond between the amino group and the hydroxyl side chain of threonine observed in the imatinib:ABL cocrystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>), severely impaired the preferred ligand−protein interaction, impeding binding and rendering both imatinib and nilotinib inactive toward the ABL<sup>T315I</sup> mutant.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29-32)</a> Such a clash is not observed in the model of <b>1a</b> when docked into the ATP-binding pocket of ABL<sup>T315I</sup> due to the less sterically demanding vinyl linkage (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), which may in part explain increased activity of <b>1a</b>−<b>c</b> against ABL<sup>T315I</sup>.</div><figure id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0021.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Generation of new lead <b>12c</b> based on multipoint variations of <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0022.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>1a</b> (green) and its “virtual” acetylene-linked analogue <b>1a′</b> (cyan) bound to ABL<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The activity of the 9-[aren(ethenyl)]purine series toward ABL<sup>T315I</sup> stimulated further exploration of an alternate, less sterically demanding two-carbon atom acetylenyl spacers in the design of inhibitors against this mutant. Incorporation of this rigid, rod-shaped linker should further reduce steric repulsion with the bulk of the isoleucine side chain. As shown in the ABL model (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), the corresponding 9-[(aren)ethynyl]purine analogue <b>1a′</b> is predicted to bind to the protein in a mode identical to <b>1a</b>. All key ligand−protein interactions, including hydrogen bonds, hydrophobic and van der Waals (vdw) contacts are maintained and the acetylene linkage further reduces steric clash with the larger Ile315 residue. This model motivated us to prepare then test two matched sets of molecules (<b>1d</b> vs <b>6a</b>, <b>1e</b> vs <b>6b</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) against the ABL<sup>T315I</sup> mutant. Encouragingly, inhibitors bearing the acetylene linkage were 30−40-fold more potent in enzymatic assays and 5−10-fold more potent in cell-based antiproliferation assays, relative to their vinyl-linked analogues. Despite increased potency against ABL<sup>T315I</sup>, both 9-[(aren)ethynyl]purine compounds <b>6a</b> and <b>6b</b> displayed poor pharmacokinetic profiles. When dosed orally in rats, <b>6a</b> exhibited low exposure (AUC<sub>0−24 h</sub>/dose =11.8 ng·h/mL/mg/kg) and a short half-life (<i>t</i><sub>1/2</sub> = 1.5 h). Note this oral exposure is 2250-fold lower than <b>1d</b> (compound <b>9i</b> from ref <a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">21a</a>), which displayed higher AUC and <i>C</i><sub>max</sub> levels when evaluated previously.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> Given the single structural modification between <b>6a</b> and <b>1d</b> (vinyl vs acetylenyl), we reasoned that it might be very challenging to make orally active inhibitors based on the 9-[(aren)ethynyl]purine template of <b>6a</b>. Furthermore, in contrast to the readily accessible 9-[(aren)ethenyl]purines via Heck-type chemistry,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> preparation of the 9-[(aren)ethynyl]purine core involved low yielding steps which made further SAR exploration with this template impractical.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">To overcome the liabilities associated with the 9-[(aren)ethynyl]purine-based inhibitors, we sought alternate ways to exploit the potency gain exhibited by the acetylene linkage. Instead of pursuing <b>1a′</b>, the direct acetylene-linked analogue of <b>1a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), we targeted inhibitors in which the linker connects the hinge binding template to the <i>N</i>-aryltoluamide subunit via carbon atoms. Such C−C≡C−C structural motifs should be chemically and pharmacologically more stable than the corresponding N−C≡C−C moiety exhibited by the ynamine-like 9-[(aren)ethynyl]purine series and are easily accessed via well-known Sonogashira coupling reactions.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Thus, we implemented a template morphing strategy initially targeting the 8-amino-imidazo[1,2-<i>a</i>]pyridine ring system because 8-NH and N-1 of this template were predicted to form paired hydrogen-bonds with the kinase hinge region. Relative to <b>1a</b>−<b>c</b>, the prototype inhibitor <b>12a</b> was 4−6-fold more potent against ABL<sup>T315I</sup> in cells (IC<sub>50</sub> = 72 nM) while retaining native ABL activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), thus validating our template morphing strategy and further highlighting the increased activity of the acetylene linkage toward ABL<sup>T315I</sup>. Despite the increased cellular potency, <b>12a</b> exhibited low oral bioavailability in rats (<i>F</i> = 5.5%) (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Likewise, the acetamide derivative <b>12b</b> retained potency but also exhibited undesirable rat PK. Further attempts to cap the primary amine with the more stable cyclopropyl group which had previously led to the orally bioavailable compound <b>1a</b>,<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> turned out to be unsuccessful. At this point, we recognized the need to determine whether the poor PK derived from C<sup>8</sup> substitution or the newly installed Ar−C≡C−Ar system itself. Previous experience with similar series (e.g., 9-[(aren)ethynyl]purines) suggested that inhibitors bearing free amino or acetamido moieties at the position equivalent to C<sup>8</sup> of the current template often exhibited undesirable PK. Thus, analogue <b>12c</b>, devoid of any C<sup>8</sup> substitution, was prepared and evaluated (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Gratifyingly, this compound demonstrated good in vitro activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) with excellent oral exposure (AUC<sub>0−24 h</sub>/dose = 5476 ng*h/mL/mg/kg) and good oral bioavailability (42%) when tested in rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Furthermore, the cellular potency of <b>12c</b> and two other C<sup>8</sup>-unsubstituted analogues <b>12d</b>−<b>e</b> correlated well with kinase activity, whereas inhibitors <b>12a</b> and <b>12b</b> exhibited larger disparities between both assays. Therefore, on the basis of the overall improved properties exhibited by <b>12c</b>, further SAR efforts focused on the C<sup>8</sup>-unsubstituted 3-(arylacetylenyl)imidazo[1,2-<i>a</i>]pyridine chemical series.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mean Pharmacokinetic Parameters Following Intravenous (iv) or Oral (po) Dosing in CD Rats<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="3" align="center" char=".">iv<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" colspan="5" align="center">po<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">DN AUC<sub>0−24 h</sub><a class="ref internalNav" href="#t7fn4" aria-label="d">d</a> (ng·h/mL/mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">15.8</td><td class="colsep0 rowsep0" align="left">151.9</td><td class="colsep0 rowsep0" align="left">234.3</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="left">5745.9</td><td class="colsep0 rowsep0" align="left">2346.4</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">21.6</td><td class="colsep0 rowsep0" align="char" char=".">42.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="left">386.3</td><td class="colsep0 rowsep0" align="left">148.7</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">24.7</td><td class="colsep0 rowsep0" align="char" char=".">29.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="left">119</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">14.3</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="char" char=".">2.04</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">BQL<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">32.7</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="char" char=".">2.44</td><td class="colsep0 rowsep0" align="char" char=".">17.7</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="left">BQL</td><td class="colsep0 rowsep0" align="left">BQL</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="char" char=".">2.90</td><td class="colsep0 rowsep0" align="char" char=".">14.7</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="left">57.0</td><td class="colsep0 rowsep0" align="left">57.8</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">16.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="left">278.5</td><td class="colsep0 rowsep0" align="left">204.8</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">18.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="char" char=".">1.02</td><td class="colsep0 rowsep0" align="char" char=".">13.1</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="left">518.0</td><td class="colsep0 rowsep0" align="left">214.8</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td><td class="colsep0 rowsep0" align="char" char=".">53.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20i</b></td><td class="colsep0 rowsep0" align="char" char=".">1.53</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="left">145.3</td><td class="colsep0 rowsep0" align="left">164.1</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20l</b></td><td class="colsep0 rowsep0" align="char" char=".">1.18</td><td class="colsep0 rowsep0" align="char" char=".">16.7</td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="left">673.8</td><td class="colsep0 rowsep0" align="left">302.1</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">20.2</td><td class="colsep0 rowsep0" align="char" char=".">79.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20m</b></td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">1707.5</td><td class="colsep0 rowsep0" align="left">1184.7</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">62.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Dosed at 5 mg/kg.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Dosed at 15 mg/kg.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">DN AUC = AUC/dose.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">BQL = below quantitation limit.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Inhibitor Series Evolution</h3><div class="NLM_p">Despite a favorable PK profile, <b>12c</b> exhibited lower cellular potency against ABL<sup>T315I</sup>, relative to <b>12a</b>. Attempts to increase potency through incorporation of water-soluble amines onto the imidazole ring resulted in only slightly increased cellular potency (<b>12d</b>−<b>e</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In further optimization, we sought to increase molecular recognition as a means to improve potency. To this end, inhibitor <b>19a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), bearing a methylpiperazine moiety at C-4 on ring B, was designed. The terminal piperazinyl nitrogen atom was expected to be protonated at physiologic pH and the subsequent quaternary salt predicted to form an H-bond with the carbonyl oxygen atom of residue Ile360 in the activation loop of the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Such ligand−protein interactions have been previously observed in both imatinib:ABL (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>) and bafetinib:ABL (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E2B">2E2B</a>) crystal structures;<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> hence we expected the increased molecular interaction would enhance potency of the designed inhibitors against both native ABL and ABL<sup>T315I</sup>. Moreover, piperazine is a widely utilized solubilizing group and its incorporation should improve cell permeability and help reduce lipophilicity and protein binding. Relative to <b>12c</b>, <b>19a</b> demonstrated 2-fold increased activity against the T315I mutated kinase and was approximately 20-fold more potent at inhibiting the growth of Ba/F3 cells expressing BCR-ABL<sup>T315I</sup> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Additionally, the presence of 340 μM human serum albumin minimally shifted the cellular potency of <b>19a</b> against native ABL (4 vs 5.9 nM) while a larger shift (8 to 51 nM) was observed with more lipophilic <b>12c</b>, suggesting that <b>19a</b> might exhibit less protein binding than <b>12c</b>. Finally, <b>19a</b> exhibited desirable pharmacokinetics when dosed orally in both rats and mice (Tables <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>) and was subsequently identified as our first orally active BCR-ABL<sup>T315I</sup> inhibitor in a pilot efficacy experiment (vide infra).</div><figure id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0023.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Model of inhibitor <b>19a</b> bound to ABL<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Mouse PK Parameters Following Oral Dosing<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0−24 h</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">11253</td><td class="colsep0 rowsep0" align="char" char=".">985.9</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">2694</td><td class="colsep0 rowsep0" align="char" char=".">521.4</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20i</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">13710</td><td class="colsep0 rowsep0" align="char" char=".">1327.2</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20l</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">6075</td><td class="colsep0 rowsep0" align="char" char=".">441.1</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">4713</td><td class="colsep0 rowsep0" align="char" char=".">416.3</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2086</td><td class="colsep0 rowsep0" align="char" char=".">209.9</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">995</td><td class="colsep0 rowsep0" align="char" char=".">122.7</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last"><i>n</i> = 3 animals per study. <b>20h</b> and <b>20m</b> were evaluated in an abbreviated assay in which plasma concentrations at 2, 6, and 24 h were determined and the following results were obtained: for <b>20h</b>, these concentrations were 622.5, 387.4, and 8.8 ng/mL, respectively, when dosed at 30 mg/kg; for <b>20m</b>, 2475.8, 2098.7, and 163.1 ng/mL. For comparison, <b>20g</b> demonstrated concentrations of 416.3, 298.9, and 4.2 ng/mL.</p></div></div></div><div class="NLM_p">Encouraged by the overall properties of <b>19a</b>, further SAR around this series was explored. The reverse amide <b>19b</b> demonstrated similar potency, essentially preserving all elements of molecular recognition. Regioisomer <b>19c</b>, with the methylpiperazine <i>meta</i>, exhibited both decreased ABL<sup>T315I</sup> kinase and cellular potency (5- and 10-fold, respectively) but was almost equipotent against native ABL. In our docking model, the terminal piperazinyl nitrogen in <b>19c</b> could also form an H-bond to the protein albeit with a different residue (Asp400), suggesting that the differential ABL<sup>T315I</sup> activity observed between <b>19a</b> and <b>19c</b> may derive from increased van der Waals interactions of the piperazinyl ring on <b>19a</b> with residues Val289, Phe359, and Asp381 in addition to the Ile360. SAR from other analogues further support this contention. The requirement of the piperazinyl H-bond was clearly demonstrated by the 12-fold decreased enzyme activity of the morphline analogue <b>19d</b> against ABL<sup>T315I</sup>. To the contrary, while the terminal nitrogens of <i>R</i>-3-(dimethylamino)pyrrolidinyl analogue <b>19e</b>, homopiperazinyl analogue <b>19f</b> and O-linked piperidinyl analogue <b>19g</b> were also predicted to form H-bonds with the protein; they all exhibited decreased potency relative to <b>19a</b>, supporting the optimal hydrophobic contact exhibited by the piperazinyl analogues. Attempts to further increase potency through terminal methyl group modifications (<b>19h</b>−<b>m</b>) were unremarkable, with no compound offering any advantage relative to the parent inhibitor <b>19a</b>. Within this series (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), potency against native ABL was insensitive to small inhibitor structural modifications, with most compounds exhibiting activity within a narrow range relative to ABL<sup>T315I</sup> inhibition where much greater sensitivity to minor structural perturbations was observed.</div><div class="NLM_p last">Earlier success (Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) with template morphing from purine to imidazo[1,2-<i>a</i>]pyridine encouraged us to next explore alternate heterocycles as hinge region binders. One approach focused on templates that could potentially form paired H-bonds with the protein; previously we had shown that an exocyclic NH at C-8 on the imidazo[1,2-<i>a</i>]pyridine core significantly increased potency (<b>12a</b> vs <b>12c</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Because of the poor PK exhibited by this analogue (vide supra) and insights from other internal programs, we targeted inhibitors possessing endocyclic NHs as H-bond donors. Several diverse heterocyclic templates were selected for investigation (<b>20a</b>−<b>d</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), however, these inhibitors did not exhibit the expected potency improvement over <b>19a</b>. In general, ABL<sup>T315I</sup> kinase activity was reduced by 2−4-fold although two compounds (<b>20a</b> and <b>20d</b>) demonstrated slightly increased cellular potency. Simultaneously, we explored additional 6/5 fused aromatic ring systems and established a goal to reduce the lipophilicity of <b>19a</b> (clogP = 6.69)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> through nitrogen atom incorporation. Three pyridine ring permutations with CH replaced by nitrogen were explored (each reduced the clogP by approximately 1 log unit). Inhibitor <b>20e</b>, with N occupying the H-bond donor C-8 position, markedly reduced potency. However, both <b>20f</b> and <b>20g</b> demonstrated increased enzyme and cellular potency relative to <b>19a</b>. Compound <b>20g</b> exhibited more favorable preliminary PK than <b>20f</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>) and so its SAR was further explored.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> SAR around <b>20g</b></h3><div class="NLM_p">To further explore SAR around the advanced lead compound <b>20g</b>, we re-examined distal piperazine nitrogen substitution and found that the SAR trends disclosed in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were largely preserved with this new template (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). For example, <b>20h</b> and <b>20i</b>, both with larger <i>N</i>-substituents exhibited similar potency to <b>20g</b>. Not surprisingly, deletion of the entire methylpiperazinyl moiety (<b>20p</b>) markedly reduced ABL<sup>T315I</sup> activity, with a decrease in potency of 25- and 130-fold in enzymatic and cellular assays, respectively. Next, the potency impact of the A-ring “flag-methyl”<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> group was briefly investigated. Chlorine substitution (<b>20l</b>) was essentially equipotent in inhibiting proliferation of BCR-ABL<sup>T315I</sup> expressing Ba/F3 cells, whereas hydrogen or fluorine substitution (<b>20k</b>, <b>20m</b>) resulted in 3−4-fold potency loss. Last, B-ring trifluoromethyl replacement with either chlorine (<b>20n</b>) or cyclopropyl (<b>20o</b>) groups significantly reduced cellular potency against mutant T315I but only marginally affected activity against native ABL.</div><div class="NLM_p">To confirm the absolute requirement of the carbon−carbon triple bond for the ABL<sup>T315I</sup> potency of <b>20g</b>, we systematically added hydrogen back across this linker. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, both the double bond linked and fully saturated molecules (<b>24a</b> and <b>24b</b>) significantly reduced ABL<sup>T315I</sup> activity.</div><div class="NLM_p">Elsewhere, we have reported the three-dimensional structure of the ABL<sup>T315I</sup>:<b>20g</b> complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3">3IK3</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The crystal structure confirmed that <b>20g</b> binds to the DFG-out conformation of the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), and the key molecular recognition components are consistent with those predicted by modeling shown in Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. The coordinates from this crystal structure were used to refine the docking model for alternate linker analogues <b>24a</b> and <b>24b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>), and the inhibitor−protein interactions were compared. All three analogues bind to the protein in a similar fashion, and all three linkers can evade steric clash from the bulky gatekeeper isoleucine. One explanation for their differing potencies is that the least sterically demanding acetylene linker makes more favorable van der Waals’ contact with gatekeeper Ile315 and Phe382 of the DFG motif (the triple bond is 3.4−3.6 Å away from Ile315 and also almost bisected by the aromatic ring of Phe382 in the crystal structure). Another potential factor contributing to the high ABL<sup>T135I</sup> potency of <b>20g</b> is that the rigidity of the acetylene linkage promotes an extended conformation of the unbound inhibitor, which favors binding to ABL<sup>T315I</sup> in a DFG-out mode. The more flexible linkers in <b>24a</b> and <b>24b</b> could bring about a folded conformation in the unbound inhibitors; transition to an extended conformation would be entropically less favorable and hence reduce potency.</div><figure id="fig6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0024.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray structure of ABL<sup>T315I</sup> in complex with inhibitor <b>20g</b> (green) and model of <b>24a</b> (brown) and <b>24b</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, the SAR studies on <b>20g</b> show that, as with the preceding chemical series, the gatekeeper T315I mutant is a more “stringent” target than native ABL. Minor structural modifications to either the acetylene linker, the methylpiperazinyl moiety, or the trifluoromethyl group significantly affected ABL<sup>T315I</sup> potency while modifications or even deletion of one of these binding elements still yielded potent native ABL inhibitors. We conclude that incorporation of multiple points of protein contact led to the high potency of <b>20g</b> against the refractory ABL mutant T315I.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Pharmacokinetics</h3><div class="NLM_p">During this program, potent inhibitors were continually evaluated for their pharmacokinetic (PK) properties in rats immediately following assessment of their in vitro activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). In general, inhibitors bearing imidazole as the B ring appendage demonstrated higher dose normalized AUC and <i>C</i><sub>max</sub> than those piperazine-containing compounds (<b>12c</b> vs <b>19a</b>). <b>12c</b> had a much smaller volume of distribution relative to <b>19a</b>, consistent with a highly protein bound species, which was confirmed by a potency shift in vitro in the presence of human serum albumin (vide supra). The exocyclic NH<sub>2</sub> at C-8 on the imidazo[1,2-<i>a</i>]pyridine template drastically reduced both AUC and <i>C</i><sub>max</sub> of imidazole-bearing inhibitors to the level of piperazine-containing compounds (<b>12c</b> vs <b>12a</b> and <b>19a</b>).</div><div class="NLM_p">Among those piperazine-bearing inhibitors possessing alternate hinge binding templates, <b>20b</b> and <b>20c</b> exhibited low oral absorption in rats. For the remaining inhibitors, their dose normalized oral exposure in rats were ranked as follows: <b>19a</b> > <b>20g</b> > <b>20a</b> ≫ <b>20f</b>, and <i>C</i><sub>max</sub><b>20g</b> > <b>19a</b> ≫ <b>20a</b> ≈ <b>20f</b>. Both <b>20g</b> and <b>19a</b> exhibited long half-lives and reduced clearance relative to <b>20f</b>. The latter exhibited the highest clearance and hence lowest AUC. Five inhibitors (<b>20g, 20h</b>, <b>20i</b>, <b>20l</b>, <b>20m</b>) bearing the same template, imidazo[1,2-<i>b</i>]pyridazine in general demonstrated good PK.</div><div class="NLM_p">Mouse PK data for these inhibitors were collected as a prerequisite to evaluating potency in in vivo efficacy models (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). In general, mouse PK exhibited similar trends to those observed in rats. For <b>20g</b>, PK parameters were determined orally at different doses; good dose proportionality was observed.</div><div class="NLM_p last">The concentration of <b>20g</b> in the brain was also measured to evaluate its ability to penetrate the blood−brain barrier (BBB). In a mouse PK study following a single oral 30 mg/kg dose, a brain/plasma concentration ratio of 1.60 was determined at 6 h postdosing, indicating high levels of BBB penetration. It should be noted that among the three approved agents for CML treatment, only dasatinib crosses the blood−brain barrier, with human cerebrospinal fluid/plasma ratios ranging from 0.05 to 0.28.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Among the inhibitors in clinical trials, bafetinib demonstrated 10-fold lower brain levels compared to plasma in mice. Despite the low levels, this concentration is sufficient for bafetinib to inhibit the growth of Ph+ leukemic cells in the murine CNS.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The higher level of BBB penetration for <b>20g</b> might suggest it has greater potential in treating CNS Ph+ leukemia that often complicates late-stage CML.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Efficacy</h3><div class="NLM_p">Several inhibitors possessing desirable in vitro kinase and cellular potency and with favorable pharmacokinetic profiles were evaluated for their antitumor activity in an aggressive mouse model of CML driven by the T315I mutation. In this model, Ba/F3 cells expressing BCR-ABL<sup>T315I</sup> were injected into the tail vein of SCID mice. After 3 days, the animals were dosed orally with inhibitors at 10 mg/kg, once daily for 19 consecutive days. The level of increased overall survival of treated mice relative to untreated control was used to assess efficacy. Median survival of untreated mice in this model was 14 days. Among all six inhibitors tested, <b>20g</b> demonstrated the greatest increased overall survival (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). At the higher dose of 30 mg/kg/day, <b>20g</b> more than doubled the survival of animals in this highly aggressive model (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) and was well tolerated for the duration of study with no signs of overt toxicity.</div><figure id="fig7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0025.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of inhibitors in a Ba/F3 BCR-ABL<sup>T315I</sup> survival model at dose level of 10 mg/kg (error bars represent SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0026.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of <b>20g</b> in a Ba/F3 BCR-ABL<sup>T315I</sup> survival model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Kinase and Mutant Selectivity Profile of <b>20g</b></h3><div class="NLM_p">To assess the kinase selectivity profile of <b>20g</b> beyond ABL, broad panel kinase screening was conducted using an enzymatic assay as previously reported.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In brief, <b>20g</b> was found to be a multitargeted inhibitor with activity against FLT3, FGFR, and VEGFR family kinases in the single digit nanomolar range. Like imatinib, nilotinib, and dasatinib, <b>20g</b> also inhibits c-Kit and PDGFRα/β. Many of these kinases are important clinical targets in a variety of other malignancies and support the potential testing of <b>20g</b> more broadly against a range of cancers. To the contrary, <b>20g</b> does not inhibit Aurora kinases and demonstrated over 500-fold selectivity relative to a number of kinases including CDK2/cyclin E, EGFR, FAK, IGF1R, JAK2, and c-Met. The relatively broad kinase specificity profile of <b>20g</b> can likely be attributed to the linear ethynyl linkage, which permits binding to kinases with hydrophobic residues at the gatekeeper position.</div><div class="NLM_p last">Elsewhere, we have reported the cellular activity of <b>20g</b> against a broad panel of clinically relevant BCR-ABL mutants, confirming its pan-BCR-ABL activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Briefly, <b>20g</b> was active against all tested mutants including, but not limited to, T315A, F317L/V, Y253H, E255K/V, and F359V, mutations which have been reported in patients failing on either dasatinib or nilotinib.<a onclick="showRef(event, 'ref11 ref12 ref40'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref40">(11, 12, 40)</a> Additionally, in an accelerated mutagenesis screen for resistance, <b>20g</b> completely suppressed the outgrowth of all mutants at a concentration of 40 nM. Together, these results are consistent with the profile of a true pan-BCR-ABL inhibitor, active against the native enzyme and all clinically relevant mutants including T315I.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from <b>1a</b>, a lead compound that emerged from our program developing DFG-out targeted ABL kinase inhibitors based on the 9-[(aren)ethenyl]purine template, extensive medicinal chemistry coupled with detailed structural investigations has led to a novel series of kinase inhibitors that potently inhibit native ABL and a broad panel of clinically relevant mutants including T315I at the gatekeeper position (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Crystallographic studies confirmed that this series binds to the inactive, “DFG-out” conformation of the protein. One unusual structural feature of these potent inhibitors is the inflexible acetylene linkage connecting the heterocycle core serving as the hinge binder and the <i>N-</i>arylbenzamide occupying the hydrophobic selectivity pocket.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This rigid, less sterically demanding linker enables binding to the enlarged Ile315 side chain of the T315I mutant and correctly directs both inhibitor segments into well-defined binding pockets making more productive interactions with the protein. Another key structural element required for achieving high potency is the hybrid <i>N</i>-arylbenzamide, which allows cooperative molecular exploitation of both trifluoromethyl and piperazinyl groups to maximize van der Waals and hydrogen-bonding interactions with the protein. In general, the piperazine tail confers excellent cellular potency and improved aqueous solubility with reduced plasma protein binding, leading to favorable pharmacokinetic properties following oral dosing in rats and mice. Inhibitor <b>20g</b> exhibited low nM cellular potency against cells lines expressing either native BCR-ABL or BCR-ABL<sup>T315I</sup> and significantly prolonged survival in an aggressive mouse model of CML driven by the T315I mutant. <b>20g</b> also potently inhibited proliferation of all clinically relevant ABL mutants in cell-based assays characterizing it as the first pan-BCR-ABL inhibitor. On the basis of these data, and its favorable overall ADME profile, <b>20g</b> was nominated as a development candidate and is currently undergoing phase I clinical evaluation in patients with refractory CML and other hematologic malignancies.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as received. <sup>1</sup>H NMR spectra were recorded on a Bruker ARX300 or a Bruker AVANCE400 spectrometer using TMS as internal standard. MS spectra were recorded on a Waters Micromass ZQ spectrometer. Elemental analyses were performed by Robertson Microlit Laboratories in Madison, NJ. HPLC was performed on an Agilent 1100 HPLC system. The purity of all SAR compounds was determined to be ≥95% by reverse phase HPLC (C-18 column, MeCN/H<sub>2</sub>O with 0.1% CF<sub>3</sub>CO<sub>2</sub>H as the mobile phase).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cyclopropyl-(9-trichlorovinyl-9<i>H</i>-purin-6-yl)amine (<b>3</b>)</h3><div class="NLM_p last">A solution of 6-(cyclopropylamino)-9<i>H</i>-purine (3 g, 17.1 mmol) in anhydrous HMPA (156 mL) was added to NaH (1.5 g, 60% dispersion in oil) under stirring until no effervescence was observed. Tetrachloroethylene was then added dropwise, and the mixture was heated at 60 °C overnight. Excess HMPA was distilled off, and the resultant mixture was quenched with methanol. The crude was extracted with EtOAc, washed with water, and then dried over Na<sub>2</sub>SO<sub>4.</sub> The solvent was removed, and the resultant residue was chromatographed over silica gel eluting with hexanes−EtOAc to furnish the desired product (0.65 g, 12% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.60 (m, 2H), 0.81 (m, 2H), 3.10 (m, 1H), 6.60 (br, 1H), 7.80 (s, 1H), 8.50 (s, 1H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Cyclopropyl-(9-ethynyl-9<i>H</i>-purin-6-yl)amine (<b>4</b>)</h3><div class="NLM_p last">To the solution of <b>3</b> (0.5 g, 1.65 mmol) in THF (17 mL) was added <i>n</i>-BuLi (2.6 mL, 6.56 mmol) at −78 °C. The reaction mixture was stirred at this temperature for one additional hour and then carefully quenched with methanol. The solvent was stripped off, and the resultant residue was partitioned between EtOAc and water. After drying and concentration, the crude was chromatographed over silica gel eluting with hexanes−EtOAc (6:4) to furnish the desired product (0.1 g, 30% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.50 (m, 2H), 0.72 (m, 2H), 2.80 (m, 1H), 3.10 (s, 1H), 5.90 (s,1H), 7.80 (s, 1H), 8.30 (s, 1H). MS: <i>m</i>/<i>z</i> 200.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-{3-[2-[(Dimethylamino)methyl]-1<i>H</i>-imidazol-1-yl]-5-(trifluoromethyl)phenyl}-3-iodo-4-methylbenzamide (<b>5d</b>)</h3><div class="NLM_p last">This was prepared analogously to <b>5c</b> via a published procedure<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> using <b>14</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> instead of imidazole. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.21 (s, 9H), 3.30 (s, 2H), 7.10 (s, 2H), 7.55 (m, 4H), 7.65 (s, 2H). MS: <i>m</i>/<i>z</i> 529.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-{2-[6-(Cyclopropylamino)purin-9-yl]ethynyl}-4-methyl-<i>N</i>-[4-(trifluoromethyl)-pyridin-2-yl]-benzamide (<b>6a</b>)</h3><div class="NLM_p last">Iodobenzamide <b>5a</b><a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> (0.44 g, 1.1 mmol) and alkyne <b>4</b> (0.2 g, 1.0 mmol) was dissolved in a mixture of toluene and triethylamine (10 mL, 1:2). To this was added Pd(PPh<sub>3</sub>)<sub>4</sub> (0.062 g, 0.05 mmol) and CuI (0.0051 g, 0.026 mmol). The resulting solution was degassed by a stream of argon for 30 min and then heated at 55 °C for 3 h. The crude was chromatographed over silica gel eluting with hexanes−EtOAc (2:8) to furnish a pale-yellow solid, which was further washed with cold methanol to afford pure product (0.029 g, 6% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.50 (m, 2H), 0.62 (m, 2H), 2.31 (s, 3H), 2.80 (s, 1H), 5.90 (s, 1H), 7.25 (m, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.70 (d <i>J</i> = 2 Hz, 1H), 7.80 (s, 1H), 8.05 (d, <i>J</i> = 1.9 Hz, 1H), 8.40 (d, <i>J</i> = 5.1 Hz, 1H), 8.50 (s, 1H), 8.61 (s, 1H), 8.65 (s, 1H). MS: <i>m</i>/<i>z</i> 479.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-{2-[6-(Cyclopropylamino)purin-9-yl]ethynyl}-<i>N</i>-[5-(1,1-dimethylethyl)isoxazol-3-yl]-4-methylbenzamide (<b>6b</b>)</h3><div class="NLM_p last">This was prepared analogously to <b>6a</b> using <b>5b</b><a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> and <b>4</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.80 δ (m, 2H), 1.00 (m, 2H), 1.70 (s, 9H), 2.61 (s, 3H), 3.10 (s, 1H), 6.50 (s, 1H), 7.05 (s, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 8.00 (d, <i>J</i> = 2.0 Hz, 1H), 8.11 (s, 1H), 8.25 (d, <i>J</i> = 1.8 Hz, 1H), 8.70 (s, 1H), 9.25 (s, 1H). MS: <i>m</i>/<i>z</i> 457.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-Bromoimidazo[1,2-<i>a</i>]pyridin-8-ylamine (<b>7a</b>)</h3><div class="NLM_p last">To a solution of <b>7b</b> (10.24 g, 40.30 mmol) in EtOH (500 mL) was added concentrared aq HCl (51 mL). The suspension was refluxed for 2 h. Upon cooling, the reaction mixture was basified under stirring with 10 N NaOH until the pH reached ∼9. EtOH was removed on a rotavap and the resulting suspension was partitioned in CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O. The organic layer was dried and concentrated, giving the desried product as a brownish solid (7.66 g, 90%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 5.79 (br, 2H), 6.36 (d, <i>J</i> = 7.4 Hz, 1H), 6.84 (dd, <i>J</i> = 6.9, 7.2 Hz, 1H), 7.57 (s, 1H), 7.62 (d, <i>J</i> = 7.4 Hz, 1H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(3-Bromoimidazo[1,2-<i>a</i>]pyridin-8-yl)acetamide (<b>7b</b>)</h3><div class="NLM_p last">Bromine was added dropwise to a solution of 8-acetamidoimidazo[1,2-<i>a</i>]pyridine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (8.0 g, 45.7 mmol) in EtOH at 0 °C. The solution was stirred at rt for 3 h, at which point HPLC indicated complete conversion. After the volatile components were removed on a rotavap, the residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and then washed with saturated aq NaHSO<sub>3</sub> and then 1N NaOH until the pH reached 7. The organic layer was passed through celite, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated on a rotavap, giving essentially pure material by NMR and HPLC. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.22 (s, 3H), 7.06 (dd, <i>J</i> = 7.2, 7.3 Hz, 1H), 7.74 (s, 1H), 8.05−8.08 (m, 2H), 10.06 (s, 1H).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(3-Bromoimidazo[1,2-<i>a</i>]pyridin-8-yl)imidodicarbonic Acid, <i>C</i>,<i>C</i>′-Bis(1,1-dimethylethyl)ester (<b>7a′</b>)</h3><div class="NLM_p last">To a solution of <b>7a</b> (5.75 g, 27.12 mmol) in THF (120 mL) was added Boc<sub>2</sub>O (3 equiv) and DMAP (0.1 equiv). After the mixture was stirred at rt for 18 h, the solvent was removed and the residue was suspended in EtOAc. Filtration gave a brownish solid, which was determined by NMR to be pure product. The filtrate was concentrated and purified by CombiFlash chromatography (30% EtOAc in hexanes), giving the second crop of product. The combined yield was 78%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.38 (s, 18H), 7.15 (dd, <i>J</i> = 7.0, 7.3 Hz, 1H), 7.39 (d, <i>J</i> = 7.3 Hz, 1H), 7.82 (s, 1H), 8.39 (d, <i>J</i> = 7.3 Hz, 1H).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure for the Preparation of Arylacetylenes <b>9</b>: 3-ethynylimidazo[1,2-<i>a</i>]pyridine (<b>9c</b>)</h3><div class="NLM_p last">To a solution of <b>7c</b> (5 g, 25.4 mmol) in MeCN (50 mL) was added Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.445 g, 0.634 mmol), CuI (0.17 g, 0.89 mmol), dicyclohexylamine (5.6 mL, 28 mmol), and ethynyltrimethylsilane (7.2 mL, 51 mmol). The solution was purged with argon for 15 min, sealed, and heated at 80 °C for 3 h, at which point HPLC indicated disappearance of starting bromide. The solvents were concentrated and to the residue was added H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub> (25 mL each). The organic layer was separated, and the aqueous layer was repeatedly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated (<i>R</i><sub>f</sub> = 0.47 in 50% hexanes in EtOAc). The resulting residue was dissolved in THF (100 mL) and treated with tetrabutyl ammonium fluoride monohydrate (8.3 g, 32 mmol) in H<sub>2</sub>O (5 mL), and the mixture was stirred at rt for 2 h. The solvents were concentrated, and the resulting residue was partitioned between H<sub>2</sub>O (25 mL) and CH<sub>2</sub>Cl<sub>2</sub> (150 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 30 mL). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated on a rotavap. The resulting residue was purified by combiflash on silica gel using hexanes−EtOAc. The desired product was eluted with 50% hexanes in EtOAc and isolated as an off-white solid in 84% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 5.08 (s, 1H), 7.13 (ddd, <i>J</i> = 0.9, 6.8, 6.9 Hz, 1H), 7.42 (ddd, <i>J</i> = 1.2, 6.8, 6.9 Hz, 1H), 7.71 (d, <i>J</i> = 6.9 Hz, 1H), 7.96 (s, 1H), 8.46 (d, <i>J</i> = 6.8 Hz, 1H). MS: <i>m</i>/<i>z</i> 200 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(3-Ethynylimidazo[1,2-<i>a</i>]pyridin-8-yl)imidodicarbonic Acid, <i>C</i>,<i>C</i>′-Bis(1,1-dimethylethyl)ester (<b>9a</b>)</h3><div class="NLM_p last">This was made from <b>7a</b> via bis-Boc protection. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.34 (s, 18H), 5.11 (s, 1H), 7.13 (dd, <i>J</i> = 6.8, 7.3 Hz, 1H), 7.39 (dd, <i>J</i> = 0.9, 7.3 Hz, 1H), 7.95 (s, 1H), 8.46 (dd, <i>J</i> = 0.9, 6.8 Hz, 1H).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(3-Ethynylimidazo[1,2-<i>a</i>]pyridin-8-yl)acetamide (<b>9b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.23 (s, 3H), 5.08 (s, 1H), 7.06 (dd, <i>J</i> = 6.9, 7.4 Hz, 1H), 7.94 (s, 1H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 8.16 (dd, <i>J</i> = 0.9, 6.7 Hz, 1H), 10.10 (s, 1H).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-Ethynylimidazo[1,2-<i>b</i>]pyridazine (<b>9d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 4.93 (s, 1H), 7.35 (dd, <i>J</i> = 4.4, 9.2 Hz, 1H), 8.11 (s, 1H), 8.21 (dd, <i>J</i> = 1.6, 9.2 Hz, 1H), 8.65 (dd, <i>J</i> = 1.6, 4.4 Hz, 1H).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure for the Preparation of Inhibitors <b>12</b>: 3-[2-(8-Aminoimidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-<i>N</i>-[3-(1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methylbenzamide (<b>12a</b>)</h3><div class="NLM_p last">Alkyne <b>9a</b> (130 mol %), iodobenzamide <b>5c</b> (0.2 mmol), Pd[(PPh<sub>3</sub>)<sub>4</sub>] (5 mol %), and CuI (7.5 mmol %) was placed in a vial with rubber septum. The mixture underwent 3 cycles of vacuum/filling with N<sub>2</sub>. DMF (1.5 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (150 mol %) was then added. The mixture was stirred at rt for 16 h and then quenched with H<sub>2</sub>O. EtOAc and more water were added for extraction. The combined organic layer was dried (over Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and the resulting residue was purified by silica gel chromatography (eluent: 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), giving the <b>12a</b>′ as an off-white solid. Standard deprotection to cleave both Boc groups with TFA furnished <b>12a</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.74 (s, 3H), 5.85 (br, 2H), 6.60 (d, <i>J</i> = 7.4 Hz, 1H), 7.06 (dd, <i>J</i> = 7.0, 7.1 Hz, 1H), 7.42 (s, 1H), 7.69 (d, <i>J</i> = 8.1 Hz, 1H), 7.86−8.10 (m, 5H), 8.38 (s, 1H), 8.40 (d, <i>J</i> = 1.3 Hz, 1H), 8.52 (s, 1H), 8.65 (s, 1H), 10.92 (s, 1H). MS: <i>m</i>/<i>z</i> 500.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 3-{2-[8-(Acetylamino)imidazo-[1,2-<i>a</i>]pyridin-3-yl]ethynyl}-<i>N</i>-[3-(1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methylbenzamide (<b>12b</b>)</h3><div class="NLM_p last">This was made from coupling of <b>9b</b> and <b>5c</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.10 (s, 3H), 2.70 (s, 3H), 7.22 (dd, <i>J</i> = 6.6, 7.4 Hz, 1H), 7.92 (d, <i>J</i> = 7.9 Hz, 1H), 7.71−8.47 (m, 11H), 10.22 (s, 1H), 10.83 (s, 1H). MS: <i>m</i>/<i>z</i> 542.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-[3-(1<i>H</i>-Imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[2-(imidazo-[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>12c</b>)</h3><div class="NLM_p last">This was made from coupling of <b>9c</b> and <b>5c</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.64 (s, 3H), 7.21 (dd, <i>J</i> = 6.6, 6.7 Hz, 1H), 7.68 (dd, <i>J</i> = 7.0, 7.1 Hz, 1H), 7.59 (d, <i>J</i> = 8.1 Hz, 1H), 7.72−7.88 (m, 3H), 7.97 (dd, <i>J</i> = 1.8, 8.0 Hz, 1H), 8.10 (s, 1H), 8.24 (s, 1H), 8.31 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.36 (overlapped singlet, 2H), 8.64 (d, <i>J</i> = 6.6 Hz, 1H), 10.76 (s, 1H). MS: <i>m</i>/<i>z</i> 486.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-{3-[2-[(Dimethylamino)methyl]-1<i>H</i>-imidazol-1-yl]-5-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>12d</b>)</h3><div class="NLM_p last">This was made from coupling of <b>9c</b> and <b>5d</b> in 59% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.41 (s, 6H), 2.50 (s, 3H), 3.75 (s, 2H), 6.90 (m, 1H), 7.00(s, 1H), 7.11 (s, 1H), 7.30 (d, <i>J</i> = 6.1 Hz, 2H), 7.60 (m, 1H), 7.71 (s, 1H), 7.83 (m, 1H), 8.11 (s, 2H), 8.33(m, 3H), 9.60 (s, 1H). MS: <i>m</i>/<i>z</i> 543.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{3-[4-(1-pyrrolidinylmethyl)-1<i>H</i>-imidazol-1-yl]-5-(trifluoromethyl)phenyl}benzamide (<b>12e</b>)</h3><div class="NLM_p last">This was made analogously to <b>12d</b> using pyrrolidine instead of dimethylamine in the first step of the reaction sequence depicted in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.20 (m, 4H), 2.51 (s, 3H), 3.55 (m, 6H), 7.40(m, 1H), 7.70(m, 1H), 7.83 (d, <i>J</i> = 8.2 Hz, 1H), 8.0 (d, <i>J</i> = 8.5 Hz, 1H), 8.11 (s, 1H), 8.20 (m, 2H), 8.30 (s, 1H), 8.44(s, H), 8.50 (d, <i>J</i> = 1.6 Hz, 1H), 8.74 (m, 2H), 8.90 (d, <i>J</i> = 6.6 Hz, 1H), 11.1 (s, 1H). MS: <i>m</i>/<i>z</i> 568.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-Methyl-4-{[4-nitro-2-(trifluoromethyl)phenyl]methyl}piperazine (<b>16a</b>)</h3><div class="NLM_p">A suspension of 2-methyl-5-nitrobenzotrifluoride (3.90 g, 19 mmol), <i>N</i>-bromosuccinimide (NBS, 3.56 g, 20 mmol), and 2,2′-azobis(2-methylpropionitrile) (AIBN, 94 mg, 0.6 mmol) in CCl<sub>4</sub> (40 mL) was refluxed under N<sub>2</sub> for 16 h, at which point HPLC indicated ca. 50% conversion. More NBS (10 mmol) and AIBN (0.6 mmol) was added, and the mixture was refluxed for another 14 h. HPLC indicated ca. 80% conversion. The reaction mixture was cooled down, and the solid was filtered off and washed with EtOAc. The combined filtrate was washed with aq NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated on rotavap, and further dried under vacuum. <sup>1</sup>H NMR indicated the ratio of desired product 2-(bromomethyl)-5-nitrobenzotrifluoride to unreacted 2-methyl-5-nitrobenzotrifluoride was 75:25, based on the integration of CH<sub>2</sub>Br (4.68 ppm in CDCl<sub>3</sub>) and CH<sub>3</sub> (2.63 ppm). This material was not purified but used directly in the next step.</div><div class="NLM_p last">To a solution of crude 2-(bromomethyl)-5-nitrobenzotrifluoride (13.33 mmol, 75% pure) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added Et<sub>3</sub>N (1.4 mL, 10 mmol) and 1-methylpiperazine (1.1 mL, 10 mmol). After stirring for 3 h at rt, aq NaHCO<sub>3</sub> was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and the resulting residue was purified by silica gel chromatography (eluent: 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), giving the product as a pale-yellow oil (72%, 2.21 g). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.46 (s, 3H), 2.66 (m, 8H), 3.84 (s, 2H), 8.10 (d, <i>J</i> = 8.4 Hz, 1H), 8.32 (dd, <i>J</i> = 2.3, 8.4 Hz, 1H), 8.58 (d, <i>J</i> = 2.3 Hz, 1H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-[(4-Methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline (<b>17a</b>)</h3><div class="NLM_p last">A suspension of <b>16a</b> (1.23 g, 4 mmol) and sodium hydrosulfite (7.0 g, 85% pure from Aldrich, 40 mmol) in acetone and water (1:1, 20 mL) was refluxed for 3 h. Upon cooling, the volatile components (mainly acetone) were removed on rotavap, and the resulting mixture was subjected to filtration. The solid was thoroughly washed with EtOAc. The combined filtrate was extracted with <i>n</i>-BuOH (4×), and the combined organic layer was washed with saturated aq NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and the resulting residue was purified by silica gel chromatography (eluent: 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, MeOH was presaturated with ammonia gas), giving the product as a pale-yellow solid (65%, 0.71 g). <sup>1</sup>H NMR: (CDCl<sub>3</sub>): δ 2.25 (s, 3H), 2.44 (m, 8H), 3.46 (s, 2H), 3.84 (br, 2H), 6.75 (dd, <i>J</i> = 2.3, 8.3 Hz, 1H), 6.88 (d, <i>J</i> = 2.4 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-Iodo-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-benzamide (<b>18a</b>)</h3><div class="NLM_p last">3-Iodo-4-methylbenzoyl chloride (0.48 g, 1.7 mmol), prepared from the reaction of 3-iodo-4-methylbenzoic acid and SOCl<sub>2</sub>, was added to a solution of <b>17a</b> (0.47 g, 1.7 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (0.26 g, 2.0 mmol), and a catalytic amount of DMAP in THF (10 mL). After stirring at rt for 2 h, the reaction was quenched with water. EtOAc was added and the layers separated. The combined organic layers were concentrated to dryness and purified by silica gel chromatography (eluent: 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, MeOH was presaturated with ammonia gas), giving the desired product as an off-white solid (57%, 0.51 g). <sup>1</sup>H NMR: (acetone-<i>d</i><sub>6</sub>): δ 2.07 (s, 3H), 2.26 (m, 8H), 2.37 (s, 3H), 3.50 (s, 2H), 7.36 (d, <i>J</i> = 7.9 Hz, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (dd, <i>J</i> = 1.8, 8.5 Hz, 1H), 7.92 (dd, <i>J</i> = 1.9, 8.5 Hz, 1H), 8.11 (d, <i>J</i> = 2.2 Hz, 1H), 8.33 (d, <i>J</i> = 1.8 Hz, 1H), 9.66 (s, 1H).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(3-Iodo-4-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-benzamide (<b>18b</b>)</h3><div class="NLM_p last"><i>N</i>-(4-(4-Methylpiperazin-1-yl)methyl)-3- (trifluoromethyl benzoic acid<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (1.0 g, 2.67 mmol) and 3-iodo-4-methyl aniline (0.68 g, 2.90 mmol) were dissolved in DMF (14 mL). To this, HATU (1.5 g, 4.00 mmol) and DIPEA (1.5 mL) were added and the mixture was stirred overnight. The solvent was removed under vacuum, and the crude residue was chromatographed over silica gel eluting initially with EtOAc and then with CH<sub>2</sub>Cl<sub>2</sub>−MeOH (95:5), giving the desired product (0.98 g, 70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.20 (s, 3H), 2.21 (s, 3H), 2.50 (m, 8H), 3.76 (s, 2H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 7.50 (m, 1H) 7.73 (br, 1H), 7.90(s, 2H), 8.00 (s, 2H). MS: <i>m</i>/<i>z</i> 518.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-Iodo-4-methyl-<i>N</i>-[4-(1-methylpiperidin-4-yloxy)-3-(trifluoromethyl)phenyl]benz-amide (<b>18g</b>)</h3><div class="NLM_p last">This was made from the reaction of 3-iodo-4-methylbenzoyl chloride with 4-(1-methylpiperidin-4-yloxy)-3-(trifluoromethyl)aniline,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> as described in the synthesis of <b>18a</b>. MS: <i>m</i>/<i>z</i> 518.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-{4-[(4-(2-Fluoroethyl)piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-iodo-4-methylbenzamide (<b>18k</b>)</h3><div class="NLM_p last">Iodobenzamide <b>18l</b> was prepared analogously to <b>18a</b> using <i>N</i>-Boc-piperazine instead of <i>N</i>-methylpiperazine in the first step of the reaction sequence depicted in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. <b>18l</b> (0.5 g) was then treated with TFA (10 mL) for 3 h. Excess solvent was removed, and the resultant salt was dissolved in DMF (4 mL). 2-Bromofluoroethane (0.15 mL) and NaHCO<sub>3</sub> (0.4 g) was then added, and the resulting mixture was heated at 80 °C for overnight. Solvent was evaporated; the residue was taken up in EtOAc and washed with water. The combined layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was then flash chromatographed over silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub>−MeOH (95:5) to furnish the desired product (0.25 g). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.41 (m, 4H), 2.51 (s, 3H), 2.50 (m, 6H), 3.82 (s, 2H), 4.50 (m, 1H), 4.69 (m, 1H), 7.25 (m, 1H), 7.80 (m, 5H), 8.20 (s, 1H). MS: <i>m</i>/<i>z</i> 518.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-{3-Cyclopropyl-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-iodo-4-methyl-benzamide (<b>18o</b>)</h3><div class="NLM_p">To a solution of 2-bromo-4-nitrobenzyl bromide (1.56 g, 3.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added Et<sub>3</sub>N (0.48 mL, 3.4 mmol) and <i>N</i>-methylpiperazine (0.38 mL, 3.4 mmol) at 0 °C. The reaction mixture was stirred for 3 h at rt before aq NaHCO<sub>3</sub> was added. The resulting solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and the resulting residue was purified by silica gel chromatography (eluent: 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), giving the product <b>21</b>as a pale-yellow oil (75%, 0.80 g). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.16 (s, 3H), 2.34 (m, 4H), 2.46 (m, 4H), 3.62 (s, 2H), 7.75 (d, <i>J</i> = 8.5 Hz, 1H), 8.23 (dd, <i>J</i> = 2.3, 8.5 Hz, 1H), 8.39 (d, <i>J</i> = 2.3 Hz, 1H).</div><div class="NLM_p">A solution of <b>21</b> (0.943 g, 3.0 mmol), cyclopropaneboronic acid (0.773 g, 9.0 mmol), K<sub>3</sub>PO<sub>4</sub> (2.87 g, 13.5 mmol), Pd(OAc)<sub>2</sub> (67 mg, 0.3 mmol), and tricyclohexylphosphine (0.168 g, 0.6 mmol) in toluene (15 mL) and water (3 mL) was degassed with N<sub>2</sub> and then heated at reflux overnight. Extraction followed by silica gel column chromatography (eluent: 5% NH<sub>3</sub> presaturated MeOH in CH<sub>2</sub>Cl<sub>2</sub>) gave the desired product <b>22</b> (0.797 g, 96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.77 (m, 2H), 1.05 (m, 1H), 2.18 (m, 1H), 2.28 (s, 3H), 2.45 (m, 4H), 2.52 (m, 4H), 3.71 (s, 2H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.33 (d, <i>J</i> = 2.4 Hz, 1H), 7.98 (dd, <i>J</i> = 2.3, 8.4 Hz, 1H).</div><div class="NLM_p last">Substituted ntrobenzene <b>22</b> was completely converted into corresponding aniline <b>17o</b> after heating in MeOH at reflux for 3 h in the presence of reducing agent Fe/HOAc. The solvent was removed and the residue was partitioned between aq NaHCO<sub>3</sub> and EtOAc. Extraction, combination of organic layer, drying over Na<sub>2</sub>SO<sub>4</sub>, and concentration afforded essentially pure material (by HPLC). This was reacted with 3-iodo-4-methylbenzoyl chloride to furnish desired amide product <b>18o</b> in a similar fashion to the preparation of 1<b>8a</b>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.60 (m, 2H), 0.94 (m, 2H), 2.20 (m, 1H), 2.48 (s, 3H), 2.50 (m, 8H), 3.65 (s, 2H), 7.18 (d, <i>J</i> = 8.2 Hz, 1H), 7.31 (s, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 1H), 7.87 (d, <i>J</i> = 8.2 Hz, 1H), 8.40 (s, 1H), 10.12 (s, 1H).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> General Procedure for the Preparation of Inhibitors <b>19</b> and <b>20</b>: 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>19a</b>)</h3><div class="NLM_p last">Alkyne <b>9c</b> (37 mg, 0.26 mmol), iodobenzamide <b>18a</b> (103.4 mg, 0.2 mmol), Pd[(PPh<sub>3</sub>)<sub>4</sub>] (11.6 mg, 5 mol %), and CuI (2.9 mg, 7.5 mmol%) was placed in a vial with a rubber septum. After the mixture underwent 3 cycles of vacuum/filling with N<sub>2</sub>, DMF (1.5 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (53 μL, 0.3 mmol) was added. The mixture was then stirred at rt for 16 h. Water was added to quench the reaction, and EtOAc was added for extraction. The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and the resulting residue was purified by silica gel chromatography (eluent: 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, MeOH was presaturated with ammonia gas), giving the titled compound as an off-white solid (53%, 56 mg). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.19 (s, 3H), 2.50 (m, 8H), 2.62 (s, 3H), 3.61 (s, 2H), 7.20 (t, <i>J</i> = 6.8 Hz, 1H), 7.46 (m, 1H), 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.72 (d, <i>J</i> = 9.4 Hz, 1H), 7.75 (d, <i>J</i> = 9.1 Hz, 1H), 7.94 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.08 (s, 1H), 8.09 (d, <i>J</i> = 9.1 Hz, 1H), 8.23 (d, <i>J</i> = 1.9 Hz, 1H), 8.27 (d, <i>J</i> = 1.6 Hz, 1H), 8.63 (d, <i>J</i> = 6.7 Hz, 1H), 10.55 (s, 1H). MS: <i>m</i>/<i>z</i> 532.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-{3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylphenyl}-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)benzamide (<b>19b</b>)</h3><div class="NLM_p last">This was made from the coupling of <b>9c</b> and <b>18b</b> in 20% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.10 (s, 3H), 2.11 (s, 3H), 2.50 (m, 8H), 3.76 (s, 2H), 7.01(m, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (m, 1H), 7.52 (m, 2H), 7.75(d, <i>J</i> = 8.2 Hz, 1H), 7.90 (s, 2H), 8.10 (m, 2H), 8.35 (d, <i>J</i> = 6.6 Hz, 1H), 10.20 (s, 1H). MS: <i>m</i>/<i>z</i> 532.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl}benzamide (<b>19c</b>)</h3><div class="NLM_p last">This was made from the coupling of <b>9c</b> and <b>18c</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> in 68% yield; characterized as HCl salt. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 2.35 (s, 3H), 2.41 (s, 3H), 2.64 (m, 8H), 3.71 (s, 2H), 7.30 (m, 1H), 7.52 (m, 3H), 7.90 (d, <i>J</i> = 9.0 Hz, 1H), 8.05 (dd, <i>J</i> = 1.8 Hz, 1H), 8.20 (m, 2H), 8.32 (s, 1H), 8.51(d, <i>J</i> = 1.6 Hz, 1H), 8.80 (d, <i>J</i> = 6.7 Hz, 1H), 10.60 (s, 1H). MS: <i>m</i>/<i>z</i> 532.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-[4-(4-morpholinylmethyl)-3-(trifluoromethyl)phenyl]benzamide (<b>19d</b>)</h3><div class="NLM_p last">This was made analogously to <b>19a</b> using morpholine instead of <i>N</i>-methylpiperazine in the first step S<sub>N</sub>2 displacement of the reaction sequence depicted in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. <sup>1</sup>H NMR (acetone-<i>d</i><sub>6</sub>): δ 2.46 (t, <i>J</i> = 4.5 Hz, 4H), 2.65 (s, 3H), 3.65 (m, 4H), 7.17 (t, <i>J</i> = 6.8 Hz, 1H), 7.46 (dd, <i>J</i> = 7.3, 7.7 Hz, 1H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.83 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.10 (s, 1H), 8.11 (d, <i>J</i> = 8.1 Hz, 1H), 8.24 (d, <i>J</i> = 1.5 Hz, 1H), 8.29 (s, 1H), 8.67 (d, <i>J</i> = 4.3 Hz, 1H), 9.83 (s, 1H). MS: <i>m</i>/<i>z</i> 518.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-{4-[[(3S)-3-(Dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>19e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.63 (m, 1H), 1.86 (m, 1H), 2.09 (s, 6H), 2.33 (m, 2H), 2.55 (m, 2H), 2.57 (s, 3H), 2.79 (m, 1H), 3.61 (s, 2H), 7.12 (t, <i>J</i> = 6.8 Hz, 1H), 7.40 (dd, <i>J</i> = 7.3, 7.7 Hz, 1H), 7.49 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (d, <i>J</i> = 9.1 Hz, 1H), 7.72 (d, <i>J</i> = 9.4 Hz, 1H), 7.89 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 7.96 (d, <i>J</i> = 9.1 Hz, 1H), 7.99 (s, 1H), 8.11 (d, <i>J</i> = 1.9 Hz, 1H), 8.19 (d, <i>J</i> = 1.6 Hz, 1H), 8.58 (d, <i>J</i> = 6.7 Hz, 1H), 10.49 (s, 1H). MS: <i>m</i>/<i>z</i> 546.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-{4-[(Hexahydro-4-methyl-1<i>H</i>-1,4-diazepin-1-yl)methyl]-3-(trifluoromethyl)-phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>19f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.80 (m, 2H), 2.27 (s, 3H), 2.63 (s, 3H), 2.64 (m, 8H), 3.74 (s, 2H), 7.20 (t, <i>J</i> = 6.8 Hz, 1H), 7.47 (dd, <i>J</i> = 7.3, 7.7 Hz, 1H), 7.57 (d, <i>J</i> = 8.2 Hz, 1H), 7.75 (d, <i>J</i> = 9.1 Hz, 1H), 7.80 (d, <i>J</i> = 9.4 Hz, 1H), 7.96 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.03 (d, <i>J</i> = 9.1 Hz, 1H), 8.06 (s, 1H), 8.18 (d, <i>J</i> = 1.9 Hz, 1H), 8.27 (d, <i>J</i> = 1.6 Hz, 1H), 8.66 (d, <i>J</i> = 6.7 Hz, 1H), 10.56 (s, 1H). MS: <i>m</i>/<i>z</i> 546.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(1-methyl-4-piperidinyl)oxy]-3-(trifluoromethyl)phenyl}benzamide (<b>19g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 1.93 (m, 2H), 2.01 (m, 2H), 2.33 (s, 3H), 2.50 (m, 2H), 2.64 (s, 3H), 2.70 (m, 2H), 4.65 (m, 1H), 7.20 (d, <i>J</i> = 8.2 Hz, 1H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.88 (dd, <i>J</i> = 2.0, 8.1 Hz, 2H), 7.93 (s, 1H), 8.00 (d, <i>J</i> = 2.5 Hz, 1H), 8.18 (d, <i>J</i> = 1.9 Hz, 1H), 8.56 (d, <i>J</i> = 6.8 Hz, 1H).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-{4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>19h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 1.10 (br, 3H), 2.42 (s, 3H), 2.60 (m, 4H), 2.71 (m, 6H), 3.81 (s, 2H), 7.20 (m, 1H), 7.54 (m, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (m, 2H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 8.15 (m, 1H), 8.22 (m, 1H), 8.31 (m, 2H), 8.60 (d, <i>J</i> = 6.6 Hz, 1H), 10.6 (s, 1H). MS: <i>m</i>/<i>z</i> 546.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[[4-(1-methyl)ethylperazin-1-yl]methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>19i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.01 (d, <i>J</i> = 6.8 Hz, 6H), 2.39 (m, 8H), 2.65 (s, 3H), 2.98 (m, 1H), 3.60 (s, 2H), 7.19 (t, <i>J</i> = 6.8 Hz, 1H), 7.47 (dd, <i>J</i> = 7.3, 7.7 Hz, 1H), 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.74 (d, <i>J</i> = 9.1 Hz, 1H), 7.80 (d, <i>J</i> = 9.4 Hz, 1H), 7.95 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.02 (d, <i>J</i> = 9.1 Hz, 1H), 8.05 (s, 1H), 8.18 (d, <i>J</i> = 1.9 Hz, 1H), 8.27 (d, <i>J</i> = 1.6 Hz, 1H), 8.65 (d, <i>J</i> = 6.7 Hz, 1H), 10.55 (s, 1H). MS: <i>m</i>/<i>z</i> 560.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-{4-[(4-(2-Hydroxyethyl)piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>19j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>): δ 2.41 (m, 6H), 2.55 (s, 3H), 2.80 (m, 4H), 3.62 (m, 2H), 3.83 (s, 2H), 7.20 (m, 1H), 7.41 (m, 2H), 7.65 (d, <i>J</i> = 9.1 Hz, 1H) 7.77 (d, <i>J</i> = 9.1 Hz, 1H), 7.81 (m, 3H), 8.05 (d, <i>J</i> = 1.9 Hz, 1H), 8.11 (d, <i>J</i> = 1.9 Hz, 1H), 8.55 (d, <i>J</i> = 6.7 Hz, 1H). MS: <i>m</i>/<i>z</i> 562.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>-{4-[(4-(2-Fluoroethyl)piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methylbenzamide (<b>19k</b>)</h3><div class="NLM_p last">This was made from coupling of <b>9c</b> and <b>18k</b> in 81% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.31 (m, 4H), 2.41 (s, 3H), 2.50 (m, 6H), 3.72 (s, 2H), 4.53 (m, 1H), 4.70 (m, 1H), 7.30 (m, 1H), 7.55 (m, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 1H), 7.81 (m, 2H), 8.10 (d, <i>J</i> = 8.1 Hz, 1H), 8.22 (m, 2H), 8.31 (s, 1H), 8.35 (s, 1H), 8.70 (d, <i>J</i> = 6.6 Hz, 1H), 10.3 (s, 1H). MS: <i>m</i>/<i>z</i> 564.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-[4-(1-piperazinylmethyl)-3-(trifluoromethyl)phenyl]benzamide (<b>19l</b>)</h3><div class="NLM_p last">This was made from coupling of <b>9c</b> and <b>18l</b> followed by standard de-Boc with TFA. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.33 (m, 4H), 2.62 (s, 3H), 2.72 (t, <i>J</i> = 4.5 Hz, 4H), 3.54 (s, 2H), 7.20 (t, <i>J</i> = 6.7 Hz, 1H), 7.47 (dd, <i>J</i> = 6.9, 8.9 Hz, 1H), 7.56 (d, <i>J</i> = 8.0 Hz, 1H), 7.73 (d, <i>J</i> = 3.9 Hz, 1H), 7.76 (d, <i>J</i> = 4.6 Hz, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 8.07 (d, <i>J</i> = 5.1 Hz, 1H), 8.08 (s, 1H), 8.22 (s, 1H), 8.27 (s, 1H), 8.63 (d, <i>J</i> = 6.6 Hz, 1H), 10.54 (s, 1H). MS: <i>m</i>/<i>z</i> 518.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-[2-(Imidazo[1,2-<i>a</i>]pyridin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(3-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>19m</b>)</h3><div class="NLM_p last">Substituted <i>N</i>-benzylpiperazine <b>16m</b> was prepared analogously to <b>16a</b> using 2-methylpiperazine instead of <i>N</i>-methylpiperazine as starting material. Coventional Boc protection (Boc<sub>2</sub>O, DMAP) of <b>16m</b> gave <b>16m′</b> in 69% yield. This was converted to <b>18m</b> similarly to the synthesis of <b>18a</b> from <b>16a</b> except that the reduction of NO<sub>2</sub> to NH<sub>2</sub> was done via hydrogenation on Pd/C in 66% yield. The coupling of <b>9c</b> and <b>18m</b> followed by standard de-Boc with TFA furnished desired product, which was purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.19 (d, <i>J</i> = 6.9 Hz, 3H), 2.15 (t, <i>J</i> = 11.2 Hz, 1H), 2.34 (t, <i>J</i> = 11.3 Hz, 1H), 2.62 (s, 3H), 2.84 (dd, <i>J</i> = 10.9, 11.7 Hz, 2H), 3.02 (d, <i>J</i> = 9.2 Hz, 1H), 3.28 (d, <i>J</i> = 10.4 Hz, 2H), 3.66 (s, 2H), 7.20 (dd, <i>J</i> = 6.5, 6.7 Hz, 1H), 7.48 (dd, <i>J</i> = 6.9, 8.1 Hz, 1H), 7.56 (d, <i>J</i> = 8.1 Hz, 1H), 7.73 (d, <i>J</i> = 7.9 Hz, 1H), 7.76 (d, <i>J</i> = 8.1 Hz, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 8.10 (s, 1H), 8.12 (d, <i>J</i> = 8.6 Hz, 1H), 8.25 (d, <i>J</i> = 9.1 Hz, 2H), 8.50 (br, 1H), 8.63 (d, <i>J</i> = 6.4 Hz, 1H), 8.93 (br, 1H), 10.59 (s, 1H). MS: <i>m</i>/<i>z</i> 532.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 4-Methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)ethynyl]benzamide (<b>20a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.17 (s, 3H), 2.33 (m, 4H), 2.40 (m, 4H), 2.58 (s, 3H), 3.57 (s, 2H), 6.52 (dd, <i>J</i> = 1.8, 3.4 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.57 (dd, <i>J</i> = 2.8, 3.2 Hz, 1H), 7.71 (d, <i>J</i> = 8.4 Hz, 1H), 7.90 (dd, <i>J</i> = 1.8, 7.8 Hz, 1H), 8.07 (dd, <i>J</i> = 1.8, 7.8 Hz, 1H), 8.17 (d, <i>J</i> = 1.8 Hz, 1H), 8.22 (m, 2H), 8.45 (d, <i>J</i> = 2.0 Hz, 1H), 10.51 (s, 3H), 11.93 (s, 3H). MS: <i>m</i>/<i>z</i> 531.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 3-[2-(3H-Imidazo[4,5-<i>b</i>]pyridin-6-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>): δ 2.27 (s, 3H), 2.47 (m, 8H), 2.55 (s, 3H), 3.63 (s, 2H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.61 (m, 1H), 7.75 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (m, 1H), 7.82 (dd, <i>J</i> = 1.8, 8.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.8 Hz, 1H), 8.07 (dd, <i>J</i> = 1.8, 8.9 Hz, 1H), 8.09 (s, 1H), 8.30 (s, 1H), 8.56 (d, <i>J</i> = 1.6 Hz, 1H), 8.88 (br, 1H).</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 4-Methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(2-oxo-2,3-dihydro-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-6-yl)ethynyl]benzamide (<b>20c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.17 (s, 3H), 2.37 (m, 8H), 2.55 (s, 3H), 3.57 (s, 2H), 7.38 (d, <i>J</i> = 1.4 Hz, 1H), 7.51 (d, <i>J</i> = 8.1 Hz, 1H), 7.71 (d, <i>J</i> = 8.6 Hz, 1H), 7.90 (dd, <i>J</i> = 1.8, 8.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.4 Hz, 1H), 8.14 (d, <i>J</i> = 1.7 Hz, 2H), 8.21 (d, <i>J</i> = 1.8 Hz, 1H), 10.50 (s, 1H), 11.03 (s, 1H), 11.61 (s, 1H). MS: <i>m</i>/<i>z</i> 549.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 4-Methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(3-oxo-3,4-dihydro-2<i>H</i>-pyrido[3,2-<i>b</i>][1,4]oxazin-7-yl)ethynyl]benzamide (<b>20d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.16 (s, 3H), 2.34 (m, 4H), 2.39 (m, 4H), 2.55 (s, 3H), 3.57 (s, 2H), 4.70 (d, <i>J</i> = 6.3 Hz, 2H), 7.51 (d, <i>J</i> = 8.2 Hz, 1H), 7.56 (d, <i>J</i> = 1.8 Hz, 1H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.92 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 8.06 (dd, <i>J</i> = 1.7, 8.5 Hz, 1H), 8.15 (d, <i>J</i> = 1.6 Hz, 1H), 8.16 (d, <i>J</i> = 1.9 Hz, 1H), 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 10.52 (s, 1H), 11.51 (s, 1H). MS: <i>m</i>/<i>z</i> 564.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-[2-(Imidazo[1,2-<i>a</i>]pyrimidin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-Methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.16 (s, 3H), 2.34 (m, 4H), 2.40 (m, 4H), 2.62 (s, 3H), 3.57 (s, 2H), 7.31 (dd, <i>J</i> = 4.2, 6.8 Hz, 1H), 7.57 (d, <i>J</i> = 8.2 Hz, 1H), 7.72 (d, <i>J</i> = 8.6 Hz, 1H), 7.95 (dd, <i>J</i> = 1.9, 8.0 Hz, 1H), 8.07 (dd, <i>J</i> = 2.0, 8.4 Hz, 1H), 8.22 (d, <i>J</i> = 2.0 Hz, 1H), 8.23 (s, 1H), 8.28 (d, <i>J</i> = 1.8 Hz, 1H), 8.67 (dd, <i>J</i> = 2.0, 4.1 Hz, 1H), 9.06 (dd, <i>J</i> = 2.0, 6.8 Hz, 1H), 10.54 (s, 1H). MS: <i>m</i>/<i>z</i> 533.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 3-[2-(Imidazo[1,2-<i>a</i>]pyrazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.10 (m, 4H), 2.17 (s, 3H), 2.40 (m, 7H), 3.71 (s, 2H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (d, <i>J</i> = 8.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 8.10 (s, 2H), 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 8.31 (s, 1H), 8.55 (d, <i>J</i> = 4.4 Hz, 1H), 9.10 (s, 1H), 10.50 (s, 1H). MS: <i>m</i>/<i>z</i> 533.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.15 (s, 3H), 2.33 (m, 4H), 2.39 (m, 4H), 2.61 (s, 3H), 3.56 (s, 2H), 7.39 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (dd, <i>J</i> = 1.9, 8.0 Hz, 1H), 8.06 (dd, <i>J</i> = 1.9, 8.5 Hz, 1H), 8.21 (d, <i>J</i> = 1.7 Hz, 2H), 8.23 (s, 1H), 8.25 (dd, <i>J</i> = 1.5, 9.2 Hz, 1H), 8.72 (dd, <i>J</i> = 1.5, 4.4 Hz, 1H), 10.54 (s, 1H). MS: <i>m</i>/<i>z</i> 533.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i>-{4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methylbenzamide (<b>20h</b>)</h3><div class="NLM_p last">Purified as HCl salts. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 2.38 (s, 3H), 3.27 (q, <i>J</i> = 7.2 Hz, 2H), 3.28 (m, 4H), 3.48 (m, 4H), 4.15 (s, 2H), 7.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (dd, <i>J</i> = 4.2, 9.6 Hz, 1H), 7.56 (d, <i>J</i> = 8.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.70 (d, <i>J</i> = 8.8 Hz, 1H), 7.88 (d, <i>J</i> = 9.2 Hz, 2H), 8.02 (s, 1H), 8.09 (d, <i>J</i> = 9.6 Hz, 1H), 8.67 (d, <i>J</i> = 4.4 Hz, 1H).</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i>-{4-[(4-(2-Hydroxyethyl)piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methylbenzamide (<b>20i</b>)</h3><div class="NLM_p last">Purified as HCl salt. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 1.25 (s, 3H), 3.44 (s, 2H), 3.61 (m, 4H), 3.71 (m, 4H), 3.94 (s, 2H), 4.44 (s, 2H), 7.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.54−7.59 (m, 3H), 7.70 (d, <i>J</i> = 8.0 Hz, 1H), 7.74 (s, 1H), 7.88 (s, 1H), 8.02 (s, 1H), 8.10 (d, <i>J</i> = 9.2 Hz, 1H), 8.70 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-[4-(1-piperazinylmethyl)-3-(trifluoromethyl)phenyl}benzamide (<b>20j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.38 (m, 4H), 2.66 (s, 3H), 2.75 (m, 4H), 3.61 (s, 2H), 7.40 (dd, <i>J</i> = 4.4, 9.2 Hz, 1H), 7.58 (d, <i>J</i> = 8.2 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.97 (dd, <i>J</i> = 1.9, 8.0 Hz, 1H), 8.09 (dd, <i>J</i> = 2.0, 8.4 Hz, 1H), 8.15−8.31 (m, 4H), 8.77 (dd, <i>J</i> = 1.5, 4.4 Hz, 1H), 10.59 (s, 1H). MS: <i>m</i>/<i>z</i> 519.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20k</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.17 (s, 3H), 2.37 (m, 8H), 3.57 (s, 2H), 7.40 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.72 (d, <i>J</i> = 8.6 Hz, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 1H), 8.04 (dd, <i>J</i> = 1.2, 9.4 Hz, 1H), 8.07 (d, <i>J</i> = 9.3 Hz, 1H), 8.22 (m, 1H), 8.23 (s, 1H), 8.25 (d, <i>J</i> = 1.6 Hz, 1H), 8.28 (d, <i>J</i> = 1.6 Hz, 1H), 8.73 (dd, <i>J</i> = 1.5, 4.4 Hz, 1H), 10.63 (s, 1H). MS: <i>m</i>/<i>z</i> 519.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4-Chloro-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20l</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.15 (s, 3H), 2.50 (m, 4H), 2.84 (m, 4H), 3.63 (s, 2H), 7.44 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.83 (d, <i>J</i> = 8.5 Hz, 1H), 8.03 (dd, <i>J</i> = 2.2, 8.5 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.28 (s, 1H), 8.29 (dd, <i>J</i> = 1.5, 9.2 Hz, 1H), 8.35 (d, <i>J</i> = 2.1 Hz, 1H), 8.74 (dd, <i>J</i> = 1.4, 4.5 Hz, 1H), 10.68 (s, 1H). MS: <i>m</i>/<i>z</i> 553.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-Fluoro-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>20m</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.20 (s, 3H), 2.50 (m, 8H), 3.59 (s, 2H), 7.43 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 7.59 (dd, <i>J</i> = 8.9, 9.1 Hz, 1H), 7.73 (d, <i>J</i> = 8.7 Hz, 1H), 8.05−8.14 (m, 2H), 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 8.29 (s, 1H), 8.30 (m, 1H), 8.35 (dd, <i>J</i> = 2.2, 6.8 Hz, 1H), 8.75 (dd, <i>J</i> = 1.5, 4.4 Hz, 1H), 10.63 (s, 1H). MS: <i>m</i>/<i>z</i> 537.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>N</i>-{3-Chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methylbenzamide (<b>20n</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.17 (s, 3H), 2.33 (m, 4H), 2.44 (m, 4H), 2.62 (s, 3H), 3.53 (s, 2H), 7.40 (dd, <i>J</i> = 4.5, 9.2 Hz, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (dd, <i>J</i> = 2.1, 9.4 Hz, 1H), 7.94 (dd, <i>J</i> = 1.9, 8.0 Hz, 1H), 7.98 (d, <i>J</i> = 2.0 Hz, 1H), 8.20 (d, <i>J</i> = 1.8 Hz, 1H), 8.24 (s, 1H), 8.27 (dd, <i>J</i> = 1.5, 9.2 Hz, 1H), 8.73 (dd, <i>J</i> = 1.5, 4.4 Hz, 1H), 10.43 (s, 1H).</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-{3-Cyclopropyl-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methylbenzamide (<b>20o</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.60 (m, 2H), 0.94 (m, 2H), 2.20 (s, 3H), 2.25 (m, 1H), 2.27−2.50 (m, 8H), 2.60 (s, 3H), 3.56 (s, 2H), 7.20 (d, <i>J</i> = 8.3 Hz, 1H), 7.34 (d, <i>J</i> = 1.9 Hz, 1H), 7.39 (dd, <i>J</i> = 4.4, 9.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.2 Hz, 1H), 7.61 (d, <i>J</i> = 8.2 Hz, 1H), 7.91 (dd, <i>J</i> = 1.7, 8.2 Hz, 1H), 8.18 (d, <i>J</i> = 1.6 Hz, 1H), 8.23 (s, 1H), 8.26 (dd, <i>J</i> = 1.4, 9.2 Hz, 1H), 8.73 (dd, <i>J</i> = 1.3, 4.4 Hz, 1H), 10.16 (s, 1H).</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-[3-(trifluoromethyl)phenyl] Benzamide (<b>20p</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.52 (d, <i>J</i> = 5.2 Hz, 1 H), 8.22 (s, 1H), 8.10 (s, 1H), 8.07 (d, <i>J</i> = 2.4 Hz, 1H), 8.04 (d, <i>J</i> = 9.2 Hz, 1H), 8.00 (s, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 1H), 7.84 (dd, <i>J</i> = 1.9, 8.0 Hz, 1 H), 7.51 (t, <i>J</i> = 8.1 Hz, 1H), 7.42 (m, 2H), 7.18 (dd, <i>J</i> = 4.8, 5.0 Hz, 1H), 2.65 (s, 3H).</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>24a</b>)</h3><div class="NLM_p last">A tri-HCl salt of <b>20g</b> (400 mg) was dissolved in water (10 mL) and then subjected to hydrogenation under 28 psi for 72 h using 10% wet Pd/C (100 mg) as the catalyst. The catalyst was then removed by filtration, and the filtrate was basified to pH ∼9 with 2 M aq NaOH. Extraction with CH<sub>2</sub>Cl<sub>2</sub> and silica gel column chromatography (eluent: 5% NH<sub>3</sub> presaturated MeOH in CH<sub>2</sub>Cl<sub>2</sub>) followed by recrystallization from EtOH gave the desired product as an off-white solid (240 mg, 70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.36 (d, <i>J</i> = 2.9 Hz, 1H), 7.95 (m, 2H), 7.89 (s, 1H), 7.74 (m, 2H), 7.61 (d, <i>J</i> = 7.9 Hz, 1H), 7.53 (s, 1H), 7.47 (s, 1H), 7.28 (d, <i>J</i> = 9.2 Hz), 7.02 (m, 1H), 3.69 (s, 2H), 3.34 (t, <i>J</i> = 7.8 Hz, 2H), 3.15 (t, <i>J</i> = 7.8 Hz, 2H), 2.67 (m, 6H), 2.48 (m, 2H), 2.42 (s, 3H), 1.27 (s, 3H). MS: <i>m</i>/<i>z</i> 537.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)vinyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (<b>24b</b>)</h3><div class="NLM_p">A solution of <b>18a</b> (189.3 mg, 0.366 mmol), tributyl(vinyl)tin (464.1 mg, 1.464 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (10 mg, 0.01 mmol), and tri(2-furyl)phosphine (18 mg, 0.074 mmol) in dry DMF (4 mL) was degassed with N<sub>2</sub> and then stirred at rt for 15 h. The solvent was evaporated, and the residue was dissolved in EtOAc. Washing with satd aq Na<sub>2</sub>CO<sub>3</sub> followed by evaporation of organic solvents and silica gel column chromatography (eluent: 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) gave substituted styrene <b>23</b> as a white solid (146 mg, 96%).</div><div class="NLM_p last">A suspension of <b>23</b> (146 mg, 0.35 mmol), <b>7d</b> (133 mg, 0.67 mmol), Pd(OAc)<sub>2</sub> (6.4 mg, 0.028 mmol), P(<i>o</i>-tol)<sub>3</sub> (17.4 mg, 0.057 mmol), and (<i>i</i>-Pr)<sub>2</sub>NEt (0.29 mL, 1.39 mmol) in DMF (3 mL) was degassed with N<sub>2</sub> and then heated at 110 °C for 15 h. Upon cooling, the reaction mixture was dilute with CH<sub>2</sub>Cl<sub>2</sub>. After washing with water and evaporation of organic solvents, the residue was purified by silica gel column chromatography (eluent: 5% NH<sub>3</sub> presaturated MeOH in CH<sub>2</sub>Cl<sub>2</sub>), giving a dark-brown solid. Recrystallization from CHCl<sub>3</sub>/ether afforded an off-white solid (50 mg, 25%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.46 (d, <i>J</i> = 3.0 Hz, 1H), 8.20 (d, <i>J</i> = 1.3 Hz, 1H), 8.06 (s, 1H), 8.04 (m, 1H), 8.02−7.97 (m, 2H), 7.93−7.86 (m, 2H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.49 (d, <i>J</i> = 16.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (t, <i>J</i> = 4.5 Hz, 1H), 3.76 (s, 2H), 2.87 (br, 6H), 2.70 (br, 2H), 2.56 (s, 3H), 1.56 (s, 3H). MS: <i>m</i>/<i>z</i> 535.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Modeling Studies</h3><div class="NLM_p last">The binding site model used for Abl docking was based on the X-ray coordinates of Abl bound with imatinib (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>). Protein side chains within a 5 Å radius of the bound ligand were allowed to relax to optimize binding interactions using the Induced Fit protocol in the Schrodinger package.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Docking studies were performed with Glide in the Schrodinger modeling package.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The solution with the best docking score was chosen and used for analysis.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Biological Characterization of Compounds</h3><div class="NLM_p last">In vitro kinase assays were carried out in-house as previously described.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> This assay configuration differed from that used in our previous publication on <b>20g</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> which was a commercial assay from Reaction Biology Corporation.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Cellular proliferation assays were performed as previously described,<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> independently of the data set previously reported for <b>20g</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pharmacokinetic analyses<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> and in vivo efficacy studies<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> were carried out according to previously published procedures.</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41583" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41583" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Sheng Huang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#83f4e6eaaef0ebe6ede4adebf6e2ede4c3e2f1eae2e7ade0ecee"><span class="__cf_email__" data-cfemail="3641535f1b455e535851185e435758517657445f57521855595b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chester A. Metcalf</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raji Sundaramoorthi</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihan Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Zou</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Mathew Thomas</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaotian Zhu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisi Cai</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Wen</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuangying Liu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Romero</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiwei Qi</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ingrid Chen</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geetha Banda</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott P. Lentini</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sasmita Das</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qihong Xu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff Keats</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Wardwell</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yaoyu Ning</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph T. Snodgrass</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc I. Broudy</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Russian</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianjun Zhou</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lois Commodore</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Narayana I. Narasimhan</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qurish K. Mohemmad</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Iuliucci</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor M. Rivera</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Dalgarno</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomi K. Sawyer</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tim Clackson</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William C. Shakespeare</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm100395q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular biology of <i>bcr-abl1</i>-positive chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1182%2Fblood-2008-03-144790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18827185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1619-1630&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Molecular+biology+of+bcr-abl1-positive+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1619-1630</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique mol. event, the BCR-ABL1 oncogene.  Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1.  In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs.  Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood.  Herein, the authors synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPO2wdma5UrVg90H21EOLACvtfcHk0ljjKWOb0Scscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D&md5=bcd7d53c3e06d3b9833fb84799f75ea7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-03-144790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-03-144790%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520biology%2520of%2520bcr-abl1-positive%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1619%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNature%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lj9ECnQf7czCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Dis.%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Imatinib and beyond—exploring the full potential of targeted therapy for CML</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKjsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=535-543&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Imatinib+and+beyond%E2%80%94exploring+the+full+potential+of+targeted+therapy+for+CML"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib and beyond-exploring the full potential of targeted therapy for CML</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">535-543</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib is the std. frontline therapy for patients with chronic myeloid leukemia (CML); however, a substantial no. require alternative therapy owing to imatinib intolerance or imatinib resistance.  Studies have shown that second-generation tyrosine kinase inhibitors are efficacious in restoring cytogenetic responses in patients who require subsequent therapy.  Quintas-Cardama et al. discuss the second-generation and third-generation targeted agents that have restored cytogenetic response in patients unresponsive to imatinib, and the strategies being explored to improve the long-term outcome.  A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy.  Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy.  Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clin. meaningful response.  A third generation of TKIs is currently undergoing clin. testing for use in patients who fail imatinib and a second-generation TKI.  Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I.  The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib.  If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as std. frontline therapy in CML.  Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-pos. CML stem cells.  Efforts aimed at achieving this goal are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUuOUUt2n7NbVg90H21EOLACvtfcHk0ljAKt_5PtYGsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKjsrjP&md5=a57b7dc913159dd58cea142fa7749388</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DImatinib%2520and%2520beyond%25E2%2580%2594exploring%2520the%2520full%2520potential%2520of%2520targeted%2520therapy%2520for%2520CML%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D535%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilhot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiffers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratwohl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span> </span><span class="NLM_article-title">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1056%2FNEJMoa062867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17151364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2408-2417&author=B.+J.+Drukerauthor=F.+Guilhotauthor=S.+G.+O%E2%80%99Brienauthor=I.+Gathmannauthor=H.+Kantarjianauthor=N.+Gattermannauthor=M.+W.+Deiningerauthor=R.+T.+Silverauthor=J.+M.+Goldmanauthor=R.+M.+Stoneauthor=F.+Cervantesauthor=A.+Hochhausauthor=B.+L.+Powellauthor=J.+L.+Gabriloveauthor=P.+Rousselotauthor=J.+Reiffersauthor=J.+J.+Cornelissenauthor=T.+Hughesauthor=H.+Agisauthor=T.+Fischerauthor=G.+Verhoefauthor=J.+Shepherdauthor=G.+Saglioauthor=A.+Gratwohlauthor=J.+L.+Nielsenauthor=J.+P.+Radichauthor=B.+Simonssonauthor=K.+Taylorauthor=M.+Baccaraniauthor=C.+Soauthor=L.+Letvakauthor=R.+A.+Larson&title=Five-year+follow-up+of+patients+receiving+imatinib+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa; Kantarjian, Hagop; Gattermann, Norbert; Deininger, Michael W. N.; Silver, Richard T.; Goldman, John M.; Stone, Richard M.; Cervantes, Francisco; Hochhaus, Andreas; Powell, Bayard L.; Gabrilove, Janice L.; Rousselot, Philippe; Reiffers, Josy; Cornelissen, Jan J.; Hughes, Timothy; Agis, Hermine; Fischer, Thomas; Verhoef, Gregor; Shepherd, John; Saglio, Giuseppe; Gratwohl, Alois; Nielsen, Johan L.; Radich, Jerald P.; Simonsson, Bengt; Taylor, Kerry; Baccarani, Michele; So, Charlene; Letvak, Laurie; Larson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase.  Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase.  For 5 years, we followed patients with CML who received imatinib as initial therapy.  METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematol., cytogenetic, and mol. responses; and adverse events.  RESULTS: The median follow-up was 60 mo.  Kaplan-Meier ests. of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 mo and 87% by 60 mo.  An estd. 7% of patients progressed to accelerated-phase CML or blast crisis, and the estd. overall survival of patients who received imatinib as initial therapy was 89% at 60 mo.  Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P < 0.001).  Grade 3 or 4 adverse events diminished over time, and there was no clin. significant change in the profile of adverse events.  CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgIGWKzVtbrVg90H21EOLACvtfcHk0lghHD_xkNNGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM&md5=7e57245d3a918c079722ce0dcd265f15</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062867%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGabrilove%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DAgis%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DC.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26atitle%3DFive-year%2520follow-up%2520of%2520patients%2520receiving%2520imatinib%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2408%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=BCR-ABL+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBCR-ABL%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+generation+inhibitors+of+BCR-ABL+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0lghHD_xkNNGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520generation%2520inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D345%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0ligJxwb6yymNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3948</span><span class="NLM_x">–</span> <span class="NLM_lpage">3954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3948-3954&author=S.+Kimuraauthor=H.+Naitoauthor=H.+Segawaauthor=J.+Kurodaauthor=T.+Yuasaauthor=K.+Satoauthor=A.+Yokotaauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=E.+Ashiharaauthor=Y.+Nakayaauthor=H.+Naruokaauthor=T.+Wakayamaauthor=K.+Nasuauthor=T.+Asakiauthor=T.+Niwaauthor=K.+Hirabayashiauthor=T.+Maekawa&title=NS-187%2C+a+potent+and+selective+dual+Bcr-Abl%2FLyn+tyrosine+kinase+inhibitor%2C+is+a+novel+agent+for+imatinib-resistant+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DSegawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DYuasa%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNakaya%26aufirst%3DY.%26aulast%3DNaruoka%26aufirst%3DH.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DNasu%26aufirst%3DK.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DNS-187%252C%2520a%2520potent%2520and%2520selective%2520dual%2520Bcr-Abl%252FLyn%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520a%2520novel%2520agent%2520for%2520imatinib-resistant%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3948%26epage%3D3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel Abl kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0ljutB-1WRwviQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520Abl%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS - 354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS+-+354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS%2520-%2520354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0liwRqaRefpYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Puttini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo activity of SKI-606, a novel Src-ABL inhibitor, against imatinib-resistant BCR-ABL+ neoplastic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11314</span><span class="NLM_x">–</span> <span class="NLM_lpage">11322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11314-11322&author=M.+Puttiniauthor=A.+M.+Colucciaauthor=F.+Boschelliauthor=L.+Clerisauthor=E.+Marchesiauthor=A.+Donella-Deanaauthor=S.+Ahmedauthor=S.+Redaelliauthor=R.+Piazzaauthor=V.+Magistroniauthor=F.+Andreoniauthor=L.+Scapozzaauthor=F.+Formelliauthor=C.+Gambacorti-Passerini&title=In+vitro+and+in+vivo+activity+of+SKI-606%2C+a+novel+Src-ABL+inhibitor%2C+against+imatinib-resistant+BCR-ABL%2B+neoplastic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuttini%26aufirst%3DM.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DFormelli%26aufirst%3DF.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520SKI-606%252C%2520a%2520novel%2520Src-ABL%2520inhibitor%252C%2520against%2520imatinib-resistant%2520BCR-ABL%252B%2520neoplastic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11314%26epage%3D11322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+BCR-ABL+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+ABL+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520BCR-ABL%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520ABL%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Deguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodohara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2Fj.leukres.2007.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18191450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Slt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=980-983&author=Y.+Deguchiauthor=S.+Kimuraauthor=E.+Ashiharaauthor=T.+Niwaauthor=K.+Hodoharaauthor=Y.+Fujiyamaauthor=T.+Maekawa&title=Comparison+of+imatinib%2C+dasatinib%2C+nilotinib+and+INNO-406+in+imatinib-resistant+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines</span></div><div class="casAuthors">Deguchi, Yasuyuki; Kimura, Shinya; Ashihara, Eishi; Niwa, Tomoko; Hodohara, Keiko; Fujiyama, Yoshihide; Maekawa, Taira</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">980-983</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We compared the growth-inhibitory effects and inhibition profile of the SRC family kinases (SFKs) of imatinib, dasatinib, nilotinib and INNO-406.  Dasatinib exhibited the strongest potency against BCR-ABL with little selectivity over SFKs.  Nilotinib exhibited a weaker affinity than the other inhibitors, but was highly specific for ABL and may be useful for the treatment of P-glycoprotein overexpressing leukemic cells.  INNO-406 had an intermediate affinity for BCR-ABL between that of dasatinib and nilotinib, and inhibited only SFKs LCK and LYN among SFKs.  Both nilotinib and INNO-406 were potent inhibitors of the dasatinib-resistant T315A, F317L and F317V BCR-ABL mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBQdgPMo2y7Vg90H21EOLACvtfcHk0lhg729Z6mpsTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Slt7Y%253D&md5=cf794bffcdb34ba4556de93069a44a34</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2007.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2007.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DDeguchi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHodohara%26aufirst%3DK.%26aulast%3DFujiyama%26aufirst%3DY.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DComparison%2520of%2520imatinib%252C%2520dasatinib%252C%2520nilotinib%2520and%2520INNO-406%2520in%2520imatinib-resistant%2520cell%2520lines%26jtitle%3DLeuk.%2520Res.%26date%3D2008%26volume%3D32%26spage%3D980%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostagno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marega, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1200%2FJCO.2008.19.8853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19075254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=469-471&author=S.+Redaelliauthor=R.+Piazzaauthor=R.+Rostagnoauthor=V.+Magistroniauthor=P.+Periniauthor=M.+Maregaauthor=C.+Gambacorti-Passeriniauthor=F.+Boschelli&title=Activity+of+bosutinib%2C+dasatinib%2C+and+nilotinib+against+18+imatinib-resistant+BCR%2FABL+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of bosutinib, dusatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Comments</span></div><div class="casAuthors">Redaelli, Sara; Piazza, Rocco; Rostagno, Roberta; Magistroni, Vera; Perini, Pietro; Marega, Manuela; Gambacorti-Passerini, Carlo; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-471</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The treatment of chronic myeloid leukemia (CML) has been radically modified by the discovery, of imatinib, a selective inhibitor of the chimeric protein BCR/ABL that causes the disease.  Patients with Philadelphia-pos. (Ph+) acute lymphoblastic leukemia also benefited from imatinib availability, although to a lesser extent.  In the present study, the activity of the tyrosine kinase inhibitors (TKIs) bosutinib, dasatinib, imatinib, and nilotinib against a panel of 18 mutated forms of BCR/ABL assocd. with imatinib resistance in CML and Ph+ acute lymphoblastic leukemia patients was investigated.  The results revealed differences in the activity spectra of the four TKIs against the 18 BCR/ABL mutations.  The obsd. activity pattern will help physicians develop rational, patient-tailored therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEwo2Cgi3qCLVg90H21EOLACvtfcHk0lhg729Z6mpsTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitF2gtrY%253D&md5=e60ba9e376011236e8a548a3334fc8f5</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.8853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.8853%26sid%3Dliteratum%253Aachs%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DRostagno%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DPerini%26aufirst%3DP.%26aulast%3DMarega%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DActivity%2520of%2520bosutinib%252C%2520dasatinib%252C%2520and%2520nilotinib%2520against%252018%2520imatinib-resistant%2520BCR%252FABL%2520mutants%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D469%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">New BCR-ABL inhibitors in chronic myeloid leukemia: keeping resistance in check</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=865-878&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=New+BCR-ABL+inhibitors+in+chronic+myeloid+leukemia%3A+keeping+resistance+in+check"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNew%2520BCR-ABL%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520keeping%2520resistance%2520in%2520check%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D865%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span> </span><span class="NLM_article-title">ABL tyrosine kinase inhibitors for overriding BCR-ABL/ T315I: from the second to third generation</span> <span class="citation_source-journal">Exp. Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1586%2F14737140.8.9.1387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18759691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1387-1398&author=R.+Tanakaauthor=S.+Kimura&title=ABL+tyrosine+kinase+inhibitors+for+overriding+BCR-ABL%2F+T315I%3A+from+the+second+to+third+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation</span></div><div class="casAuthors">Tanaka, Ruriko; Kimura, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1398</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate.  However, primary and secondary resistance have frequently been reported, particularly in patients with advanced-stage disease.  Point mutations within the Abl kinase domain that interfere with imatinib binding are the most crit. cause of imatinib resistance.  In order to override this resistance, several second generation ATP-competitive Abl TKIs including dasatinib, nilotinib, bosutinib and INNO-406 have been developed.  Despite promising clin. results from these novel Abl TKIs for most mutations, the frequently obsd. mutant T315I is not effectively targeted by any of these agents.  Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks.  In this review, the current status of novel agents for CML treatment is overviewed as follows: pathogenesis and features of CML; imatinib and second-generation Abl TKIs; why Abl TKIs are not effective against T315I; and novel agents that may override the T315I mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHnGTn_O-afbVg90H21EOLACvtfcHk0lhe5sGu8DmOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO&md5=afe3c45934c38478967b259deddd2cb9</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1586%2F14737140.8.9.1387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.8.9.1387%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26atitle%3DABL%2520tyrosine%2520kinase%2520inhibitors%2520for%2520overriding%2520BCR-ABL%252F%2520T315I%253A%2520from%2520the%2520second%2520to%2520third%2520generation%26jtitle%3DExp.%2520Rev.%2520Anticancer%2520Ther.%26date%3D2008%26volume%3D8%26spage%3D1387%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lh2dy66jsP9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0ljPkAdj26XkUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of Abl kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+Abl+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0lhnWgk6tmGenA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520Abl%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chow, C. P.; Cao, J.; Dneprovskaia, E.; Fine, R. M.; Hanna, E.; Hood, J.; Hwang, L.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Palanki, M. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H.</span><span> </span><span class="NLM_article-title">Design and SAR of thiazole-based inhibitors for the ABL-T315I enzyme</span>. <span class="NLM_conf-name">234th ACS National Meeting</span>, <span class="NLM_conf-loc">Boston, MA</span>, <span class="NLM_conf-date">August 19−23, 2007</span>, Abstract MED-358.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chow%2C+C.+P.%3B+Cao%2C+J.%3B+Dneprovskaia%2C+E.%3B+Fine%2C+R.+M.%3B+Hanna%2C+E.%3B+Hood%2C+J.%3B+Hwang%2C+L.%3B+Kang%2C+X.%3B+Klebansky%2C+B.%3B+Lohse%2C+D.%3B+Mak%2C+C.+C.%3B+McPherson%2C+A.%3B+Noronha%2C+G.%3B+Palanki%2C+M.+S.%3B+Pathak%2C+V.+P.%3B+Renick%2C+J.%3B+Soll%2C+R.%3B+Zeng%2C+B.%3B+Zhu%2C+H.+Design+and+SAR+of+thiazole-based+inhibitors+for+the+ABL-T315I+enzyme.+234th+ACS+National+Meeting%2C+Boston%2C+MA%2C+August+19%E2%88%9223%2C+2007%2C+Abstract+MED-358."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DC.%2BP.%26atitle%3DDesign%2520and%2520SAR%2520of%2520thiazole-based%2520inhibitors%2520for%2520the%2520ABL-T315I%2520enzyme" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gontarewicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balabanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummendorf, T. H.</span><span> </span><span class="NLM_article-title">Simultaneous targeting of Aurora kinases and BCR-ABL kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4355</span><span class="NLM_x">–</span> <span class="NLM_lpage">4364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4355-4364&author=A.+Gontarewiczauthor=S.+Balabanovauthor=G.+Kellerauthor=R.+Colomboauthor=A.+Grazianoauthor=E.+Pesentiauthor=D.+Bentenauthor=C.+Bokemeyerauthor=W.+Fiedlerauthor=J.+Mollauthor=T.+H.+Brummendorf&title=Simultaneous+targeting+of+Aurora+kinases+and+BCR-ABL+kinase+by+the+small+molecule+inhibitor+PHA-739358+is+effective+against+imatinib-resistant+BCR-ABL+mutations+including+T315I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGontarewicz%26aufirst%3DA.%26aulast%3DBalabanov%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DBenten%26aufirst%3DD.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DBrummendorf%26aufirst%3DT.%2BH.%26atitle%3DSimultaneous%2520targeting%2520of%2520Aurora%2520kinases%2520and%2520BCR-ABL%2520kinase%2520by%2520the%2520small%2520molecule%2520inhibitor%2520PHA-739358%2520is%2520effective%2520against%2520imatinib-resistant%2520BCR-ABL%2520mutations%2520including%2520T315I%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4355%26epage%3D4364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multi-kinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multi-kinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multi-kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as dual Src/ABL kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">4756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-4756&author=W.-S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+dual+Src%2FABL+kinase+inhibitors+targeting+the+inactive+conformation%3A+design%2C+synthesis%2C+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520dual%2520Src%252FABL%2520kinase%2520inhibitors%2520targeting%2520the%2520inactive%2520conformation%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4743%26epage%3D4756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span> </span><span class="NLM_article-title">Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2009.00905.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19895503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=18-28&author=T.+Zhouauthor=L.+Parillonauthor=W.-S.+Huangauthor=Y.+Wangauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeareauthor=T.+Clacksonauthor=X.+Zhuauthor=D.+C.+Dalgarno&title=Structural+analysis+of+DFG-in+and+DFG-out+dual+Src-Abl+inhibitors+sharing+a+common+vinyl+purine+template"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template</span></div><div class="casAuthors">Zhou, Tianjun; Commodore, Lois; Huang, Wei-Sheng; Wang, Yihan; Sawyer, Tomi K.; Shakespeare, William C.; Clackson, Tim; Zhu, Xiaotian; Dalgarno, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-28</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bcr-Abl is the oncogenic protein tyrosine kinase responsible for chronic myeloid leukemia (CML).  Treatment of the disease with imatinib (Gleevec) often results in drug resistance via kinase mutations at the advanced phases of the disease, which has necessitated the development of new mutation-resistant inhibitors, notably against the T315I gatekeeper mutation.  As part of the authors' efforts to discover such mutation resistant Abl inhibitors, the authors have focused on optimizing purine template kinase inhibitors, leading to the discovery of potent DFG-in and DFG-out series of Abl inhibitors that are also potent Src inhibitors.  Here the authors present crystal structures of Abl bound by two such inhibitors, based on a common N9-arenyl purine, and that represent both DFG-in and -out binding modes.  In each structure the purine template is bound deeply in the adenine pocket and the novel vinyl linker forms a non-classical hydrogen bond to the gatekeeper residue, Thr 315.  Specific template substitutions promote either a DFG-in or -out binding mode, with the kinase binding site adjusting to optimize mol. recognition.  Bcr-Abl T315I mutant kinase is resistant to all currently marketed Abl inhibitors, and is the focus of intense drug discovery efforts.  Notably, the authors' DFG-out inhibitor, AP24163, exhibits modest activity against this mutant, illustrating that this kinase mutant can be inhibited by DFG-out class inhibitors.  Furthermore the authors' DFG-out inhibitor exhibits dual Src-Abl activity, absent from the prototypical DFG-out inhibitor, imatinib as well as its analog, nilotinib.  The data presented here provides structural guidance for the further design of novel potent DFG-out class inhibitors against Src, Abl and Abl T315I mutant kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcsXyX0NgLrbVg90H21EOLACvtfcHk0lgBir4DjLCfmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfP&md5=380bc5982df61ad8402fe0db5ec61d9d</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00905.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00905.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26atitle%3DStructural%2520analysis%2520of%2520DFG-in%2520and%2520DFG-out%2520dual%2520Src-Abl%2520inhibitors%2520sharing%2520a%2520common%2520vinyl%2520purine%2520template%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26spage%3D18%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppress in vitro resistance</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2009.00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=20028401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=223-227&author=M.+Azamauthor=J.+T.+Powersauthor=W.+Einhornauthor=W.-S.+Huangauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=AP24163+inhibits+the+gatekeeper+mutant+of+BCR-ABL+and+suppress+in+vitro+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">AP24163 inhibits the gatekeeper Mutant of BCR-ABL and suppresses in vitro resistance</span></div><div class="casAuthors">Azam, Mohammad; Powers, John T.; Einhorn, William; Huang, Wei-Sheng; Shakespeare, William C.; Zhu, Xiaotian; Dalgarno, David; Clackson, Tim; Sawyer, Tomi K.; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia.  The second generation BCR/ABL inhibitors nilotinib and dasatinib effectively inhibit most imatinib resistance variants, but are ineffective against the gatekeeper mutant, T315I.  Gatekeeper mutation activates the kinase by stabilizing the hydrophobic spine.  Here, we describe that the rationally designed compd. AP24163 can inhibit native and gatekeeper mutants of the BCR/ABL kinase.  Structural modeling suggests that AP24163 affects the flexibility of the P-loop and destabilizes the active conformation by disrupting the hydrophobic spine.  In vitro screening for drug resistance identified clones with compd. mutations involving both the P-loop and T315I.  Our studies provide structural insights for the design of inhibitors against the gatekeeper mutant and suggest that up-front combination therapy may be required to prevent the emergence of compd.-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxnyZvn4pGQ7Vg90H21EOLACvtfcHk0lgBir4DjLCfmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVSguw%253D%253D&md5=4e9674ecae74ed04ae30719899d93507</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DJ.%2BT.%26aulast%3DEinhorn%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DAP24163%2520inhibits%2520the%2520gatekeeper%2520mutant%2520of%2520BCR-ABL%2520and%2520suppress%2520in%2520vitro%2520resistance%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26spage%3D223%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Joshi, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksebati, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drach, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemlicka, J.</span><span> </span><span class="NLM_article-title">Synthesis, transformations and biological activity of chloro enamines and ynamines derived from chloroalkenyl- and alkynyl-<i>N</i>-substituted purine and pyrimidine bases of nucleic acids</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=1089-1098&author=R.+V.+Joshiauthor=Z.-Q.+Xuauthor=M.+B.+Ksebatiauthor=D.+Kesselauthor=T.+H.+Corbettauthor=J.+C.+Drachauthor=J.+Zemlicka&title=Synthesis%2C+transformations+and+biological+activity+of+chloro+enamines+and+ynamines+derived+from+chloroalkenyl-+and+alkynyl-N-substituted+purine+and+pyrimidine+bases+of+nucleic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DR.%2BV.%26aulast%3DXu%26aufirst%3DZ.-Q.%26aulast%3DKsebati%26aufirst%3DM.%2BB.%26aulast%3DKessel%26aufirst%3DD.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DDrach%26aufirst%3DJ.%2BC.%26aulast%3DZemlicka%26aufirst%3DJ.%26atitle%3DSynthesis%252C%2520transformations%2520and%2520biological%2520activity%2520of%2520chloro%2520enamines%2520and%2520ynamines%2520derived%2520from%2520chloroalkenyl-%2520and%2520alkynyl-N-substituted%2520purine%2520and%2520pyrimidine%2520bases%2520of%2520nucleic%2520acids%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1994%26spage%3D1089%26epage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Chinchilla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, C.</span><span> </span><span class="NLM_article-title">The Sonogashira reaction: a booming methodology in synthetic organic chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr050992x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=874-922&author=R.+Chinchillaauthor=C.+Najera&title=The+Sonogashira+reaction%3A+a+booming+methodology+in+synthetic+organic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Sonogashira reaction: a booming methodology in synthetic organic chemistry</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">874-922</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The palladium-catalyzed sp2-sp coupling reaction between aryl or alkenyl halides or triflates and terminal alkynes, with or without the presence of copper(I) cocatalyst, was reviewed.  The mechanism of Sonogashira reaction was discussed, and the catalysts and reaction conditions were explored as well.  In addn., the application of Sonogashira cross-coupling reaction was also introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ8ePd8RdbSrVg90H21EOLACvtfcHk0lgEXHL-l_Et6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWjtbc%253D&md5=91f627efbf940c60809c2acfe597d3b7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcr050992x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr050992x%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DNajera%26aufirst%3DC.%26atitle%3DThe%2520Sonogashira%2520reaction%253A%2520a%2520booming%2520methodology%2520in%2520synthetic%2520organic%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D874%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hand, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smakula, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, W.</span><span> </span><span class="NLM_article-title">Teleamination of the imidazo[1,2-<i>a</i>]pyridine system</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2900</span><span class="NLM_x">–</span> <span class="NLM_lpage">2906</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00408a033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1978&pages=2900-2906&author=E.+Handauthor=P.+Smakulaauthor=W.+William&title=Teleamination+of+the+imidazo%5B1%2C2-a%5Dpyridine+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjo00408a033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00408a033%26sid%3Dliteratum%253Aachs%26aulast%3DHand%26aufirst%3DE.%26aulast%3DSmakula%26aufirst%3DP.%26aulast%3DWilliam%26aufirst%3DW.%26atitle%3DTeleamination%2520of%2520the%2520imidazo%255B1%252C2-a%255Dpyridine%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1978%26volume%3D43%26spage%3D2900%26epage%3D2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">An efficient synthesis of nilotinib (AMN107)</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1055%2Fs-2007-983754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=2121-2124&author=W.-S.+Huangauthor=W.+C.+Shakespeare&title=An+efficient+synthesis+of+nilotinib+%28AMN107%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of nilotinib (AMN107)</span></div><div class="casAuthors">Huang, Wei-Sheng; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2121-2124</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A concise synthesis of AMN107, a compd. currently undergoing several phase II/III clin. trials for chronic myelogenous leukemia, is described.  The new procedure reduces the no. of synthetic steps from eight to four, with an overall yield of 65%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVk1pQeYvBWbVg90H21EOLACvtfcHk0lgEXHL-l_Et6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D&md5=4ca31907c33acd3510b7dcfa4e70374c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-983754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-983754%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520nilotinib%2520%2528AMN107%2529%26jtitle%3DSynthesis%26date%3D2007%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ding, Q.; Gray, N. S.; Li, B.; Liu, Y.; Sim, T.; Uno, T.; Zhang, G.; Pissot-Soldermann, C.; Breitenstein, W.; Bold, G.; Caravatti, G.; Furet, P.; Guagnano, V.; Lang, M.; Manley, P. W.; Schoepfer, J.; Spanka, C.</span><span> </span><span class="NLM_article-title">Preparation of pyrimidine urea derivatives as kinase inhibitors for use against proliferative diseases</span>. PCT Int. Appl. WO 2006000420,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Q.+Ding&author=N.+S.+Gray&author=B.+Li&author=Y.+Liu&author=T.+Sim&author=T.+Uno&author=G.+Zhang&author=C.+Pissot-Soldermann&author=W.+Breitenstein&author=G.+Bold&author=G.+Caravatti&author=P.+Furet&author=V.+Guagnano&author=M.+Lang&author=P.+W.+Manley&author=J.+Schoepfer&author=C.+Spanka&title=Preparation+of+pyrimidine+urea+derivatives+as+kinase+inhibitors+for+use+against+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520pyrimidine%2520urea%2520derivatives%2520as%2520kinase%2520inhibitors%2520for%2520use%2520against%2520proliferative%2520diseases%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Bold, G.; Caravatti, G.; Floersheimer, A.; Guagnano, V.; Imbach, P.; Masuya, K.; Roesel, J.; Vaupel, A.; Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Diaryl urea derivatives, particularly <i>N</i>-[4-(pyrimidin-4-yloxy)phenyl]-<i>N</i>′-phenylureas, useful in the treatment of protein kinase dependent diseases, especially neoplasm, and their preparation</span>. PCT Int. Appl. WO 2005051366,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+Bold&author=G.+Caravatti&author=A.+Floersheimer&author=V.+Guagnano&author=P.+Imbach&author=K.+Masuya&author=J.+Roesel&author=A.+Vaupel&author=C.+Garcia-Echeverria&title=Diaryl+urea+derivatives%2C+particularly+N-%5B4-%28pyrimidin-4-yloxy%29phenyl%5D-N%E2%80%B2-phenylureas%2C+useful+in+the+treatment+of+protein+kinase+dependent+diseases%2C+especially+neoplasm%2C+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3DDiaryl%2520urea%2520derivatives%252C%2520particularly%2520N-%255B4-%2528pyrimidin-4-yloxy%2529phenyl%255D-N%25E2%2580%25B2-phenylureas%252C%2520useful%2520in%2520the%2520treatment%2520of%2520protein%2520kinase%2520dependent%2520diseases%252C%2520especially%2520neoplasm%252C%2520and%2520their%2520preparation%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Chaffee, S. C.; Albrecht, B. K.; Hodous, B. L.; Martin, M. W.; McGowan, D. C.; Dimauro, E. F.; Reddy, G.; Cee, V. J.; Olivieri, P. R.; Reed, A.; Romero, K.</span><span> </span><span class="NLM_article-title">Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy</span>. PCT Int. Appl. WO 2006044823,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+C.+Chaffee&author=B.+K.+Albrecht&author=B.+L.+Hodous&author=M.+W.+Martin&author=D.+C.+McGowan&author=E.+F.+Dimauro&author=G.+Reddy&author=V.+J.+Cee&author=P.+R.+Olivieri&author=A.+Reed&author=K.+Romero&title=Heteroaryl-substituted+alkyne+compounds+as+protein+kinase+inhibitors%2C+their+preparation%2C+pharmaceutical+compositions%2C+and+use+in+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26atitle%3DHeteroaryl-substituted%2520alkyne%2520compounds%2520as%2520protein%2520kinase%2520inhibitors%252C%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520in%2520therapy%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I ABL mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+ABL+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520ABL%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lhgdDdw4MuEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Analysis of the structural basis of specificity of inhibition of the ABL kinase by STI571</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">32214</span><span class="NLM_x">–</span> <span class="NLM_lpage">32219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32214-32219&author=A.+S.+Corbinauthor=E.+Buchdungerauthor=F.+Pascalauthor=B.+J.+Druker&title=Analysis+of+the+structural+basis+of+specificity+of+inhibition+of+the+ABL+kinase+by+STI571"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DPascal%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520basis%2520of%2520specificity%2520of%2520inhibition%2520of%2520the%2520ABL%2520kinase%2520by%2520STI571%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D32214%26epage%3D32219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2FS0092-8674%2803%2900190-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12654249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=831-843&author=M.+Azamauthor=R.+R.+Latekauthor=G.+Q.+Daley&title=Mechanisms+of+autoinhibition+and+STI-571%2Fimatinib+resistance+revealed+by+mutagenesis+of+BCR-ABL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL</span></div><div class="casAuthors">Azam, Mohammad; Latek, Robert R.; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">831-843</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl fusion protein kinase causes chronic myeloid leukemia and is targeted by the signal transduction inhibitor STI-571/Gleevec/imatinib (STI-571).  Sequencing of the BCR-ABL gene in patients who have relapsed after STI-571 chemotherapy has revealed a limited set of kinase domain mutations that mediate drug resistance.  To obtain a more comprehensive survey of the amino acid substitutions that confer STI-571 resistance, we performed an in vitro screen of randomly mutagenized BCR-ABL and recovered all of the major mutations previously identified in patients and numerous others that illuminate novel mechanisms of acquired drug resistance.  Structural modeling implies that a novel class of variants acts allosterically to destabilize the autoinhibited conformation of the ABL kinase to which STI-571 preferentially binds.  This screening strategy is a paradigm applicable to a growing list of target-directed anti-cancer agents and provides a means of anticipating the drug-resistant amino acid substitutions that are likely to be clin. problematic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkB-4Z31c31bVg90H21EOLACvtfcHk0lhgdDdw4MuEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVWjsbY%253D&md5=eb949f0f59c31b5c821eba8931fcf4ce</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900190-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900190-9%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DMechanisms%2520of%2520autoinhibition%2520and%2520STI-571%252Fimatinib%2520resistance%2520revealed%2520by%2520mutagenesis%2520of%2520BCR-ABL%26jtitle%3DCell%26date%3D2003%26volume%3D112%26spage%3D831%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Facile synthesis of 9-(arenethenyl)purines via Heck reaction of 9-vinylpurines and aryl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7388</span><span class="NLM_x">–</span> <span class="NLM_lpage">7391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7388-7391&author=W.-S.+Huangauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=D.+Wenauthor=S.+Liuauthor=S.+P.+Lentiniauthor=S.+Dasauthor=G.+Bandaauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=Facile+synthesis+of+9-%28arenethenyl%29purines+via+Heck+reaction+of+9-vinylpurines+and+aryl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DFacile%2520synthesis%2520of%25209-%2528arenethenyl%2529purines%2520via%2520Heck%2520reaction%2520of%25209-vinylpurines%2520and%2520aryl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7388%26epage%3D7391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgaAT-cHXfvXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Horio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2712</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2712-2717&author=T.+Horioauthor=T.+Hamasakiauthor=T.+Inoueauthor=T.+Wakayamaauthor=S.+Itouauthor=H.+Naitoauthor=T.+Asakiauthor=H.+Hayaseauthor=T.+Niwa&title=Structural+factors+contributing+to+the+Abl%2FLyn+dual+inhibitory+activity+of+3-substituted+benzamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DHamasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHayase%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DStructural%2520factors%2520contributing%2520to%2520the%2520Abl%252FLyn%2520dual%2520inhibitory%2520activity%2520of%25203-substituted%2520benzamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2712%26epage%3D2717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_publisher-name">Daylight Chemical Information System, Inc.</span><a href="http://www.daylight.com" class="extLink">http://www.daylight.com</a>. Accessed November 2005.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight+Chemical+Information+System%2C+Inc.http%3A%2F%2Fwww.daylight.com.+Accessed+November+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26pub%3DDaylight%2520Chemical%2520Information%2520System%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+ABL-kinase%3A+phenylaminopyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520ABL-kinase%253A%2520phenylaminopyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskenvesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimpilainen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brethon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccersley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjorth-Hansen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoglund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klamova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brito-Babapulle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span> </span><span class="NLM_article-title">Dasatinib crosses the blood−brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1005-1012&author=K.+Porkkaauthor=P.+Koskenvesaauthor=T.+Lundanauthor=J.+Rimpilainenauthor=S.+Mustjokiauthor=R.+Smyklaauthor=R.+Wildauthor=R.+Luoauthor=M.+Arnanauthor=B.+Brethonauthor=L.+Eccersleyauthor=H.+Hjorth-Hansenauthor=M.+Hoglundauthor=H.+Klamovaauthor=H.+Knutsenauthor=S.+Parikhauthor=E.+Raffouxauthor=F.+Gruberauthor=F.+Brito-Babapulleauthor=H.+Dombretauthor=R.+F.+Duarteauthor=E.+Elonenauthor=R.+Paquetteauthor=C.+M.+Zwaanauthor=F.+Y.+F.+Lee&title=Dasatinib+crosses+the+blood%E2%88%92brain+barrier+and+is+an+efficient+therapy+for+central+nervous+system+Philadelphia+chromosome-positive+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DKoskenvesa%26aufirst%3DP.%26aulast%3DLundan%26aufirst%3DT.%26aulast%3DRimpilainen%26aufirst%3DJ.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DSmykla%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DArnan%26aufirst%3DM.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DEccersley%26aufirst%3DL.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DHoglund%26aufirst%3DM.%26aulast%3DKlamova%26aufirst%3DH.%26aulast%3DKnutsen%26aufirst%3DH.%26aulast%3DParikh%26aufirst%3DS.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DF.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DElonen%26aufirst%3DE.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DZwaan%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26atitle%3DDasatinib%2520crosses%2520the%2520blood%25E2%2588%2592brain%2520barrier%2520and%2520is%2520an%2520efficient%2520therapy%2520for%2520central%2520nervous%2520system%2520Philadelphia%2520chromosome-positive%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1005%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruthardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=306-314&author=A.+Yokotaauthor=S.+Kimuraauthor=S.+Masudaauthor=E.+Ashiharaauthor=J.+Kurodaauthor=K.+Satoauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=Y.+Deguchiauthor=Y.+Urasakiauthor=Y.+Teruiauthor=M.+Ruthardtauthor=T.+Uedaauthor=K.+Hatakeauthor=K.-i.+Inuiauthor=T.+Maekawa&title=INNO-406%2C+a+novel+BCR-ABL%2FLyn+dual+tyrosine+kinase+inhibitor%2C+suppresses+the+growth+of+Ph%2B+leukemia+cells+in+the+central+nervous+system%2C+and+cyclosporine+A+augments+its+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DDeguchi%26aufirst%3DY.%26aulast%3DUrasaki%26aufirst%3DY.%26aulast%3DTerui%26aufirst%3DY.%26aulast%3DRuthardt%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DHatake%26aufirst%3DK.%26aulast%3DInui%26aufirst%3DK.-i.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DINNO-406%252C%2520a%2520novel%2520BCR-ABL%252FLyn%2520dual%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520Ph%252B%2520leukemia%2520cells%2520in%2520the%2520central%2520nervous%2520system%252C%2520and%2520cyclosporine%2520A%2520augments%2520its%2520in%2520vivo%2520activity%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D306%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beppu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erben, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span> </span><span class="NLM_article-title">Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4204</span><span class="NLM_x">–</span> <span class="NLM_lpage">4210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1200%2FJCO.2009.21.8230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19652056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4204-4210&author=T.+Hughesauthor=G.+Saglioauthor=S.+Branfordauthor=S.+Soveriniauthor=D.-W.+Kimauthor=M.+C.+Mullerauthor=G.+Martinelliauthor=J.+Cortesauthor=L.+Beppuauthor=E.+Gottardiauthor=D.+Kimauthor=P.+Erbenauthor=Y.+Shouauthor=A.+Haqueauthor=N.+Gallagherauthor=J.+Radichauthor=A.+Hochhaus&title=Impact+of+baseline+BCR-ABL+mutations+on+response+to+nilotinib+in+patients+with+chronic+myeloid+leukemia+in+chronic+phase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase</span></div><div class="casAuthors">Hughes, Timothy; Saglio, Giuseppe; Branford, Susan; Soverini, Simona; Kim, Dong-Wook; Muller, Martin C.; Martinelli, Giovanni; Cortes, Jorge; Beppu, Lan; Gottardi, Enrico; Kim, Dongho; Erben, Philipp; Shou, Yaping; Haque, Ariful; Gallagher, Neil; Radich, Jerald; Hochhaus, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4204-4210</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy.  In this subanal. of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed.  Patients and Methods: Baseline mutation data were assessed in 281 (88%) of 321 patients with CML-CP in the phase II nilotinib registration trial.  Results: Among imatinib-resistant patients, the frequency of mutations at baseline was 55%.  After 12 mo of therapy, major cytogenetic response (MCyR) was achieved in 60%, complete cytogenetic response (CCyR) in 40%, and major mol. response (MMR) in 29% of patients without baseline mutations vs. 49% (P = .145), 32% (P = .285), and 22% (P = .366), resp., of patients with mutations.  Responses in patients who harbored mutations with high in vitro sensitivity to nilotinib (50% inhibitory concn. [IC50] ≤ 150 nM) or mutations with unknown nilotinib sensitivity were equiv. to those responses for patients without mutations (not significant).  Patients with mutations that were less sensitive to nilotinib in vitro (IC50 > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, resp., achieved MCyR; none achieved CCyR.  Conclusion: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response.  However, mutational status at baseline may influence response.  Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be assocd. with less favorable responses to nilotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6idp3ScsGrVg90H21EOLACvtfcHk0lhjdyV0saL5LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrF&md5=dcffe456f1084d39ad2941fc9b683e69</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.21.8230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.21.8230%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBeppu%26aufirst%3DL.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DErben%26aufirst%3DP.%26aulast%3DShou%26aufirst%3DY.%26aulast%3DHaque%26aufirst%3DA.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DRadich%26aufirst%3DJ.%26aulast%3DHochhaus%26aufirst%3DA.%26atitle%3DImpact%2520of%2520baseline%2520BCR-ABL%2520mutations%2520on%2520response%2520to%2520nilotinib%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520in%2520chronic%2520phase%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4204%26epage%3D4210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">For other examples using the acetylene linker in kinase inhibitor design:</p></div><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061112p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=627-640&author=V.+J.+Ceeauthor=B.+K.+Albrechtauthor=S.+Geuns-Meyerauthor=P.+Hughesauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=B.+L.+Hodousauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=D.+McGowanauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=D.+Powersauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Alkynylpyrimidine+amide+derivatives+as+potent%2C+selective%2C+and+orally+active+inhibitors+of+Tie-2+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1021%2Fjm061112p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061112p%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DAlkynylpyrimidine%2520amide%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520inhibitors%2520of%2520Tie-2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D627%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hartung, I.; Bothe, U.; Kettschau, G.; Luecking, U.; Mengel, A.; Krueger, M.; Thierauch, K. H.; Lienau, P; Boemer, U.</span><span> </span><span class="NLM_article-title">Alkynylpyrimidines as Tie2 kinase inhibitors</span>. PCT Int. Appl. WO 2008155140,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Hartung&author=U.+Bothe&author=G.+Kettschau&author=U.+Luecking&author=A.+Mengel&author=M.+Krueger&author=K.+H.+Thierauch&author=P+Lienau&author=U.+Boemer&title=Alkynylpyrimidines+as+Tie2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartung%26aufirst%3DI.%26atitle%3DAlkynylpyrimidines%2520as%2520Tie2%2520kinase%2520inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jones, C. D.; Luke, R. W. A.; Mccoull, W.</span><span> </span><span class="NLM_article-title">Preparation of ethynylpyrimidine derivatives as Tie2 receptor tyrosine kinase inhibitors for the treatment of cancer</span>. PCT Int. Appl. WO 2006103449,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+D.+Jones&author=R.+W.+A.+Luke&author=W.+Mccoull&title=Preparation+of+ethynylpyrimidine+derivatives+as+Tie2+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26atitle%3DPreparation%2520of%2520ethynylpyrimidine%2520derivatives%2520as%2520Tie2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Askew, B. C.; Brugger, N.; Lan, R.; Sutton, A.</span><span> </span><span class="NLM_article-title">Pyrrolopyridine and thienopyrimidine derivatives as protein kinase inhibitors useful in the treatment of various diseases and their preparation</span>. PCT Int. Appl. WO 2009094123,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+C.+Askew&author=N.+Brugger&author=R.+Lan&author=A.+Sutton&title=Pyrrolopyridine+and+thienopyrimidine+derivatives+as+protein+kinase+inhibitors+useful+in+the+treatment+of+various+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAskew%26aufirst%3DB.%2BC.%26atitle%3DPyrrolopyridine%2520and%2520thienopyrimidine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%2520useful%2520in%2520the%2520treatment%2520of%2520various%2520diseases%2520and%2520their%2520preparation%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Vaisburg, A.; Moradei, O.; Frechette, S.; Saavedra, O.; Isakovic, L.; Raeppel, S.; Gaudette, F.</span><span> </span><span class="NLM_article-title">Preparation of inhibitors of kinase activity with 1,2-di-cyclyl substituted alkynes</span>. PCT Int. Appl. WO 2009100536,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Vaisburg&author=O.+Moradei&author=S.+Frechette&author=O.+Saavedra&author=L.+Isakovic&author=S.+Raeppel&author=F.+Gaudette&title=Preparation+of+inhibitors+of+kinase+activity+with+1%2C2-di-cyclyl+substituted+alkynes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520inhibitors%2520of%2520kinase%2520activity%2520with%25201%252C2-di-cyclyl%2520substituted%2520alkynes%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span>NCT00660920, <a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>. Accessed January 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT00660920%2C+http%3A%2F%2Fwww.clinicaltrials.gov.+Accessed+January+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span>Reaction Biology Corporation, <a href="http://www.reactionbiology.com" class="extLink">http://www.reactionbiology.com</a>. Accessed August 2009.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Reaction+Biology+Corporation%2C+http%3A%2F%2Fwww.reactionbiology.com.+Accessed+August+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teleha, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span> </span><span class="NLM_article-title">Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1729</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0497949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1729-1744&author=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=Q.+Hanauthor=D.+J.+P.+Pintoauthor=M.+Y.+Heauthor=R.+Liauthor=C.+D.+Ellisauthor=C.+G.+Clarkauthor=C.+A.+Telehaauthor=J.-H.+Sunauthor=R.+S.+Alexanderauthor=S.+Baiauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=P.+C.+Wongauthor=R.+R.+Wexler&title=Discovery+of+1-%283%E2%80%B2-Aminobenzisoxazol-5%E2%80%B2-yl%29-3-trifluoromethyl-N-%5B2-fluoro-4-+%5B%282%E2%80%B2-dimethylaminomethyl%29imidazol-1-yl%5Dphenyl%5D-1H-pyrazole-5-carboxyamide+Hydrochloride+%28Razaxaban%29%2C+a+Highly+Potent%2C+Selective%2C+and+Orally+Bioavailable+Factor+Xa+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span></div><div class="casAuthors">Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1729-1744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein.  Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding.  The SAR and pharmacokinetic profile of this series of compds. is described.  These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa.  On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compd. was selected for clin. development as razaxaban (DPC 906, BMS-561389).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSs9m3fldmGbVg90H21EOLACvtfcHk0liLuur4-mPaBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D&md5=c16a8d1ca98191a873f2e53cb0c5678c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0497949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497949%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DC.%2BD.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DTeleha%26aufirst%3DC.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DDiscovery%2520of%25201-%25283%25E2%2580%25B2-Aminobenzisoxazol-5%25E2%2580%25B2-yl%2529-3-trifluoromethyl-N-%255B2-fluoro-4-%2520%255B%25282%25E2%2580%25B2-dimethylaminomethyl%2529imidazol-1-yl%255Dphenyl%255D-1H-pyrazole-5-carboxyamide%2520Hydrochloride%2520%2528Razaxaban%2529%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Factor%2520Xa%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1729%26epage%3D1744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0li_3Nh3p29vXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b','cit13c','cit13d'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41a','cit41b','cit41c','cit41d','cit41e'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 211 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Dongfeng Zhang, Peng Li, Yongxin Gao, Yaoyao Song, Yaqin Zhu, Hong Su, Beibei Yang, Li Li, Gang Li, Ningbo Gong, Yang Lu, Huanjie Shao, Chunrong Yu, <span class="NLM_string-name hlFld-ContribAuthor">Haihong Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7434-7452. <a href="https://doi.org/10.1021/acs.jmedchem.1c00082" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BCandidate%252BContaining%252Ban%252B%252528S%252529-3%25252C3-Difluoro-1-%2525284-methylpiperazin-1-yl%252529-2%25252C3-dihydro-1H-inden%252BScaffold%252Bas%252Ba%252BHighly%252BPotent%252BPan-Inhibitor%252Bof%252Bthe%252BBCR-ABL%252BKinase%252BIncluding%252Bthe%252BT315I-Resistant%252BMutant%252Bfor%252Bthe%252BTreatment%252Bof%252BChronic%252BMyeloid%252BLeukemia%26aulast%3DZhang%26aufirst%3DDongfeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17012021%26date%3D20052021%26volume%3D64%26issue%3D11%26spage%3D7434%26epage%3D7452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Charlotte Juillet, Ludmila Ermolenko, Dina Boyarskaya, Blandine Baratte, Béatrice Josselin, Hristo Nedev, Stéphane Bach, Bogdan I. Iorga, Jérôme Bignon, Sandrine Ruchaud, <span class="NLM_string-name hlFld-ContribAuthor">Ali Al-Mourabit</span>. </span><span class="cited-content_cbyCitation_article-title">From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 1197-1219. <a href="https://doi.org/10.1021/acs.jmedchem.0c02064" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02064%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BSynthetic%252BSimplified%252BMarine%252BMetabolite%252BAnalogues%252Bto%252BNew%252BSelective%252BAllosteric%252BInhibitor%252Bof%252BAurora%252BB%252BKinase%26aulast%3DJuillet%26aufirst%3DCharlotte%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27112020%26date%3D08012021%26volume%3D64%26issue%3D2%26spage%3D1197%26epage%3D1219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yiqing Yang, Hongying Gao, Xiuyun Sun, Yonghui Sun, Yueping Qiu, Qinjie Weng, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8567-8583. <a href="https://doi.org/10.1021/acs.jmedchem.0c00967" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00967%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGlobal%252BPROTAC%252BToolbox%252Bfor%252BDegrading%252BBCR%2525E2%252580%252593ABL%252BOvercomes%252BDrug-Resistant%252BMutants%252Band%252BAdverse%252BEffects%26aulast%3DYang%26aufirst%3DYiqing%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06062020%26date%3D23072020%26date%3D13072020%26volume%3D63%26issue%3D15%26spage%3D8567%26epage%3D8583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bruno A. Martek, Martin Gazvoda, Damijana Urankar, <span class="NLM_string-name hlFld-ContribAuthor">Janez Košmrlj</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Homogeneous Copper-Free Sonogashira Reaction through a Prism of Pd–Pd Transmetalation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (13)
                                     , 4938-4943. <a href="https://doi.org/10.1021/acs.orglett.0c01227" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01227%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDesigning%252BHomogeneous%252BCopper-Free%252BSonogashira%252BReaction%252Bthrough%252Ba%252BPrism%252Bof%252BPd%2525E2%252580%252593Pd%252BTransmetalation%26aulast%3DMartek%26aufirst%3DBruno%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06042020%26date%3D07052020%26volume%3D22%26issue%3D13%26spage%3D4938%26epage%3D4943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylene Group, Friend or Foe in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5625-5663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAcetylene%252BGroup%25252C%252BFriend%252Bor%252BFoe%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D29092019%26date%3D19022020%26date%3D07022020%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven J. Mansfield, Russell C. Smith, Jonathan R. J. Yong, Olivia L. Garry, <span class="NLM_string-name hlFld-ContribAuthor">Edward A. Anderson</span>. </span><span class="cited-content_cbyCitation_article-title">A General Copper-Catalyzed Synthesis of Ynamides from 1,2-Dichloroenamides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2918-2922. <a href="https://doi.org/10.1021/acs.orglett.9b00971" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00971</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00971%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BGeneral%252BCopper-Catalyzed%252BSynthesis%252Bof%252BYnamides%252Bfrom%252B1%25252C2-Dichloroenamides%26aulast%3DMansfield%26aufirst%3DSteven%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19032019%26date%3D03042019%26volume%3D21%26issue%3D8%26spage%3D2918%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen Philip, Malika Kumarasiri, Theodosia Teo, Mingfeng Yu, <span class="NLM_string-name hlFld-ContribAuthor">Shudong Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5073-5092. <a href="https://doi.org/10.1021/acs.jmedchem.7b00901" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00901%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclin-Dependent%252BKinase%252B8%25253A%252BA%252BNew%252BHope%252Bin%252BTargeted%252BCancer%252BTherapy%25253F%26aulast%3DPhilip%26aufirst%3DStephen%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D19062017%26date%3D09012018%26date%3D21122017%26volume%3D61%26issue%3D12%26spage%3D5073%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masato Yoshikawa, Morihisa Saitoh, Taisuke Katoh, Tomohiro Seki, Simone V. Bigi, Yuji Shimizu, Tsuyoshi Ishii, Takuro Okai, Masako Kuno, Harumi Hattori, Etsuro Watanabe, Kumar S. Saikatendu, Hua Zou, Masanori Nakakariya, Takayuki Tatamiya, Yoshihisa Nakada, <span class="NLM_string-name hlFld-ContribAuthor">Takatoshi Yogo</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure–Kinetic Relationships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2384-2409. <a href="https://doi.org/10.1021/acs.jmedchem.7b01647" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01647%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B7-Oxo-2%25252C4%25252C5%25252C7-tetrahydro-6H-pyrazolo%25255B3%25252C4-c%25255Dpyridine%252BDerivatives%252Bas%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BBrain-Penetrating%252BReceptor%252BInteracting%252BProtein%252B1%252B%252528RIP1%252529%252BKinase%252BInhibitors%25253A%252BAnalysis%252Bof%252BStructure%2525E2%252580%252593Kinetic%252BRelationships%26aulast%3DYoshikawa%26aufirst%3DMasato%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D08112017%26date%3D06032018%26date%3D27022018%26volume%3D61%26issue%3D6%26spage%3D2384%26epage%3D2409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helena  Kaitsiotou</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Christiane  Ehrt</span>, <span class="hlFld-ContribAuthor ">Jasmin  Krüll</span>, <span class="hlFld-ContribAuthor ">Federico  Medda</span>, <span class="hlFld-ContribAuthor ">Oliver  Koch</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 8801-8815. <a href="https://doi.org/10.1021/acs.jmedchem.7b00841" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00841%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitors%252Bto%252BOvercome%252BSecondary%252BMutations%252Bin%252Bthe%252BStem%252BCell%252BFactor%252BReceptor%252BKIT%26aulast%3DKaitsiotou%26aufirst%3DHelena%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08062017%26date%3D24102017%26date%3D09112017%26date%3D09102017%26volume%3D60%26issue%3D21%26spage%3D8801%26epage%3D8815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Xie</span>, <span class="hlFld-ContribAuthor ">Lei  Xie</span>, and <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>  . </span><span class="cited-content_cbyCitation_article-title">Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (9)
                                     , 4326-4341. <a href="https://doi.org/10.1021/acs.jmedchem.5b02041" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b02041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b02041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b02041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDelineation%252Bof%252BPolypharmacology%252Bacross%252Bthe%252BHuman%252BStructural%252BKinome%252BUsing%252Ba%252BFunctional%252BSite%252BInteraction%252BFingerprint%252BApproach%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D31122015%26date%3D17032016%26date%3D12052016%26date%3D01032016%26volume%3D59%26issue%3D9%26spage%3D4326%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Jiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhanni  Gu</span>, <span class="hlFld-ContribAuthor ">Shuni  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">José Luis  Aceña</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (2)
                                     , 422-518. <a href="https://doi.org/10.1021/acs.chemrev.5b00392" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00392%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DNext%252BGeneration%252Bof%252BFluorine-Containing%252BPharmaceuticals%25252C%252BCompounds%252BCurrently%252Bin%252BPhase%252BII%2525E2%252580%252593III%252BClinical%252BTrials%252Bof%252BMajor%252BPharmaceutical%252BCompanies%25253A%252BNew%252BStructural%252BTrends%252Band%252BTherapeutic%252BAreas%26aulast%3DZhou%26aufirst%3DYu%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06072015%26date%3D12012016%26date%3D27012016%26volume%3D116%26issue%3D2%26spage%3D422%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Liu</span>, <span class="hlFld-ContribAuthor ">Alvin  Kung</span>, <span class="hlFld-ContribAuthor ">Brock  Malinoski</span>, <span class="hlFld-ContribAuthor ">G. K. Surya  Prakash</span>, and <span class="hlFld-ContribAuthor ">Chao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9228-9237. <a href="https://doi.org/10.1021/acs.jmedchem.5b01125" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlkyne-Containing%252BPyrazolopyrimidines%252BTo%252BOvercome%252BDrug%252BResistance%252Bof%252BBcr-Abl%252BKinase%26aulast%3DLiu%26aufirst%3DXu%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17072015%26date%3D20112015%26date%3D10122015%26date%3D12112015%26volume%3D58%26issue%3D23%26spage%3D9228%26epage%3D9237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Santosh  Keshipeddy</span>, <span class="hlFld-ContribAuthor ">Stephanie M.  Reeve</span>, <span class="hlFld-ContribAuthor ">Amy C.  Anderson</span>, and <span class="hlFld-ContribAuthor ">Dennis L.  Wright</span>  . </span><span class="cited-content_cbyCitation_article-title">Nonracemic Antifolates Stereoselectively Recruit Alternate Cofactors and Overcome Resistance in S. aureus. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (28)
                                     , 8983-8990. <a href="https://doi.org/10.1021/jacs.5b01442" title="DOI URL">https://doi.org/10.1021/jacs.5b01442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b01442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b01442%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DNonracemic%252BAntifolates%252BStereoselectively%252BRecruit%252BAlternate%252BCofactors%252Band%252BOvercome%252BResistance%252Bin%252BS.%252Baureus%26aulast%3DKeshipeddy%26aufirst%3DSantosh%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D13022015%26date%3D08072015%26date%3D22072015%26date%3D22062015%26volume%3D137%26issue%3D28%26spage%3D8983%26epage%3D8990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Wu  Zheng</span>, <span class="hlFld-ContribAuthor ">Ya-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Xing-Dong  Lin</span>, <span class="hlFld-ContribAuthor ">Mei  Huang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Wan-Ting  Lin</span>, <span class="hlFld-ContribAuthor ">Yan  Jiao</span>, <span class="hlFld-ContribAuthor ">Xiao-Ai  Wu</span>, <span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Li-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Ying-Lan  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Cheng</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (9)
                                     , 3957-3974. <a href="https://doi.org/10.1021/acs.jmedchem.5b00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252B3-%252528Phenylethynyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252Ba%252BNew%252BClass%252Bof%252BSrc%252BInhibitors%252Bwith%252BPotent%252BActivities%252Bin%252BModels%252Bof%252BTriple%252BNegative%252BBreast%252BCancer%26aulast%3DZhang%26aufirst%3DChun-Hui%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D15022015%26date%3D16042015%26date%3D14052015%26date%3D02042015%26volume%3D58%26issue%3D9%26spage%3D3957%26epage%3D3974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xitao  Li</span>, <span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Guanghui  Tang</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Yiqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueying  Wang</span>, <span class="hlFld-ContribAuthor ">Tianlin  Guo</span>, <span class="hlFld-ContribAuthor ">Mengying  Xia</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, and <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5112-5128. <a href="https://doi.org/10.1021/jm4017762" title="DOI URL">https://doi.org/10.1021/jm4017762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4017762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252B2%25252C5-Diaminopyrimidine%252BCovalent%252BIrreversible%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252Bin%252BVivo%252BAntitumor%252BActivity%26aulast%3DLi%26aufirst%3DXitao%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D16112013%26date%3D10062014%26date%3D26062014%26volume%3D57%26issue%3D12%26spage%3D5112%26epage%3D5128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjay B.  Hari</span>, <span class="hlFld-ContribAuthor ">B. Gayani K.  Perera</span>, <span class="hlFld-ContribAuthor ">Pratistha  Ranjitkar</span>, <span class="hlFld-ContribAuthor ">Markus A.  Seeliger</span>, and <span class="hlFld-ContribAuthor ">Dustin J.  Maly</span>  . </span><span class="cited-content_cbyCitation_article-title">Conformation-Selective Inhibitors Reveal Differences in the Activation and Phosphate-Binding Loops of the Tyrosine Kinases Abl and Src. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2013,</strong> <em>8 </em>
                                    (12)
                                     , 2734-2743. <a href="https://doi.org/10.1021/cb400663k" title="DOI URL">https://doi.org/10.1021/cb400663k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb400663k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb400663k%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DConformation-Selective%252BInhibitors%252BReveal%252BDifferences%252Bin%252Bthe%252BActivation%252Band%252BPhosphate-Binding%252BLoops%252Bof%252Bthe%252BTyrosine%252BKinases%252BAbl%252Band%252BSrc%26aulast%3DHari%26aufirst%3DSanjay%2BB.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D27062013%26date%3D09102013%26date%3D29102013%26date%3D20122013%26date%3D09102013%26volume%3D8%26issue%3D12%26spage%3D2734%26epage%3D2743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geoffrey D.  Miller</span>, <span class="hlFld-ContribAuthor ">David W.  Woessner</span>, <span class="hlFld-ContribAuthor ">Monika J.  Sirch</span>, and <span class="hlFld-ContribAuthor ">Carol S.  Lim</span>  . </span><span class="cited-content_cbyCitation_article-title">Multidomain Targeting of Bcr-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2013,</strong> <em>10 </em>
                                    (9)
                                     , 3475-3483. <a href="https://doi.org/10.1021/mp400323c" title="DOI URL">https://doi.org/10.1021/mp400323c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp400323c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp400323c%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DMultidomain%252BTargeting%252Bof%252BBcr-Abl%252Bby%252BDisruption%252Bof%252BOligomerization%252Band%252BTyrosine%252BKinase%252BInhibition%25253A%252BToward%252BEradication%252Bof%252BCML%26aulast%3DMiller%26aufirst%3DGeoffrey%2BD.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03062013%26date%3D05082013%26date%3D25072013%26date%3D20082013%26date%3D03092013%26date%3D05082013%26volume%3D10%26issue%3D9%26spage%3D3475%26epage%3D3483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Radi</span>, <span class="hlFld-ContribAuthor ">Cristina  Tintori</span>, <span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Claudio  Zamperini</span>, <span class="hlFld-ContribAuthor ">Elena  Dreassi</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Giulia  Vignaroli</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>, <span class="hlFld-ContribAuthor ">Samantha  Zanoli</span>, <span class="hlFld-ContribAuthor ">Ilaria  Laurenzana</span>, <span class="hlFld-ContribAuthor ">Irene  Filippi</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Adriano  Angelucci</span>, and <span class="hlFld-ContribAuthor ">Maurizio  Botta</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (13)
                                     , 5382-5394. <a href="https://doi.org/10.1021/jm400233w" title="DOI URL">https://doi.org/10.1021/jm400233w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400233w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400233w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidines%252BActive%252Bin%252BVivo%252Bon%252Bthe%252BBcr-Abl%252BT315I%252BMutant%26aulast%3DRadi%26aufirst%3DMarco%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D14022013%26date%3D20062013%26date%3D11072013%26date%3D07062013%26volume%3D56%26issue%3D13%26spage%3D5382%26epage%3D5394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2013,</strong> <em>135 </em>
                                    (22)
                                     , 8227-8237. <a href="https://doi.org/10.1021/ja311756u" title="DOI URL">https://doi.org/10.1021/ja311756u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja311756u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja311756u%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDiscovery%252Bof%252BPicomolar%252BABL%252BKinase%252BInhibitors%252BEquipotent%252Bfor%252BWild%252BType%252Band%252BT315I%252BMutant%252Bvia%252BStructure-Based%252Bde%252BNovo%252BDesign%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D03122012%26date%3D24052013%26date%3D05062013%26date%3D16052013%26volume%3D135%26issue%3D22%26spage%3D8227%26epage%3D8237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, <span class="hlFld-ContribAuthor ">Sun-Mi  Yun</span>, <span class="hlFld-ContribAuthor ">Hyunseung  Lee</span>, <span class="hlFld-ContribAuthor ">Yoonsu  Park</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (9)
                                     , 3531-3545. <a href="https://doi.org/10.1021/jm301891t" title="DOI URL">https://doi.org/10.1021/jm301891t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301891t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301891t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNew%252BBenzothiazole-Based%252BInhibitors%252Bof%252BBreakpoint%252BCluster%252BRegion-Abelson%252BKinase%252BIncluding%252Bthe%252BT315I%252BMutant%26aulast%3DHong%26aufirst%3DSeunghee%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D22122012%26date%3D19042013%26date%3D09052013%26volume%3D56%26issue%3D9%26spage%3D3531%26epage%3D3545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingshan  Gao</span>, <span class="hlFld-ContribAuthor ">Lei  Duan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (8)
                                     , 3281-3295. <a href="https://doi.org/10.1021/jm301824k" title="DOI URL">https://doi.org/10.1021/jm301824k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301824k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301824k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252B3-%2525282-%252528Pyrazolo%25255B1%25252C5-a%25255Dpyrimidin-6-yl%252529ethynyl%252529benzamides%252Bas%252BNovel%252BSelective%252Band%252BOrally%252BBioavailable%252BDiscoidin%252BDomain%252BReceptor%252B1%252B%252528DDR1%252529%252BInhibitors%26aulast%3DGao%26aufirst%3DMingshan%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D11122012%26date%3D10042013%26date%3D25042013%26date%3D22032013%26volume%3D56%26issue%3D8%26spage%3D3281%26epage%3D3295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bimbisar  Desai</span>, <span class="hlFld-ContribAuthor ">Karen  Dixon</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Farrant</span>, <span class="hlFld-ContribAuthor ">Qixing  Feng</span>, <span class="hlFld-ContribAuthor ">Karl R.  Gibson</span>, <span class="hlFld-ContribAuthor ">Willem P.  van Hoorn</span>, <span class="hlFld-ContribAuthor ">James  Mills</span>, <span class="hlFld-ContribAuthor ">Trevor  Morgan</span>, <span class="hlFld-ContribAuthor ">David M.  Parry</span>, <span class="hlFld-ContribAuthor ">Manoj K.  Ramjee</span>, <span class="hlFld-ContribAuthor ">Christopher N.  Selway</span>, <span class="hlFld-ContribAuthor ">Gary J.  Tarver</span>, <span class="hlFld-ContribAuthor ">Gavin  Whitlock</span>, and <span class="hlFld-ContribAuthor ">Adrian G.  Wright</span>  . </span><span class="cited-content_cbyCitation_article-title">Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (7)
                                     , 3033-3047. <a href="https://doi.org/10.1021/jm400099d" title="DOI URL">https://doi.org/10.1021/jm400099d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400099d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400099d%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRapid%252BDiscovery%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BAbl%252BKinase%252BInhibitors%252Bby%252BApplication%252Bof%252Ban%252BIntegrated%252BMicrofluidic%252BSynthesis%252Band%252BScreening%252BPlatform%26aulast%3DDesai%26aufirst%3DBimbisar%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D21012013%26date%3D25032013%26date%3D11042013%26date%3D26022013%26volume%3D56%26issue%3D7%26spage%3D3033%26epage%3D3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yubing  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Xingfen  Lang</span>, <span class="hlFld-ContribAuthor ">Yang  Bai</span>, <span class="hlFld-ContribAuthor ">Miaoqin  She</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Jingxuan  Pan</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (3)
                                     , 879-894. <a href="https://doi.org/10.1021/jm301581y" title="DOI URL">https://doi.org/10.1021/jm301581y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301581y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BGZD824%252Bas%252Ban%252BOrally%252BBioavailable%252BInhibitor%252BThat%252BTargets%252BPhosphorylated%252Band%252BNonphosphorylated%252BBreakpoint%252BCluster%252BRegion%2525E2%252580%252593Abelson%252B%252528Bcr-Abl%252529%252BKinase%252Band%252BOvercomes%252BClinically%252BAcquired%252BMutation-Induced%252BResistance%252Bagainst%252BImatinib%26aulast%3DRen%26aufirst%3DXiaomei%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D17092012%26date%3D28012013%26date%3D14022013%26date%3D09012013%26volume%3D56%26issue%3D3%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Mengjie  Shen</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Yingjun  Li</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (22)
                                     , 10033-10046. <a href="https://doi.org/10.1021/jm301188x" title="DOI URL">https://doi.org/10.1021/jm301188x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301188x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301188x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B3-%2525281H-1%25252C2%25252C3-Triazol-1-yl%252529benzamide%252BDerivatives%252Bas%252BPotent%252BPan%252BBcr-Abl%252BInhibitors%252BIncluding%252Bthe%252BThreonine315%2525E2%252586%252592Isoleucine315%252BMutant%26aulast%3DLi%26aufirst%3DYupeng%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D12082012%26date%3D01112012%26date%3D26112012%26date%3D22102012%26volume%3D55%26issue%3D22%26spage%3D10033%26epage%3D10046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vito  Guagnano</span>, <span class="hlFld-ContribAuthor ">Pascal  Furet</span>, <span class="hlFld-ContribAuthor ">Carsten  Spanka</span>, <span class="hlFld-ContribAuthor ">Vincent  Bordas</span>, <span class="hlFld-ContribAuthor ">Mickaël  Le Douget</span>, <span class="hlFld-ContribAuthor ">Christelle  Stamm</span>, <span class="hlFld-ContribAuthor ">Josef  Brueggen</span>, <span class="hlFld-ContribAuthor ">Michael R.  Jensen</span>, <span class="hlFld-ContribAuthor ">Christian  Schnell</span>, <span class="hlFld-ContribAuthor ">Herbert  Schmid</span>, <span class="hlFld-ContribAuthor ">Markus  Wartmann</span>, <span class="hlFld-ContribAuthor ">Joerg  Berghausen</span>, <span class="hlFld-ContribAuthor ">Peter  Drueckes</span>, <span class="hlFld-ContribAuthor ">Alfred  Zimmerlin</span>, <span class="hlFld-ContribAuthor ">Dirksen  Bussiere</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, and <span class="hlFld-ContribAuthor ">Diana  Graus Porta</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (20)
                                     , 7066-7083. <a href="https://doi.org/10.1021/jm2006222" title="DOI URL">https://doi.org/10.1021/jm2006222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm2006222%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%2525282%25252C6-Dichloro-3%25252C5-dimethoxy-phenyl%252529-1-%25257B6-%25255B4-%2525284-ethyl-piperazin-1-yl%252529-phenylamino%25255D-pyrimidin-4-yl%25257D-1-methyl-urea%252B%252528NVP-BGJ398%252529%25252C%252BA%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252Bthe%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252BFamily%252Bof%252BReceptor%252BTyrosine%252BKinase%26aulast%3DGuagnano%26aufirst%3DVito%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D17052011%26date%3D21092011%26date%3D27102011%26volume%3D54%26issue%3D20%26spage%3D7066%26epage%3D7083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (29)
                                     , 16041-16047. <a href="https://doi.org/10.1002/ange.202101328" title="DOI URL">https://doi.org/10.1002/ange.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D29%26spage%3D16041%26epage%3D16047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (29)
                                     , 15905-15911. <a href="https://doi.org/10.1002/anie.202101328" title="DOI URL">https://doi.org/10.1002/anie.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D29%26spage%3D15905%26epage%3D15911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tommaso  Fantoni</span>, <span class="hlFld-ContribAuthor ">Sara  Bernardoni</span>, <span class="hlFld-ContribAuthor ">Alexia  Mattellone</span>, <span class="hlFld-ContribAuthor ">Giulia  Martelli</span>, <span class="hlFld-ContribAuthor ">Lucia  Ferrazzano</span>, <span class="hlFld-ContribAuthor ">Paolo  Cantelmi</span>, <span class="hlFld-ContribAuthor ">Dario  Corbisiero</span>, <span class="hlFld-ContribAuthor ">Alessandra  Tolomelli</span>, <span class="hlFld-ContribAuthor ">Walter  Cabri</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Francesca  Ferlenghi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Antonio  Ricci</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium Catalyst Recycling for Heck‐Cassar‐Sonogashira Cross‐Coupling Reactions in Green Solvent/Base Blend. </span><span class="cited-content_cbyCitation_journal-name">ChemSusChem</span><span> <strong>2021,</strong> <em>14 </em>
                                    (12)
                                     , 2591-2600. <a href="https://doi.org/10.1002/cssc.202100623" title="DOI URL">https://doi.org/10.1002/cssc.202100623</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cssc.202100623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcssc.202100623%26sid%3Dliteratum%253Aachs%26jtitle%3DChemSusChem%26atitle%3DPalladium%252BCatalyst%252BRecycling%252Bfor%252BHeck%2525E2%252580%252590Cassar%2525E2%252580%252590Sonogashira%252BCross%2525E2%252580%252590Coupling%252BReactions%252Bin%252BGreen%252BSolvent%25252FBase%252BBlend%26aulast%3DFantoni%26aufirst%3DTommaso%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D12%26spage%3D2591%26epage%3D2600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexey A.  Kruzhilin</span>, <span class="hlFld-ContribAuthor ">Evgeniya A.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">Khidmet S.  Shikhaliev</span>, <span class="hlFld-ContribAuthor ">Gleb L.  Denisov</span>, <span class="hlFld-ContribAuthor ">Dmitriy Yu.  Vandyshev</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective Synthesis of Imidazo[1,5‐
              b
              ]pyridazines by Cascade Cyclizations of 1,2‐Diamino‐4H‐phenylimidazole with 1,3‐Diketones, Acetoacetic Ester and Their Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 5801-5806. <a href="https://doi.org/10.1002/slct.202101372" title="DOI URL">https://doi.org/10.1002/slct.202101372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRegioselective%252BSynthesis%252Bof%252BImidazo%25255B1%25252C5%2525E2%252580%252590%252Bb%252B%25255Dpyridazines%252Bby%252BCascade%252BCyclizations%252Bof%252B1%25252C2%2525E2%252580%252590Diamino%2525E2%252580%2525904H%2525E2%252580%252590phenylimidazole%252Bwith%252B1%25252C3%2525E2%252580%252590Diketones%25252C%252BAcetoacetic%252BEster%252Band%252BTheir%252BDerivatives%26aulast%3DKruzhilin%26aufirst%3DAlexey%2BA.%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D23%26spage%3D5801%26epage%3D5806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marlene  Mathuber</span>, <span class="hlFld-ContribAuthor ">Michael  Gutmann</span>, <span class="hlFld-ContribAuthor ">Mery  La Franca</span>, <span class="hlFld-ContribAuthor ">Petra  Vician</span>, <span class="hlFld-ContribAuthor ">Anna  Laemmerer</span>, <span class="hlFld-ContribAuthor ">Patrick  Moser</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>, <span class="hlFld-ContribAuthor ">Christian R.  Kowol</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a cobalt(
              iii
              )-based ponatinib prodrug system. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (10)
                                     , 2468-2485. <a href="https://doi.org/10.1039/D1QI00211B" title="DOI URL">https://doi.org/10.1039/D1QI00211B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QI00211B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QI00211B%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%2520Frontiers%26atitle%3DDevelopment%252Bof%252Ba%252Bcobalt%252528%252Biii%252B%252529-based%252Bponatinib%252Bprodrug%252Bsystem%26aulast%3DMathuber%26aufirst%3DMarlene%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D10%26spage%3D2468%26epage%3D2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuting  Wang</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Sihua  Zhu</span>, <span class="hlFld-ContribAuthor ">Sanfang  Tu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (5)
                                     , 1315-1328. <a href="https://doi.org/10.1016/j.apsb.2020.11.009" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252BBcr-Abl%252BPROTACs%252Bto%252Bovercome%252BT315I%252Bmutation%26aulast%3DJiang%26aufirst%3DLiang%26date%3D2021%26volume%3D11%26issue%3D5%26spage%3D1315%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenesis Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-66. <a href="https://doi.org/10.1002/0471266949.bmc271" title="DOI URL">https://doi.org/10.1002/0471266949.bmc271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc271%26sid%3Dliteratum%253Aachs%26atitle%3DAngiogenesis%252BInhibitors%26aulast%3DShi%26aufirst%3DLei%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D66%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jung Wuk  Lee</span>, <span class="hlFld-ContribAuthor ">Jiwon  Park</span>, <span class="hlFld-ContribAuthor ">Jina  Kim</span>, <span class="hlFld-ContribAuthor ">Jihyung  Kim</span>, <span class="hlFld-ContribAuthor ">Changyu  Choi</span>, <span class="hlFld-ContribAuthor ">Kyung Hoon  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113298. <a href="https://doi.org/10.1016/j.ejmech.2021.113298" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113298%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bcolony-stimulating%252Bfactor%252B1%252Breceptor%252Binhibitors%252Bby%252Breplacement%252Bof%252Bhinge-binder%252Bmoieties%26aulast%3DLee%26aufirst%3DJung%2BWuk%26date%3D2021%26volume%3D216%26spage%3D113298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyo In  Kim</span>, <span class="hlFld-ContribAuthor ">Seungbeom  Lee</span>, <span class="hlFld-ContribAuthor ">Juhee  Lim</span>, <span class="hlFld-ContribAuthor ">Sungkyun  Chung</span>, <span class="hlFld-ContribAuthor ">Tae-Sung  Koo</span>, <span class="hlFld-ContribAuthor ">Yu-Geun  Ji</span>, <span class="hlFld-ContribAuthor ">Young-Ger  Suh</span>, <span class="hlFld-ContribAuthor ">Woo Sung  Son</span>, <span class="hlFld-ContribAuthor ">Seok-Ho  Kim</span>, <span class="hlFld-ContribAuthor ">Hyun Jin  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">ERRγ ligand HPB2 upregulates BDNF-TrkB and enhances dopaminergic neuronal phenotype. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>165 </em>, 105423. <a href="https://doi.org/10.1016/j.phrs.2021.105423" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105423%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DERR%2525CE%2525B3%252Bligand%252BHPB2%252Bupregulates%252BBDNF-TrkB%252Band%252Benhances%252Bdopaminergic%252Bneuronal%252Bphenotype%26aulast%3DKim%26aufirst%3DHyo%2BIn%26date%3D2021%26volume%3D165%26spage%3D105423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Honglin  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>, <span class="hlFld-ContribAuthor ">Xuan  Cao</span>, <span class="hlFld-ContribAuthor ">Junmei  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 649-664. <a href="https://doi.org/10.1111/cbdd.13801" title="DOI URL">https://doi.org/10.1111/cbdd.13801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13801%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DRecent%252Badvances%252Bin%252BBcr%2525E2%252580%252590Abl%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Boverriding%252BT315I%252Bmutation%26aulast%3DLiu%26aufirst%3DJuan%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D649%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Liang</span>, <span class="hlFld-ContribAuthor ">Juelan  Wang</span>, <span class="hlFld-ContribAuthor ">Liyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Jun  Hou</span>, <span class="hlFld-ContribAuthor ">Yonghe  Hu</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of dual FGFR inhibitors as a novel therapy for cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113205. <a href="https://doi.org/10.1016/j.ejmech.2021.113205" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113205</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113205%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252Bdual%252BFGFR%252Binhibitors%252Bas%252Ba%252Bnovel%252Btherapy%252Bfor%252Bcancer%26aulast%3DLiang%26aufirst%3DQi%26date%3D2021%26volume%3D214%26spage%3D113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francois  Gonzalvez</span>, <span class="hlFld-ContribAuthor ">Sylvie  Vincent</span>, <span class="hlFld-ContribAuthor ">Theresa E.  Baker</span>, <span class="hlFld-ContribAuthor ">Alexandra E.  Gould</span>, <span class="hlFld-ContribAuthor ">Shuai  Li</span>, <span class="hlFld-ContribAuthor ">Scott D.  Wardwell</span>, <span class="hlFld-ContribAuthor ">Sara  Nadworny</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Sen  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Yongbo  Hu</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Greenfield</span>, <span class="hlFld-ContribAuthor ">Stephan G.  Zech</span>, <span class="hlFld-ContribAuthor ">Biplab  Das</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>, <span class="hlFld-ContribAuthor ">Michael  Fitzgerald</span>, <span class="hlFld-ContribAuthor ">Johara  Chouitar</span>, <span class="hlFld-ContribAuthor ">Robert J.  Griffin</span>, <span class="hlFld-ContribAuthor ">Shengwu  Liu</span>, <span class="hlFld-ContribAuthor ">Kwok-kin  Wong</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>. </span><span class="cited-content_cbyCitation_article-title">Mobocertinib (TAK-788): A Targeted Inhibitor of
              EGFR
              Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1158/2159-8290.CD-20-1683" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-20-1683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-20-1683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-20-1683%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DMobocertinib%252B%252528TAK-788%252529%25253A%252BA%252BTargeted%252BInhibitor%252Bof%252BEGFR%252BExon%252B20%252BInsertion%252BMutants%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DGonzalvez%26aufirst%3DFrancois%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew B.  Benowitz</span>, <span class="hlFld-ContribAuthor ">Katherine L.  Jones</span>, <span class="hlFld-ContribAuthor ">John D.  Harling</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic potential of PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (1)
                                     , 1-24. <a href="https://doi.org/10.1080/13543776.2021.1840553" title="DOI URL">https://doi.org/10.1080/13543776.2021.1840553</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1840553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1840553%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DThe%252Btherapeutic%252Bpotential%252Bof%252BPROTACs%26aulast%3DBenowitz%26aufirst%3DAndrew%2BB.%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D1%26spage%3D1%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhang-Xu  He</span>, <span class="hlFld-ContribAuthor ">Yun-Peng  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112946. <a href="https://doi.org/10.1016/j.ejmech.2020.112946" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112946%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyridazine%252Bas%252Ba%252Bprivileged%252Bstructure%25253A%252BAn%252Bupdated%252Breview%252Bon%252Banticancer%252Bactivity%252Bof%252Bpyridazine%252Bcontaining%252Bbioactive%252Bmolecules%26aulast%3DHe%26aufirst%3DZhang-Xu%26date%3D2021%26volume%3D209%26spage%3D112946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinayak  Palve</span>, <span class="hlFld-ContribAuthor ">Yi  Liao</span>, <span class="hlFld-ContribAuthor ">Lily L.  Remsing Rix</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">Turning liabilities into opportunities: Off-target based drug repurposing in cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>68 </em>, 209-229. <a href="https://doi.org/10.1016/j.semcancer.2020.02.003" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DTurning%252Bliabilities%252Binto%252Bopportunities%25253A%252BOff-target%252Bbased%252Bdrug%252Brepurposing%252Bin%252Bcancer%26aulast%3DPalve%26aufirst%3DVinayak%26date%3D2021%26volume%3D68%26spage%3D209%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Valent</span>, <span class="hlFld-ContribAuthor ">Alberto  Orfao</span>, <span class="hlFld-ContribAuthor ">Stefan  Kubicek</span>, <span class="hlFld-ContribAuthor ">Philipp  Staber</span>, <span class="hlFld-ContribAuthor ">Torsten  Haferlach</span>, <span class="hlFld-ContribAuthor ">Michael  Deininger</span>, <span class="hlFld-ContribAuthor ">Karoline  Kollmann</span>, <span class="hlFld-ContribAuthor ">Thomas  Lion</span>, <span class="hlFld-ContribAuthor ">Irene  Virgolini</span>, <span class="hlFld-ContribAuthor ">Georg  Winter</span>, <span class="hlFld-ContribAuthor ">Oliver  Hantschel</span>, <span class="hlFld-ContribAuthor ">Lukas  Kenner</span>, <span class="hlFld-ContribAuthor ">Johannes  Zuber</span>, <span class="hlFld-ContribAuthor ">Florian  Grebien</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Gregor  Hoermann</span>, <span class="hlFld-ContribAuthor ">Olivier  Hermine</span>, <span class="hlFld-ContribAuthor ">Michael  Andreeff</span>, <span class="hlFld-ContribAuthor ">Christoph  Bock</span>, <span class="hlFld-ContribAuthor ">Tariq  Mughal</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Robert  Kralovics</span>, <span class="hlFld-ContribAuthor ">Veronika  Sexl</span>, <span class="hlFld-ContribAuthor ">Radek  Skoda</span>, <span class="hlFld-ContribAuthor ">Giulio  Superti-Furga</span>, <span class="hlFld-ContribAuthor ">Ulrich  Jäger</span>. </span><span class="cited-content_cbyCitation_article-title">Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. </span><span class="cited-content_cbyCitation_journal-name">HemaSphere</span><span> <strong>2021,</strong> <em>5 </em>
                                    (3)
                                     , e536. <a href="https://doi.org/10.1097/HS9.0000000000000536" title="DOI URL">https://doi.org/10.1097/HS9.0000000000000536</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/HS9.0000000000000536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FHS9.0000000000000536%26sid%3Dliteratum%253Aachs%26jtitle%3DHemaSphere%26atitle%3DPrecision%252BMedicine%252Bin%252BHematology%252B2021%25253A%252BDefinitions%25252C%252BTools%25252C%252BPerspectives%25252C%252Band%252BOpen%252BQuestions%26aulast%3DValent%26aufirst%3DPeter%26date%3D2021%26date%3D2021%26volume%3D5%26issue%3D3%26spage%3De536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Heewon  Jin</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Eun-Kyoung  Bang</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112710. <a href="https://doi.org/10.1016/j.ejmech.2020.112710" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112710%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluations%252Bof%252Bnovel%252B3-amino-4-ethynyl%252Bindazole%252Bderivatives%252Bas%252BBcr-Abl%252Bkinase%252Binhibitors%252Bwith%252Bpotent%252Bcellular%252Bantileukemic%252Bactivity%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BK.%26date%3D2020%26volume%3D207%26spage%3D112710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf K.  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Md Mamunul  Haque</span>, <span class="hlFld-ContribAuthor ">Jung Woo  Park</span>, <span class="hlFld-ContribAuthor ">Sang Chul  Shin</span>, <span class="hlFld-ContribAuthor ">Jun-Seok  Lee</span>, <span class="hlFld-ContribAuthor ">Eunice  EunKyeong Kim</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112756. <a href="https://doi.org/10.1016/j.ejmech.2020.112756" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112756%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Anilinoquinoline%252Bbased%252Barylamides%252Bas%252Bbroad%252Bspectrum%252Banticancer%252Bagents%252Bwith%252BB-RAFV600E%25252FC-RAF%252Bkinase%252Binhibitory%252Beffects%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bin%2525C2%2525A0vitro%252Bcell-based%252Band%252Boncogenic%252Bkinase%252Bassessments%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BK.%26date%3D2020%26volume%3D208%26spage%3D112756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Nie</span>, <span class="hlFld-ContribAuthor ">Wanqing  Wu</span>, <span class="hlFld-ContribAuthor ">Yingjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the synthesis of bridgehead (or ring-junction) nitrogen heterocycles
              via
              transition metal-catalyzed C–H bond activation and functionalization. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (19)
                                     , 3067-3099. <a href="https://doi.org/10.1039/D0QO00510J" title="DOI URL">https://doi.org/10.1039/D0QO00510J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO00510J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO00510J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bsynthesis%252Bof%252Bbridgehead%252B%252528or%252Bring-junction%252529%252Bnitrogen%252Bheterocycles%252Bvia%252Btransition%252Bmetal-catalyzed%252BC%2525E2%252580%252593H%252Bbond%252Bactivation%252Band%252Bfunctionalization%26aulast%3DNie%26aufirst%3DBiao%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D19%26spage%3D3067%26epage%3D3099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. P.  Maksimova</span>, <span class="hlFld-ContribAuthor ">J. V.  Makus</span>, <span class="hlFld-ContribAuthor ">O. G.  Usalka</span>, <span class="hlFld-ContribAuthor ">E. S.  Lylova</span>, <span class="hlFld-ContribAuthor ">P. E.  Bugaeva</span>, <span class="hlFld-ContribAuthor ">E. M.  Zhidkova</span>, <span class="hlFld-ContribAuthor ">D. A.  Fedorov</span>, <span class="hlFld-ContribAuthor ">O. P.  Lizogub</span>, <span class="hlFld-ContribAuthor ">E. A.  Lesovaya</span>, <span class="hlFld-ContribAuthor ">G. A.  Belitsky</span>, <span class="hlFld-ContribAuthor ">M. G.  Yakubovskaya</span>, <span class="hlFld-ContribAuthor ">K. I.  Kirsanov</span>. </span><span class="cited-content_cbyCitation_article-title">EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS. </span><span class="cited-content_cbyCitation_journal-name">Siberian journal of oncology</span><span> <strong>2020,</strong> <em>19 </em>
                                    (4)
                                     , 67-78. <a href="https://doi.org/10.21294/1814-4861-2020-19-4-67-78" title="DOI URL">https://doi.org/10.21294/1814-4861-2020-19-4-67-78</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.21294/1814-4861-2020-19-4-67-78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.21294%2F1814-4861-2020-19-4-67-78%26sid%3Dliteratum%253Aachs%26jtitle%3DSiberian%2520journal%2520of%2520oncology%26atitle%3DEPIGENETIC%252BEFFECTS%252BOF%252BENZASTAURIN%252B%2525E2%252580%252593%252BA%252BNEW%252BASPECT%252BIN%252BTHE%252BMECHANISM%252BOF%252BACTION%252BOF%252BAN%252BANTICANCER%252BDRUG%252BFROM%252BPROTEIN%252BKINASE%252BINHIBITORS%26aulast%3DMaksimova%26aufirst%3DV.%2BP.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D4%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nadia S.  El-Hamdi</span>, <span class="hlFld-ContribAuthor ">K. Yeon  Choi</span>, <span class="hlFld-ContribAuthor ">Alistair  McGregor</span>. </span><span class="cited-content_cbyCitation_article-title">Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry. </span><span class="cited-content_cbyCitation_journal-name">Virology</span><span> <strong>2020,</strong> <em>548 </em>, 236-249. <a href="https://doi.org/10.1016/j.virol.2020.05.012" title="DOI URL">https://doi.org/10.1016/j.virol.2020.05.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.virol.2020.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.virol.2020.05.012%26sid%3Dliteratum%253Aachs%26jtitle%3DVirology%26atitle%3DGuinea%252Bpig%252Bcytomegalovirus%252Btrimer%252Bcomplex%252BgH%25252FgL%25252FgO%252Buses%252BPDGFRA%252Bas%252Buniversal%252Breceptor%252Bfor%252Bcell%252Bfusion%252Band%252Bentry%26aulast%3DEl-Hamdi%26aufirst%3DNadia%2BS.%26date%3D2020%26volume%3D548%26spage%3D236%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia‐Bao  He</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi‐Wen  Guo</span>, <span class="hlFld-ContribAuthor ">Miao‐Miao  Liu</span>, <span class="hlFld-ContribAuthor ">Na  Xu</span>, <span class="hlFld-ContribAuthor ">Fen  Huang</span>, <span class="hlFld-ContribAuthor ">Zhi‐Ping  Fan</span>, <span class="hlFld-ContribAuthor ">Li  Xuan</span>, <span class="hlFld-ContribAuthor ">Lan  Deng</span>, <span class="hlFld-ContribAuthor ">Shu‐Hua  Lin</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Qi‐Fa  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib therapy in recurrent Philadelphia chromosome‐positive central nervous system leukemia with T315I mutation after Allo‐HSCT. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2020,</strong> <em>147 </em>
                                    (4)
                                     , 1071-1077. <a href="https://doi.org/10.1002/ijc.32817" title="DOI URL">https://doi.org/10.1002/ijc.32817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.32817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.32817%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DPonatinib%252Btherapy%252Bin%252Brecurrent%252BPhiladelphia%252Bchromosome%2525E2%252580%252590positive%252Bcentral%252Bnervous%252Bsystem%252Bleukemia%252Bwith%252BT315I%252Bmutation%252Bafter%252BAllo%2525E2%252580%252590HSCT%26aulast%3DHe%26aufirst%3DJia%25E2%2580%2590Bao%26date%3D2020%26date%3D2019%26volume%3D147%26issue%3D4%26spage%3D1071%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairui  Wu</span>, <span class="hlFld-ContribAuthor ">Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Jinling  Li</span>, <span class="hlFld-ContribAuthor ">Mingxing  Wang</span>, <span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Yuan</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potential platelet-derived growth factor receptor α inhibitors by computational screening and binding simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>96 </em>, 107527. <a href="https://doi.org/10.1016/j.jmgm.2019.107527" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.107527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.107527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.107527%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DIdentification%252Bof%252Bpotential%252Bplatelet-derived%252Bgrowth%252Bfactor%252Breceptor%252B%2525CE%2525B1%252Binhibitors%252Bby%252Bcomputational%252Bscreening%252Band%252Bbinding%252Bsimulations%26aulast%3DWu%26aufirst%3DHairui%26date%3D2020%26volume%3D96%26spage%3D107527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athina  Moschopoulou</span>, <span class="hlFld-ContribAuthor ">Stefan  Zwirner</span>, <span class="hlFld-ContribAuthor ">Lars  Zender</span>, <span class="hlFld-ContribAuthor ">Daniel  Dauch</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 125-153. <a href="https://doi.org/10.1007/7355_2020_100" title="DOI URL">https://doi.org/10.1007/7355_2020_100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_100%26sid%3Dliteratum%253Aachs%26atitle%3DExploiting%252BKinase%252BInhibitors%252Bfor%252BCancer%252BTreatment%25253A%252BAn%252BOverview%252Bof%252BClinical%252BResults%252Band%252BOutlook%26aulast%3DMoschopoulou%26aufirst%3DAthina%26date%3D2020%26date%3D2020%26spage%3D125%26epage%3D153%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenbo  Yu</span>, <span class="hlFld-ContribAuthor ">David J.  Weber</span>, <span class="hlFld-ContribAuthor ">Paul  Shapiro</span>, <span class="hlFld-ContribAuthor ">Alexander D.  MacKerell</span>. </span><span class="cited-content_cbyCitation_article-title">Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 81-108. <a href="https://doi.org/10.1007/978-3-030-48283-1_5" title="DOI URL">https://doi.org/10.1007/978-3-030-48283-1_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-48283-1_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-48283-1_5%26sid%3Dliteratum%253Aachs%26atitle%3DDeveloping%252BKinase%252BInhibitors%252BUsing%252BComputer-Aided%252BDrug%252BDesign%252BApproaches%26aulast%3DYu%26aufirst%3DWenbo%26date%3D2020%26date%3D2020%26spage%3D81%26epage%3D108%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNext%252BGeneration%252BKinase%252BInhibitors%26aulast%3DShapiro%26aufirst%3DPaul%26date%3D2020%26volume%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>151 </em>, 104567. <a href="https://doi.org/10.1016/j.phrs.2019.104567" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104567%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B%252528FGFR%252529%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%252Bincluding%252Bthose%252Bof%252Bthe%252Burinary%252Bbladder%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D151%26spage%3D104567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anu R.  Melge</span>, <span class="hlFld-ContribAuthor ">Lekshmi G.  Kumar</span>, <span class="hlFld-ContribAuthor ">Pavithran  K</span>, <span class="hlFld-ContribAuthor ">Shantikumar V.  Nair</span>, <span class="hlFld-ContribAuthor ">Manzoor  K</span>, <span class="hlFld-ContribAuthor ">Gopi Mohan  C</span>. </span><span class="cited-content_cbyCitation_article-title">Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (18)
                                     , 4747-4766. <a href="https://doi.org/10.1080/07391102.2018.1559765" title="DOI URL">https://doi.org/10.1080/07391102.2018.1559765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1559765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1559765%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DPredictive%252Bmodels%252Bfor%252Bdesigning%252Bpotent%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%252Bfor%252Bunderstanding%252Bits%252Bmolecular%252Bmechanism%252Bof%252Bresistance%252Bby%252Bmolecular%252Bdocking%252Band%252Bdynamics%252Bsimulations%26aulast%3DMelge%26aufirst%3DAnu%2BR.%26date%3D2019%26date%3D2019%26volume%3D37%26issue%3D18%26spage%3D4747%26epage%3D4766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enrico  Zanforlin</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Zagotto</span>, <span class="hlFld-ContribAuthor ">Giovanni  Ribaudo</span>. </span><span class="cited-content_cbyCitation_article-title">A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance: Learning from Chronic Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (33)
                                     , 6033-6052. <a href="https://doi.org/10.2174/0929867325666180607092451" title="DOI URL">https://doi.org/10.2174/0929867325666180607092451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180607092451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180607092451%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DA%252BChemical%252BApproach%252Bto%252BOvercome%252BTyrosine%252BKinase%252BInhibitors%252BResistance%25253A%252BLearning%252Bfrom%252BChronic%252BMyeloid%252BLeukemia%26aulast%3DZanforlin%26aufirst%3DEnrico%26date%3D2019%26volume%3D26%26issue%3D33%26spage%3D6033%26epage%3D6052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuyun  Sun</span>, <span class="hlFld-ContribAuthor ">Hongying  Gao</span>, <span class="hlFld-ContribAuthor ">Yiqing  Yang</span>, <span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Yugang  Song</span>, <span class="hlFld-ContribAuthor ">Yan  Tong</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs: great opportunities for academia and industry. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-019-0101-6" title="DOI URL">https://doi.org/10.1038/s41392-019-0101-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DPROTACs%25253A%252Bgreat%252Bopportunities%252Bfor%252Bacademia%252Band%252Bindustry%26aulast%3DSun%26aufirst%3DXiuyun%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rasapalli  Sivappa</span>, <span class="hlFld-ContribAuthor ">Vamshikrishna Reddy  Sammeta</span>, <span class="hlFld-ContribAuthor ">Yanchang  Huang</span>, <span class="hlFld-ContribAuthor ">James A.  Golen</span>, <span class="hlFld-ContribAuthor ">Sergey N.  Savinov</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of 3-substituted imidazo[1,2-
              a
              ]pyridines through formimidamide chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (51)
                                     , 29659-29664. <a href="https://doi.org/10.1039/C9RA05841A" title="DOI URL">https://doi.org/10.1039/C9RA05841A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA05841A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA05841A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DFacile%252Bsynthesis%252Bof%252B3-substituted%252Bimidazo%25255B1%25252C2-%252Ba%252B%25255Dpyridines%252Bthrough%252Bformimidamide%252Bchemistry%26aulast%3DSivappa%26aufirst%3DRasapalli%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D51%26spage%3D29659%26epage%3D29664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Sas</span>, <span class="hlFld-ContribAuthor ">Vlad  Moisoiu</span>, <span class="hlFld-ContribAuthor ">Patric  Teodorescu</span>, <span class="hlFld-ContribAuthor ">Sebastian  Tranca</span>, <span class="hlFld-ContribAuthor ">Laura  Pop</span>, <span class="hlFld-ContribAuthor ">Sabina  Iluta</span>, <span class="hlFld-ContribAuthor ">Sergiu  Pasca</span>, <span class="hlFld-ContribAuthor ">Cristina  Blag</span>, <span class="hlFld-ContribAuthor ">Sorin  Man</span>, <span class="hlFld-ContribAuthor ">Andrei  Roman</span>, <span class="hlFld-ContribAuthor ">Catalin  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Ioana  Rus</span>, <span class="hlFld-ContribAuthor ">Mihail  Buse</span>, <span class="hlFld-ContribAuthor ">Bogdan  Fetica</span>, <span class="hlFld-ContribAuthor ">Mirela  Marian</span>, <span class="hlFld-ContribAuthor ">Cristina  Selicean</span>, <span class="hlFld-ContribAuthor ">Ioana  Berindan-Neagoe</span>, <span class="hlFld-ContribAuthor ">Bobe  Petrushev</span>, <span class="hlFld-ContribAuthor ">Horia  Bumbea</span>, <span class="hlFld-ContribAuthor ">Alina  Tanase</span>, <span class="hlFld-ContribAuthor ">Mihnea  Zdrenghea</span>, <span class="hlFld-ContribAuthor ">Shigeo  Fuji</span>, <span class="hlFld-ContribAuthor ">Shigehisa  Kitano</span>, <span class="hlFld-ContribAuthor ">Ciprian  Tomuleasa</span>, . </span><span class="cited-content_cbyCitation_article-title">Approach to the Adult Acute Lymphoblastic Leukemia Patient. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2019,</strong> <em>8 </em>
                                    (8)
                                     , 1175. <a href="https://doi.org/10.3390/jcm8081175" title="DOI URL">https://doi.org/10.3390/jcm8081175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm8081175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm8081175%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DApproach%252Bto%252Bthe%252BAdult%252BAcute%252BLymphoblastic%252BLeukemia%252BPatient%26aulast%3DSas%26aufirst%3DValentina%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D1175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel Nisakar  Meenakshi Sundaram</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Jiang</span>, <span class="hlFld-ContribAuthor ">Joseph M.  Brandwein</span>, <span class="hlFld-ContribAuthor ">Juliana  Valencia-Serna</span>, <span class="hlFld-ContribAuthor ">K.C.  Remant</span>, <span class="hlFld-ContribAuthor ">Hasan  Uludağ</span>. </span><span class="cited-content_cbyCitation_article-title">Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (7)
                                     , 1355-1369. <a href="https://doi.org/10.1016/j.drudis.2019.05.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.05.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.05.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DCurrent%252Boutlook%252Bon%252Bdrug%252Bresistance%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%252B%252528CML%252529%252Band%252Bpotential%252Btherapeutic%252Boptions%26aulast%3DMeenakshi%2BSundaram%26aufirst%3DDaniel%2BNisakar%26date%3D2019%26volume%3D24%26issue%3D7%26spage%3D1355%26epage%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddharth J.  Modi</span>, <span class="hlFld-ContribAuthor ">Vithal M.  Kulkarni</span>. </span><span class="cited-content_cbyCitation_article-title">Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2019,</strong> <em>2 </em>, 100009. <a href="https://doi.org/10.1016/j.medidd.2019.100009" title="DOI URL">https://doi.org/10.1016/j.medidd.2019.100009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2019.100009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2019.100009%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%252B%252528VEGFR-2%252529%25252FKDR%252BInhibitors%25253A%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DModi%26aufirst%3DSiddharth%2BJ.%26date%3D2019%26volume%3D2%26spage%3D100009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Balakrishna  Moku</span>, <span class="hlFld-ContribAuthor ">Lekkala  Ravindar</span>, <span class="hlFld-ContribAuthor ">K.P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">The significance of N-methylpicolinamides in the development of anticancer therapeutics: Synthesis and structure-activity relationship (SAR) studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>86 </em>, 513-537. <a href="https://doi.org/10.1016/j.bioorg.2019.02.030" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.02.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.02.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bsignificance%252Bof%252BN-methylpicolinamides%252Bin%252Bthe%252Bdevelopment%252Bof%252Banticancer%252Btherapeutics%25253A%252BSynthesis%252Band%252Bstructure-activity%252Brelationship%252B%252528SAR%252529%252Bstudies%26aulast%3DMoku%26aufirst%3DBalakrishna%26date%3D2019%26volume%3D86%26spage%3D513%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anand P  Singh</span>, <span class="hlFld-ContribAuthor ">Michael S  Glennon</span>, <span class="hlFld-ContribAuthor ">Prachi  Umbarkar</span>, <span class="hlFld-ContribAuthor ">Manisha  Gupte</span>, <span class="hlFld-ContribAuthor ">Cristi L  Galindo</span>, <span class="hlFld-ContribAuthor ">Qinkun  Zhang</span>, <span class="hlFld-ContribAuthor ">Thomas  Force</span>, <span class="hlFld-ContribAuthor ">Jason R  Becker</span>, <span class="hlFld-ContribAuthor ">Hind  Lal</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. </span><span class="cited-content_cbyCitation_journal-name">Cardiovascular Research</span><span> <strong>2019,</strong> <em>115 </em>
                                    (5)
                                     , 966-977. <a href="https://doi.org/10.1093/cvr/cvz006" title="DOI URL">https://doi.org/10.1093/cvr/cvz006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/cvr/cvz006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fcvr%2Fcvz006%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiovascular%2520Research%26atitle%3DPonatinib-induced%252Bcardiotoxicity%25253A%252Bdelineating%252Bthe%252Bsignalling%252Bmechanisms%252Band%252Bpotential%252Brescue%252Bstrategies%26aulast%3DSingh%26aufirst%3DAnand%2BP%26date%3D2019%26date%3D2019%26volume%3D115%26issue%3D5%26spage%3D966%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rieko  Oyama</span>, <span class="hlFld-ContribAuthor ">Fusako  Kito</span>, <span class="hlFld-ContribAuthor ">Mami  Takahashi</span>, <span class="hlFld-ContribAuthor ">Marimu  Sakumoto</span>, <span class="hlFld-ContribAuthor ">Kumiko  Shiozawa</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Qiao</span>, <span class="hlFld-ContribAuthor ">Rei  Noguchi</span>, <span class="hlFld-ContribAuthor ">Takashi  Kubo</span>, <span class="hlFld-ContribAuthor ">Shunichi  Toki</span>, <span class="hlFld-ContribAuthor ">Fumihiko  Nakatani</span>, <span class="hlFld-ContribAuthor ">Akihiko  Yoshida</span>, <span class="hlFld-ContribAuthor ">Akira  Kawai</span>, <span class="hlFld-ContribAuthor ">Tadashi  Kondo</span>. </span><span class="cited-content_cbyCitation_article-title">Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. </span><span class="cited-content_cbyCitation_journal-name">Human Cell</span><span> <strong>2019,</strong> <em>32 </em>
                                    (2)
                                     , 202-213. <a href="https://doi.org/10.1007/s13577-018-00232-2" title="DOI URL">https://doi.org/10.1007/s13577-018-00232-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13577-018-00232-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13577-018-00232-2%26sid%3Dliteratum%253Aachs%26jtitle%3DHuman%2520Cell%26atitle%3DEstablishment%252Band%252Bcharacterization%252Bof%252Ba%252Bnovel%252Bdedifferentiated%252Bchondrosarcoma%252Bcell%252Bline%25252C%252BNCC-dCS1-C1%26aulast%3DOyama%26aufirst%3DRieko%26date%3D2019%26date%3D2019%26volume%3D32%26issue%3D2%26spage%3D202%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Jin</span>, <span class="hlFld-ContribAuthor ">Fabrice  Gallou</span>, <span class="hlFld-ContribAuthor ">John  Reilly</span>, <span class="hlFld-ContribAuthor ">Bruce H.  Lipshutz</span>. </span><span class="cited-content_cbyCitation_article-title">ppm Pd-catalyzed, Cu-free Sonogashira couplings in water using commercially available catalyst precursors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (12)
                                     , 3481-3485. <a href="https://doi.org/10.1039/C8SC05618H" title="DOI URL">https://doi.org/10.1039/C8SC05618H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8SC05618H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8SC05618H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3Dppm%252BPd-catalyzed%25252C%252BCu-free%252BSonogashira%252Bcouplings%252Bin%252Bwater%252Busing%252Bcommercially%252Bavailable%252Bcatalyst%252Bprecursors%26aulast%3DJin%26aufirst%3DBo%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D3481%26epage%3D3485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (11)
                                     , 3336-3383. <a href="https://doi.org/10.1002/ange.201802416" title="DOI URL">https://doi.org/10.1002/ange.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEine%252Bstrukturelle%252BEvaluierung%252Bmedizinalchemischer%252BStrategien%252Bgegen%252BWirkstoffresistenzen%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D11%26spage%3D3336%26epage%3D3383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">A Structural View on Medicinal Chemistry Strategies against Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (11)
                                     , 3300-3345. <a href="https://doi.org/10.1002/anie.201802416" title="DOI URL">https://doi.org/10.1002/anie.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BStructural%252BView%252Bon%252BMedicinal%252BChemistry%252BStrategies%252Bagainst%252BDrug%252BResistance%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D11%26spage%3D3300%26epage%3D3345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brandon  Reinus</span>, <span class="hlFld-ContribAuthor ">Sean  Kerwin</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation and Utility of N-Alkynyl Azoles in Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 422. <a href="https://doi.org/10.3390/molecules24030422" title="DOI URL">https://doi.org/10.3390/molecules24030422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24030422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24030422%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPreparation%252Band%252BUtility%252Bof%252BN-Alkynyl%252BAzoles%252Bin%252BSynthesis%26aulast%3DReinus%26aufirst%3DBrandon%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingbin  Cui</span>, <span class="hlFld-ContribAuthor ">Pranav  Gupta</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 13-27. <a href="https://doi.org/10.1016/B978-0-12-816435-8.00002-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-816435-8.00002-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816435-8.00002-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816435-8.00002-X%26sid%3Dliteratum%253Aachs%26atitle%3DBCR-ABL%252BInhibitors%252Bas%252BSensitizing%252BAgents%252Bfor%252BCancer%252BChemotherapy%26aulast%3DCui%26aufirst%3DQingbin%26date%3D2019%26spage%3D13%26epage%3D27%26pub%3DElsevier%26atitle%3DProtein%252BKinase%252BInhibitors%252Bas%252BSensitizing%252BAgents%252Bfor%252BChemotherapy%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matteo  Molica</span>, <span class="hlFld-ContribAuthor ">Emilia  Scalzulli</span>, <span class="hlFld-ContribAuthor ">Gioia  Colafigli</span>, <span class="hlFld-ContribAuthor ">Robin  Foà</span>, <span class="hlFld-ContribAuthor ">Massimo  Breccia</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Hematology</span><span> <strong>2019,</strong> <em>10 </em>, 204062071982644. <a href="https://doi.org/10.1177/2040620719826444" title="DOI URL">https://doi.org/10.1177/2040620719826444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2040620719826444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2040620719826444%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Hematology%26atitle%3DInsights%252Binto%252Bthe%252Boptimal%252Buse%252Bof%252Bponatinib%252Bin%252Bpatients%252Bwith%252Bchronic%252Bphase%252Bchronic%252Bmyeloid%252Bleukaemia%26aulast%3DMolica%26aufirst%3DMatteo%26date%3D2019%26date%3D2019%26volume%3D10%26spage%3D204062071982644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina  Pavlovsky</span>, <span class="hlFld-ContribAuthor ">Onyee  Chan</span>, <span class="hlFld-ContribAuthor ">Chetasi  Talati</span>, <span class="hlFld-ContribAuthor ">Javier  Pinilla-Ibarz</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (3)
                                     , 257-269. <a href="https://doi.org/10.2217/fon-2018-0371" title="DOI URL">https://doi.org/10.2217/fon-2018-0371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0371%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DPonatinib%252Bin%252Bthe%252Btreatment%252Bof%252Bchronic%252Bmyeloid%252Bleukemia%252Band%252Bphiladelphia%252Bchromosome%252Bpositive%252Bacute%252Blymphoblastic%252Bleukemia%26aulast%3DPavlovsky%26aufirst%3DCarolina%26date%3D2019%26volume%3D15%26issue%3D3%26spage%3D257%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Yicong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>160 </em>, 61-81. <a href="https://doi.org/10.1016/j.ejmech.2018.10.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-%252528%2525284-methylpiperazin-1-yl%252529methyl%252529-3-%252528trifluoromethyl%252529phenyl%252529-3-%252528%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thio%252529propanamide%252B%252528CHMFL-ABL-121%252529%252Bas%252Ba%252Bhighly%252Bpotent%252BABL%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Ba%252Bvariety%252Bof%252BABL%252Bmutants%252Bincluding%252BT315I%252Bfor%252Bchronic%252Bmyeloid%252Bleukemia%26aulast%3DLiu%26aufirst%3DXuesong%26date%3D2018%26volume%3D160%26spage%3D61%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajiv Gandhi  Govindaraj</span>, <span class="hlFld-ContribAuthor ">Misagh  Naderi</span>, <span class="hlFld-ContribAuthor ">Manali  Singha</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Lemoine</span>, <span class="hlFld-ContribAuthor ">Michal  Brylinski</span>. </span><span class="cited-content_cbyCitation_article-title">Large-scale computational drug repositioning to find treatments for rare diseases. </span><span class="cited-content_cbyCitation_journal-name">npj Systems Biology and Applications</span><span> <strong>2018,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41540-018-0050-7" title="DOI URL">https://doi.org/10.1038/s41540-018-0050-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41540-018-0050-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41540-018-0050-7%26sid%3Dliteratum%253Aachs%26jtitle%3Dnpj%2520Systems%2520Biology%2520and%2520Applications%26atitle%3DLarge-scale%252Bcomputational%252Bdrug%252Brepositioning%252Bto%252Bfind%252Btreatments%252Bfor%252Brare%252Bdiseases%26aulast%3DGovindaraj%26aufirst%3DRajiv%2BGandhi%26date%3D2018%26date%3D2018%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annette D.  Rieg</span>, <span class="hlFld-ContribAuthor ">Said  Suleiman</span>, <span class="hlFld-ContribAuthor ">Carolin  Anker</span>, <span class="hlFld-ContribAuthor ">Eva  Verjans</span>, <span class="hlFld-ContribAuthor ">Rolf  Rossaint</span>, <span class="hlFld-ContribAuthor ">Stefan  Uhlig</span>, <span class="hlFld-ContribAuthor ">Christian  Martin</span>. </span><span class="cited-content_cbyCitation_article-title">PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2018,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-018-0829-5" title="DOI URL">https://doi.org/10.1186/s12931-018-0829-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-018-0829-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-018-0829-5%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DPDGF-BB%252Bregulates%252Bthe%252Bpulmonary%252Bvascular%252Btone%25253A%252Bimpact%252Bof%252Bprostaglandins%25252C%252Bcalcium%25252C%252BMAPK-%252Band%252BPI3K%25252FAKT%25252FmTOR%252Bsignalling%252Band%252Bactin%252Bpolymerisation%252Bin%252Bpulmonary%252Bveins%252Bof%252Bguinea%252Bpigs%26aulast%3DRieg%26aufirst%3DAnnette%2BD.%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho Jin  Lee</span>, <span class="hlFld-ContribAuthor ">Phuong Chi  Pham</span>, <span class="hlFld-ContribAuthor ">Seung Yeob  Hyun</span>, <span class="hlFld-ContribAuthor ">Byungyeob  Baek</span>, <span class="hlFld-ContribAuthor ">Byungjin  Kim</span>, <span class="hlFld-ContribAuthor ">Yunha  Kim</span>, <span class="hlFld-ContribAuthor ">Hye-Young  Min</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0802-4" title="DOI URL">https://doi.org/10.1186/s12943-018-0802-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0802-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0802-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DDevelopment%252Bof%252Ba%252B4-aminopyrazolo%25255B3%25252C4-d%25255Dpyrimidine-based%252Bdual%252BIGF1R%25252FSrc%252Binhibitor%252Bas%252Ba%252Bnovel%252Banticancer%252Bagent%252Bwith%252Bminimal%252Btoxicity%26aulast%3DLee%26aufirst%3DHo%2BJin%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federico  Rossari</span>, <span class="hlFld-ContribAuthor ">Filippo  Minutolo</span>, <span class="hlFld-ContribAuthor ">Enrico  Orciuolo</span>. </span><span class="cited-content_cbyCitation_article-title">Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2018,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-018-0624-2" title="DOI URL">https://doi.org/10.1186/s13045-018-0624-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-018-0624-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-018-0624-2%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DPast%25252C%252Bpresent%25252C%252Band%252Bfuture%252Bof%252BBcr-Abl%252Binhibitors%25253A%252Bfrom%252Bchemical%252Bdevelopment%252Bto%252Bclinical%252Befficacy%26aulast%3DRossari%26aufirst%3DFederico%26date%3D2018%26date%3D2018%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pradnya  Chopade</span>, <span class="hlFld-ContribAuthor ">Luke P.  Akard</span>. </span><span class="cited-content_cbyCitation_article-title">Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lymphoma Myeloma and Leukemia</span><span> <strong>2018,</strong> <em>18 </em>
                                    (11)
                                     , 710-723. <a href="https://doi.org/10.1016/j.clml.2018.06.029" title="DOI URL">https://doi.org/10.1016/j.clml.2018.06.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clml.2018.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clml.2018.06.029%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lymphoma%2520Myeloma%2520and%2520Leukemia%26atitle%3DImproving%252BOutcomes%252Bin%252BChronic%252BMyeloid%252BLeukemia%252BOver%252BTime%252Bin%252Bthe%252BEra%252Bof%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DChopade%26aufirst%3DPradnya%26date%3D2018%26volume%3D18%26issue%3D11%26spage%3D710%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sebastian  Kallus</span>, <span class="hlFld-ContribAuthor ">Bernhard  Englinger</span>, <span class="hlFld-ContribAuthor ">Julia  Senkiv</span>, <span class="hlFld-ContribAuthor ">Anna  Laemmerer</span>, <span class="hlFld-ContribAuthor ">Petra  Heffeter</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>, <span class="hlFld-ContribAuthor ">Christian R.  Kowol</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>. </span><span class="cited-content_cbyCitation_article-title">Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2018,</strong> <em>14 </em>
                                    (8)
                                     , 2632-2643. <a href="https://doi.org/10.1016/j.nano.2018.08.001" title="DOI URL">https://doi.org/10.1016/j.nano.2018.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2018.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DNanoformulations%252Bof%252Banticancer%252BFGFR%252Binhibitors%252Bwith%252Bimproved%252Btherapeutic%252Bindex%26aulast%3DKallus%26aufirst%3DSebastian%26date%3D2018%26volume%3D14%26issue%3D8%26spage%3D2632%26epage%3D2643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaesung P.  Choi</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Xi  Yang</span>, <span class="hlFld-ContribAuthor ">Xian  Wang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Ka Ka  Ting</span>, <span class="hlFld-ContribAuthor ">Matthew  Foley</span>, <span class="hlFld-ContribAuthor ">Victoria  Cogger</span>, <span class="hlFld-ContribAuthor ">Zhuo  Yang</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Zhiming  Han</span>, <span class="hlFld-ContribAuthor ">Renjing  Liu</span>, <span class="hlFld-ContribAuthor ">Jonathan  Baell</span>, <span class="hlFld-ContribAuthor ">Xiangjian  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2018,</strong> <em>4 </em>
                                    (11)
                                     , eaau0731. <a href="https://doi.org/10.1126/sciadv.aau0731" title="DOI URL">https://doi.org/10.1126/sciadv.aau0731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.aau0731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.aau0731%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DPonatinib%252B%252528AP24534%252529%252Binhibits%252BMEKK3-KLF%252Bsignaling%252Band%252Bprevents%252Bformation%252Band%252Bprogression%252Bof%252Bcerebral%252Bcavernous%252Bmalformations%26aulast%3DChoi%26aufirst%3DJaesung%2BP.%26date%3D2018%26date%3D2018%26volume%3D4%26issue%3D11%26spage%3Deaau0731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter T.  Harrison</span>, <span class="hlFld-ContribAuthor ">Paul H.  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. </span><span class="cited-content_cbyCitation_journal-name">Essays in Biochemistry</span><span> <strong>2018,</strong> <em>62 </em>
                                    (4)
                                     , 583-593. <a href="https://doi.org/10.1042/EBC20180016" title="DOI URL">https://doi.org/10.1042/EBC20180016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/EBC20180016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FEBC20180016%26sid%3Dliteratum%253Aachs%26jtitle%3DEssays%2520in%2520Biochemistry%26atitle%3DExploiting%252Bvulnerabilities%252Bin%252Bcancer%252Bsignalling%252Bnetworks%252Bto%252Bcombat%252Btargeted%252Btherapy%252Bresistance%26aulast%3DHarrison%26aufirst%3DPeter%25C2%25A0T.%26date%3D2018%26date%3D2018%26volume%3D62%26issue%3D4%26spage%3D583%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liu  Lu</span>, <span class="hlFld-ContribAuthor ">Chung Hoow  Kok</span>, <span class="hlFld-ContribAuthor ">Verity Ann  Saunders</span>, <span class="hlFld-ContribAuthor ">Jueqiong  Wang</span>, <span class="hlFld-ContribAuthor ">Jennifer Anne  McLean</span>, <span class="hlFld-ContribAuthor ">Timothy Peter  Hughes</span>, <span class="hlFld-ContribAuthor ">Deborah Lee  White</span>. </span><span class="cited-content_cbyCitation_article-title">Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant
              BCR-ABL1
              + cell lines. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (78)
                                     , 34735-34747. <a href="https://doi.org/10.18632/oncotarget.26187" title="DOI URL">https://doi.org/10.18632/oncotarget.26187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26187%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DModelling%252Bponatinib%252Bresistance%252Bin%252Btyrosine%252Bkinase%252Binhibitor-na%2525C3%2525AFve%252Band%252Bdasatinib%252Bresistant%252BBCR-ABL1%252B%25252B%252Bcell%252Blines%26aulast%3DLu%26aufirst%3DLiu%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D78%26spage%3D34735%26epage%3D34747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monira  Hoque</span>, <span class="hlFld-ContribAuthor ">Ramzi H.  Abbassi</span>, <span class="hlFld-ContribAuthor ">Danielle  Froio</span>, <span class="hlFld-ContribAuthor ">Jennifer  Man</span>, <span class="hlFld-ContribAuthor ">Terrance G.  Johns</span>, <span class="hlFld-ContribAuthor ">Brett W.  Stringer</span>, <span class="hlFld-ContribAuthor ">Bryan W.  Day</span>, <span class="hlFld-ContribAuthor ">Marina  Pajic</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>, <span class="hlFld-ContribAuthor ">Lenka  Munoz</span>. </span><span class="cited-content_cbyCitation_article-title">Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>134 </em>, 166-178. <a href="https://doi.org/10.1016/j.phrs.2018.06.023" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DChanges%252Bin%252Bcell%252Bmorphology%252Bguide%252Bidentification%252Bof%252Btubulin%252Bas%252Bthe%252Boff-target%252Bfor%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DHoque%26aufirst%3DMonira%26date%3D2018%26volume%3D134%26spage%3D166%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>133 </em>, 35-52. <a href="https://doi.org/10.1016/j.phrs.2018.04.020" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.04.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.04.020%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bsmall%252Bmolecule%252BKit%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bneoplastic%252Bdisorders%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2018%26volume%3D133%26spage%3D35%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Breccia</span>, <span class="hlFld-ContribAuthor ">Fabio  Efficace</span>, <span class="hlFld-ContribAuthor ">Alessandra  Iurlo</span>, <span class="hlFld-ContribAuthor ">Luigiana  Luciano</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Abruzzese</span>, <span class="hlFld-ContribAuthor ">Antonella  Gozzini</span>, <span class="hlFld-ContribAuthor ">Patrizia  Pregno</span>, <span class="hlFld-ContribAuthor ">Mario  Tiribelli</span>, <span class="hlFld-ContribAuthor ">Gianantonio  Rosti</span>, <span class="hlFld-ContribAuthor ">Giorgio  Minotti</span>. </span><span class="cited-content_cbyCitation_article-title">Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Safety</span><span> <strong>2018,</strong> <em>17 </em>
                                    (6)
                                     , 623-628. <a href="https://doi.org/10.1080/14740338.2018.1480719" title="DOI URL">https://doi.org/10.1080/14740338.2018.1480719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14740338.2018.1480719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14740338.2018.1480719%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Safety%26atitle%3DIntolerance%252Bto%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%25253A%252Bthe%252Bpossible%252Brole%252Bof%252Bponatinib%26aulast%3DBreccia%26aufirst%3DMassimo%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D6%26spage%3D623%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Freja Aksel  Jacobsen</span>, <span class="hlFld-ContribAuthor ">Alexander N.  Scherer</span>, <span class="hlFld-ContribAuthor ">Jeppe  Mouritsen</span>, <span class="hlFld-ContribAuthor ">Hera  Bragadóttir</span>, <span class="hlFld-ContribAuthor ">B.  Thomas Bäckström</span>, <span class="hlFld-ContribAuthor ">Samra  Sardar</span>, <span class="hlFld-ContribAuthor ">Dan  Holmberg</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Koleske</span>, <span class="hlFld-ContribAuthor ">Åsa  Andersson</span>. </span><span class="cited-content_cbyCitation_article-title">A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuroimmune Pharmacology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (2)
                                     , 265-276. <a href="https://doi.org/10.1007/s11481-018-9783-8" title="DOI URL">https://doi.org/10.1007/s11481-018-9783-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11481-018-9783-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11481-018-9783-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuroimmune%2520Pharmacology%26atitle%3DA%252BRole%252Bfor%252Bthe%252BNon-Receptor%252BTyrosine%252BKinase%252BAbl2%25252FArg%252Bin%252BExperimental%252BNeuroinflammation%26aulast%3DJacobsen%26aufirst%3DFreja%2BAksel%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D265%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica D.  Lang</span>, <span class="hlFld-ContribAuthor ">William P.D.  Hendricks</span>, <span class="hlFld-ContribAuthor ">Krystal A.  Orlando</span>, <span class="hlFld-ContribAuthor ">Hongwei  Yin</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Kiefer</span>, <span class="hlFld-ContribAuthor ">Pilar  Ramos</span>, <span class="hlFld-ContribAuthor ">Ritin  Sharma</span>, <span class="hlFld-ContribAuthor ">Patrick  Pirrotte</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Raupach</span>, <span class="hlFld-ContribAuthor ">Chris  Sereduk</span>, <span class="hlFld-ContribAuthor ">Nanyun  Tang</span>, <span class="hlFld-ContribAuthor ">Winnie S.  Liang</span>, <span class="hlFld-ContribAuthor ">Megan  Washington</span>, <span class="hlFld-ContribAuthor ">Salvatore J.  Facista</span>, <span class="hlFld-ContribAuthor ">Victoria L.  Zismann</span>, <span class="hlFld-ContribAuthor ">Emily M.  Cousins</span>, <span class="hlFld-ContribAuthor ">Michael B.  Major</span>, <span class="hlFld-ContribAuthor ">Yemin  Wang</span>, <span class="hlFld-ContribAuthor ">Anthony N.  Karnezis</span>, <span class="hlFld-ContribAuthor ">Aleksandar  Sekulic</span>, <span class="hlFld-ContribAuthor ">Ralf  Hass</span>, <span class="hlFld-ContribAuthor ">Barbara C.  Vanderhyden</span>, <span class="hlFld-ContribAuthor ">Praveen  Nair</span>, <span class="hlFld-ContribAuthor ">Bernard E.  Weissman</span>, <span class="hlFld-ContribAuthor ">David G.  Huntsman</span>, <span class="hlFld-ContribAuthor ">Jeffrey M.  Trent</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (8)
                                     , 1932-1943. <a href="https://doi.org/10.1158/1078-0432.CCR-17-1928" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-1928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-1928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-1928%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPonatinib%252BShows%252BPotent%252BAntitumor%252BActivity%252Bin%252BSmall%252BCell%252BCarcinoma%252Bof%252Bthe%252BOvary%252BHypercalcemic%252BType%252B%252528SCCOHT%252529%252Bthrough%252BMultikinase%252BInhibition%26aulast%3DLang%26aufirst%3DJessica%2BD.%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D8%26spage%3D1932%26epage%3D1943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>129 </em>, 65-83. <a href="https://doi.org/10.1016/j.phrs.2018.01.021" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.01.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.01.021%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bsmall%252Bmolecule%252Bplatelet-derived%252Bgrowth%252Bfactor%252Breceptor%252B%252528PDGFR%252529%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bneoplastic%252Bdisorders%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2018%26volume%3D129%26spage%3D65%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph M.  Fortunak</span>, <span class="hlFld-ContribAuthor ">Ji  Zhang</span>, <span class="hlFld-ContribAuthor ">Frederick E.  Nytko</span>, <span class="hlFld-ContribAuthor ">Tiffany N.  Ellison</span>. </span><span class="cited-content_cbyCitation_article-title">Green Process Chemistry in the Pharmaceutical Industry: Case Studies Update (2012-2016). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 621-647. <a href="https://doi.org/10.1002/9781119288152.ch23" title="DOI URL">https://doi.org/10.1002/9781119288152.ch23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119288152.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119288152.ch23%26sid%3Dliteratum%253Aachs%26atitle%3DGreen%252BProcess%252BChemistry%252Bin%252Bthe%252BPharmaceutical%252BIndustry%25253A%252BCase%252BStudies%252BUpdate%2525C2%2525A0%2525282012-2016%252529%26aulast%3DFortunak%26aufirst%3DJoseph%2BM.%26date%3D2018%26date%3D2018%26spage%3D621%26epage%3D647%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DGreen%252BTechniques%252Bfor%252BOrganic%252BSynthesis%252Band%252BMedicinal%252BChemistry%26aulast%3DZhang%26aufirst%3DWei%26date%3D2018%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riad  El Fakih</span>, <span class="hlFld-ContribAuthor ">Elias  Jabbour</span>, <span class="hlFld-ContribAuthor ">Farhad  Ravandi</span>, <span class="hlFld-ContribAuthor ">Mona  Hassanein</span>, <span class="hlFld-ContribAuthor ">Farhan  Anjum</span>, <span class="hlFld-ContribAuthor ">Syed  Ahmed</span>, <span class="hlFld-ContribAuthor ">Hagop  Kantarjian</span>. </span><span class="cited-content_cbyCitation_article-title">Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Hematology</span><span> <strong>2018,</strong> <em>93 </em>
                                    (2)
                                     , 286-295. <a href="https://doi.org/10.1002/ajh.24926" title="DOI URL">https://doi.org/10.1002/ajh.24926</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajh.24926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajh.24926%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Hematology%26atitle%3DCurrent%252Bparadigms%252Bin%252Bthe%252Bmanagement%252Bof%252BPhiladelphia%252Bchromosome%252Bpositive%252Bacute%252Blymphoblastic%252Bleukemia%252Bin%252Badults%26aulast%3DEl%2BFakih%26aufirst%3DRiad%26date%3D2018%26date%3D2017%26volume%3D93%26issue%3D2%26spage%3D286%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tiancen  Hu</span>, <span class="hlFld-ContribAuthor ">Elizabeth R.  Sprague</span>, <span class="hlFld-ContribAuthor ">Michelle  Fodor</span>, <span class="hlFld-ContribAuthor ">Travis  Stams</span>, <span class="hlFld-ContribAuthor ">Kirk L.  Clark</span>, <span class="hlFld-ContribAuthor ">Sandra W.  Cowan-Jacob</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of structural biology in medicine illustrated with four case studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Medicine</span><span> <strong>2018,</strong> <em>96 </em>
                                    (1)
                                     , 9-19. <a href="https://doi.org/10.1007/s00109-017-1565-x" title="DOI URL">https://doi.org/10.1007/s00109-017-1565-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00109-017-1565-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00109-017-1565-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Medicine%26atitle%3DThe%252Bimpact%252Bof%252Bstructural%252Bbiology%252Bin%252Bmedicine%252Billustrated%252Bwith%252Bfour%252Bcase%252Bstudies%26aulast%3DHu%26aufirst%3DTiancen%26date%3D2018%26date%3D2017%26volume%3D96%26issue%3D1%26spage%3D9%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nina A.  Maihöfer</span>, <span class="hlFld-ContribAuthor ">Said  Suleiman</span>, <span class="hlFld-ContribAuthor ">Daniela  Dreymüller</span>, <span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Rolf  Rossaint</span>, <span class="hlFld-ContribAuthor ">Stefan  Uhlig</span>, <span class="hlFld-ContribAuthor ">Christian  Martin</span>, <span class="hlFld-ContribAuthor ">Annette D.  Rieg</span>. </span><span class="cited-content_cbyCitation_article-title">Imatinib relaxes the pulmonary venous bed of guinea pigs. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2017,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-017-0514-0" title="DOI URL">https://doi.org/10.1186/s12931-017-0514-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-017-0514-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-017-0514-0%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DImatinib%252Brelaxes%252Bthe%252Bpulmonary%252Bvenous%252Bbed%252Bof%252Bguinea%252Bpigs%26aulast%3DMaih%25C3%25B6fer%26aufirst%3DNina%2BA.%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Shiv K.  Gupta</span>, <span class="hlFld-ContribAuthor ">Karen E.  Parrish</span>, <span class="hlFld-ContribAuthor ">Shuangling  Zhang</span>, <span class="hlFld-ContribAuthor ">Katrina K.  Bakken</span>, <span class="hlFld-ContribAuthor ">Brett L.  Carlson</span>, <span class="hlFld-ContribAuthor ">Ann C.  Mladek</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Ma</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>363 </em>
                                    (2)
                                     , 136-147. <a href="https://doi.org/10.1124/jpet.117.243477" title="DOI URL">https://doi.org/10.1124/jpet.117.243477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.117.243477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.117.243477%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DHeterogeneous%252BBinding%252Band%252BCentral%252BNervous%252BSystem%252BDistribution%252Bof%252Bthe%252BMultitargeted%252BKinase%252BInhibitor%252BPonatinib%252BRestrict%252BOrthotopic%252BEfficacy%252Bin%252Ba%252BPatient-Derived%252BXenograft%252BModel%252Bof%252BGlioblastoma%26aulast%3DLaramy%26aufirst%3DJanice%2BK.%26date%3D2017%26date%3D2017%26volume%3D363%26issue%3D2%26spage%3D136%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">De  Lin</span>, <span class="hlFld-ContribAuthor ">Rumen  Kostov</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.-J.  Huang</span>, <span class="hlFld-ContribAuthor ">Colin J.  Henderson</span>, <span class="hlFld-ContribAuthor ">C. Roland  Wolf</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>363 </em>
                                    (1)
                                     , 12-19. <a href="https://doi.org/10.1124/jpet.117.243246" title="DOI URL">https://doi.org/10.1124/jpet.117.243246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.117.243246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.117.243246%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DNovel%252BPathways%252Bof%252BPonatinib%252BDisposition%252BCatalyzed%252BBy%252BCYP1A1%252BInvolving%252BGeneration%252Bof%252BPotentially%252BToxic%252BMetabolites%26aulast%3DLin%26aufirst%3DDe%26date%3D2017%26date%3D2017%26volume%3D363%26issue%3D1%26spage%3D12%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miho J.  Fuse</span>, <span class="hlFld-ContribAuthor ">Koutaroh  Okada</span>, <span class="hlFld-ContribAuthor ">Tomoko  Oh-hara</span>, <span class="hlFld-ContribAuthor ">Hayato  Ogura</span>, <span class="hlFld-ContribAuthor ">Naoya  Fujita</span>, <span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2017,</strong> <em>16 </em>
                                    (10)
                                     , 2130-2143. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0909" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0909%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DMechanisms%252Bof%252BResistance%252Bto%252BNTRK%252BInhibitors%252Band%252BTherapeutic%252BStrategies%252Bin%252BNTRK1-Rearranged%252BCancers%26aulast%3DFuse%26aufirst%3DMiho%2BJ.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D10%26spage%3D2130%26epage%3D2143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic and Immunomodulating Agents (L). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-56. <a href="https://doi.org/10.1002/14356007.a05_001.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252Band%252BImmunomodulating%252BAgents%252B%252528L%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D56%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Breccia</span>, <span class="hlFld-ContribAuthor ">Patrizia  Pregno</span>, <span class="hlFld-ContribAuthor ">Paolo  Spallarossa</span>, <span class="hlFld-ContribAuthor ">Eleonora  Arboscello</span>, <span class="hlFld-ContribAuthor ">Fabio  Ciceri</span>, <span class="hlFld-ContribAuthor ">Mauro  Giorgi</span>, <span class="hlFld-ContribAuthor ">Alberto  Grossi</span>, <span class="hlFld-ContribAuthor ">Mario  Mallardo</span>, <span class="hlFld-ContribAuthor ">Savina  Nodari</span>, <span class="hlFld-ContribAuthor ">Stefano  Ottolini</span>, <span class="hlFld-ContribAuthor ">Carla  Sala</span>, <span class="hlFld-ContribAuthor ">Giovanni  Tortorella</span>, <span class="hlFld-ContribAuthor ">Gianantonio  Rosti</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Pane</span>, <span class="hlFld-ContribAuthor ">Giorgio  Minotti</span>, <span class="hlFld-ContribAuthor ">Michele  Baccarani</span>. </span><span class="cited-content_cbyCitation_article-title">Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. </span><span class="cited-content_cbyCitation_journal-name">Annals of Hematology</span><span> <strong>2017,</strong> <em>96 </em>
                                    (4)
                                     , 549-558. <a href="https://doi.org/10.1007/s00277-016-2820-x" title="DOI URL">https://doi.org/10.1007/s00277-016-2820-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00277-016-2820-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00277-016-2820-x%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Hematology%26atitle%3DIdentification%25252C%252Bprevention%252Band%252Bmanagement%252Bof%252Bcardiovascular%252Brisk%252Bin%252Bchronic%252Bmyeloid%252Bleukaemia%252Bpatients%252Bcandidate%252Bto%252Bponatinib%25253A%252Ban%252Bexpert%252Bopinion%26aulast%3DBreccia%26aufirst%3DMassimo%26date%3D2017%26date%3D2016%26volume%3D96%26issue%3D4%26spage%3D549%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yihua E.  Ye</span>, <span class="hlFld-ContribAuthor ">Caroline N.  Woodward</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>. </span><span class="cited-content_cbyCitation_article-title">Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2017,</strong> <em>79 </em>
                                    (3)
                                     , 507-518. <a href="https://doi.org/10.1007/s00280-017-3240-x" title="DOI URL">https://doi.org/10.1007/s00280-017-3240-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3240-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3240-x%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DAbsorption%25252C%252Bmetabolism%25252C%252Band%252Bexcretion%252Bof%252B%25255B14C%25255Dponatinib%252Bafter%252Ba%252Bsingle%252Boral%252Bdose%252Bin%252Bhumans%26aulast%3DYe%26aufirst%3DYihua%2BE.%26date%3D2017%26date%3D2017%26volume%3D79%26issue%3D3%26spage%3D507%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Nikolaus J.  Stiefl</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-37. <a href="https://doi.org/10.1007/7355_2017_5" title="DOI URL">https://doi.org/10.1007/7355_2017_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_5%26sid%3Dliteratum%253Aachs%26atitle%3DProgress%252Bin%252Bthe%252BDiscovery%252Bof%252BBCR-ABL%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BLeukemia%26aulast%3DManley%26aufirst%3DPaul%2BW.%26date%3D2017%26spage%3D1%26epage%3D37%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm100395q&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-12%3Barticle%3Aarticle%3A10.1021%2Fjm100395q&amp;citedByCount=211&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0019.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. BCR-ABL<sup>T315I</sup> kinase inhibitors with disclosed chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0020.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key medicinal chemistry optimization leading to clinical candidate <b>20g</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 9-(Ethynyl)purine Based Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) tetrachloroethylene, NaH, HMPA, 60 °C; (b) <i>n</i>-BuLi, THF, −78 °C; (c) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 2.6 mol % CuI, Et<sub>3</sub>N, Tol, 55 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Methods for the Synthesis of Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitors <b>12a</b>−<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Br<sub>2</sub>, EtOH, rt; (b) trimethylsilylacetylene, 5 mol % Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 80 °C; (c) TBAF, THF, rt; (d) conc. HCl, EtOH, reflux; (e) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt; (f) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) aq Me<sub>2</sub>NH, NaBH<sub>4</sub>; (i) 3-bromo-5-trifluoromethylaniline, 15 mol % 8-hydroxyquinoline, 15 mol % CuI, K<sub>2</sub>CO<sub>3</sub>, DMSO, 120 °C; (j) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Inhibitor <b>19a</b> and Chemical Structures of <b>18b</b>, <b>18c</b>, and <b>18g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methylpiperazine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, acetone/water, reflux; (c) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt; (d) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Inhibitors <b>19k</b>−<b>m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) 2-bromofluoroethane, NaHCO<sub>3</sub>, DMF, 80 °C; (c) 5 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, 7.5 mol % CuI, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, rt; (d) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt; (e) (i) 10% Pd on carbon, 50 psi H<sub>2</sub>, EtOH, rt, (ii) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Aniline <b>17o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1-methylpiperazine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) cyclopropaneboronic acid, 10 mol % Pd(OAc)<sub>2</sub>, 20 mol % P(c-hexyl)<sub>3</sub>; K<sub>3</sub>PO<sub>4</sub>, Tol/H<sub>2</sub>O, reflux; (c) Fe/HOAc, MeOH, reflux.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of Inhibitor <b>24b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3 equiv tributyl(vinyl)tin, 2.7 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 20 mol % P(2-furyl)<sub>3</sub>, DMF, rt; (b) 8 mol % Pd(OAc)<sub>2</sub>, 16 mol % P(<i>o</i>-tol)<sub>3</sub>, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 110 °C.</p></p></figure><figure data-id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0021.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Generation of new lead <b>12c</b> based on multipoint variations of <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0022.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Model of <b>1a</b> (green) and its “virtual” acetylene-linked analogue <b>1a′</b> (cyan) bound to ABL<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0023.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Model of inhibitor <b>19a</b> bound to ABL<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0024.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray structure of ABL<sup>T315I</sup> in complex with inhibitor <b>20g</b> (green) and model of <b>24a</b> (brown) and <b>24b</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0025.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of inhibitors in a Ba/F3 BCR-ABL<sup>T315I</sup> survival model at dose level of 10 mg/kg (error bars represent SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/medium/jm-2010-00395q_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0026.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of <b>20g</b> in a Ba/F3 BCR-ABL<sup>T315I</sup> survival model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-12/jm100395q/production/images/large/jm-2010-00395q_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100395q&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular biology of <i>bcr-abl1</i>-positive chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1182%2Fblood-2008-03-144790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18827185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1619-1630&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Molecular+biology+of+bcr-abl1-positive+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1619-1630</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique mol. event, the BCR-ABL1 oncogene.  Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1.  In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs.  Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood.  Herein, the authors synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPO2wdma5UrVg90H21EOLACvtfcHk0lirrq9jOqtHtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D&md5=bcd7d53c3e06d3b9833fb84799f75ea7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-03-144790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-03-144790%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520biology%2520of%2520bcr-abl1-positive%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1619%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNature%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lirrq9jOqtHtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Dis.%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Imatinib and beyond—exploring the full potential of targeted therapy for CML</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKjsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=535-543&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Imatinib+and+beyond%E2%80%94exploring+the+full+potential+of+targeted+therapy+for+CML"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib and beyond-exploring the full potential of targeted therapy for CML</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">535-543</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib is the std. frontline therapy for patients with chronic myeloid leukemia (CML); however, a substantial no. require alternative therapy owing to imatinib intolerance or imatinib resistance.  Studies have shown that second-generation tyrosine kinase inhibitors are efficacious in restoring cytogenetic responses in patients who require subsequent therapy.  Quintas-Cardama et al. discuss the second-generation and third-generation targeted agents that have restored cytogenetic response in patients unresponsive to imatinib, and the strategies being explored to improve the long-term outcome.  A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy.  Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy.  Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clin. meaningful response.  A third generation of TKIs is currently undergoing clin. testing for use in patients who fail imatinib and a second-generation TKI.  Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I.  The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib.  If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as std. frontline therapy in CML.  Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-pos. CML stem cells.  Efforts aimed at achieving this goal are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUuOUUt2n7NbVg90H21EOLACvtfcHk0ligFM4IvvWknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKjsrjP&md5=a57b7dc913159dd58cea142fa7749388</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DImatinib%2520and%2520beyond%25E2%2580%2594exploring%2520the%2520full%2520potential%2520of%2520targeted%2520therapy%2520for%2520CML%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D535%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilhot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiffers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratwohl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span> </span><span class="NLM_article-title">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">–</span> <span class="NLM_lpage">2417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1056%2FNEJMoa062867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17151364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2408-2417&author=B.+J.+Drukerauthor=F.+Guilhotauthor=S.+G.+O%E2%80%99Brienauthor=I.+Gathmannauthor=H.+Kantarjianauthor=N.+Gattermannauthor=M.+W.+Deiningerauthor=R.+T.+Silverauthor=J.+M.+Goldmanauthor=R.+M.+Stoneauthor=F.+Cervantesauthor=A.+Hochhausauthor=B.+L.+Powellauthor=J.+L.+Gabriloveauthor=P.+Rousselotauthor=J.+Reiffersauthor=J.+J.+Cornelissenauthor=T.+Hughesauthor=H.+Agisauthor=T.+Fischerauthor=G.+Verhoefauthor=J.+Shepherdauthor=G.+Saglioauthor=A.+Gratwohlauthor=J.+L.+Nielsenauthor=J.+P.+Radichauthor=B.+Simonssonauthor=K.+Taylorauthor=M.+Baccaraniauthor=C.+Soauthor=L.+Letvakauthor=R.+A.+Larson&title=Five-year+follow-up+of+patients+receiving+imatinib+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa; Kantarjian, Hagop; Gattermann, Norbert; Deininger, Michael W. N.; Silver, Richard T.; Goldman, John M.; Stone, Richard M.; Cervantes, Francisco; Hochhaus, Andreas; Powell, Bayard L.; Gabrilove, Janice L.; Rousselot, Philippe; Reiffers, Josy; Cornelissen, Jan J.; Hughes, Timothy; Agis, Hermine; Fischer, Thomas; Verhoef, Gregor; Shepherd, John; Saglio, Giuseppe; Gratwohl, Alois; Nielsen, Johan L.; Radich, Jerald P.; Simonsson, Bengt; Taylor, Kerry; Baccarani, Michele; So, Charlene; Letvak, Laurie; Larson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase.  Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase.  For 5 years, we followed patients with CML who received imatinib as initial therapy.  METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematol., cytogenetic, and mol. responses; and adverse events.  RESULTS: The median follow-up was 60 mo.  Kaplan-Meier ests. of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 mo and 87% by 60 mo.  An estd. 7% of patients progressed to accelerated-phase CML or blast crisis, and the estd. overall survival of patients who received imatinib as initial therapy was 89% at 60 mo.  Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P < 0.001).  Grade 3 or 4 adverse events diminished over time, and there was no clin. significant change in the profile of adverse events.  CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgIGWKzVtbrVg90H21EOLACvtfcHk0ligFM4IvvWknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ntrzM&md5=7e57245d3a918c079722ce0dcd265f15</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062867%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DSilver%26aufirst%3DR.%2BT.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGabrilove%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DAgis%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DC.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26atitle%3DFive-year%2520follow-up%2520of%2520patients%2520receiving%2520imatinib%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2408%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=BCR-ABL+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBCR-ABL%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+generation+inhibitors+of+BCR-ABL+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0ligFM4IvvWknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520generation%2520inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D345%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lguV4kKD678VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3948</span><span class="NLM_x">–</span> <span class="NLM_lpage">3954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3948-3954&author=S.+Kimuraauthor=H.+Naitoauthor=H.+Segawaauthor=J.+Kurodaauthor=T.+Yuasaauthor=K.+Satoauthor=A.+Yokotaauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=E.+Ashiharaauthor=Y.+Nakayaauthor=H.+Naruokaauthor=T.+Wakayamaauthor=K.+Nasuauthor=T.+Asakiauthor=T.+Niwaauthor=K.+Hirabayashiauthor=T.+Maekawa&title=NS-187%2C+a+potent+and+selective+dual+Bcr-Abl%2FLyn+tyrosine+kinase+inhibitor%2C+is+a+novel+agent+for+imatinib-resistant+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DSegawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DYuasa%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNakaya%26aufirst%3DY.%26aulast%3DNaruoka%26aufirst%3DH.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DNasu%26aufirst%3DK.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DNS-187%252C%2520a%2520potent%2520and%2520selective%2520dual%2520Bcr-Abl%252FLyn%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520a%2520novel%2520agent%2520for%2520imatinib-resistant%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3948%26epage%3D3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel Abl kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0lguV4kKD678VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520Abl%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS - 354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS+-+354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS%2520-%2520354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0ljTzf4M1pMjkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Puttini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo activity of SKI-606, a novel Src-ABL inhibitor, against imatinib-resistant BCR-ABL+ neoplastic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11314</span><span class="NLM_x">–</span> <span class="NLM_lpage">11322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11314-11322&author=M.+Puttiniauthor=A.+M.+Colucciaauthor=F.+Boschelliauthor=L.+Clerisauthor=E.+Marchesiauthor=A.+Donella-Deanaauthor=S.+Ahmedauthor=S.+Redaelliauthor=R.+Piazzaauthor=V.+Magistroniauthor=F.+Andreoniauthor=L.+Scapozzaauthor=F.+Formelliauthor=C.+Gambacorti-Passerini&title=In+vitro+and+in+vivo+activity+of+SKI-606%2C+a+novel+Src-ABL+inhibitor%2C+against+imatinib-resistant+BCR-ABL%2B+neoplastic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuttini%26aufirst%3DM.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DCleris%26aufirst%3DL.%26aulast%3DMarchesi%26aufirst%3DE.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DFormelli%26aufirst%3DF.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520SKI-606%252C%2520a%2520novel%2520Src-ABL%2520inhibitor%252C%2520against%2520imatinib-resistant%2520BCR-ABL%252B%2520neoplastic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11314%26epage%3D11322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+BCR-ABL+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+ABL+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520BCR-ABL%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520ABL%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Deguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodohara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2Fj.leukres.2007.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18191450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Slt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=980-983&author=Y.+Deguchiauthor=S.+Kimuraauthor=E.+Ashiharaauthor=T.+Niwaauthor=K.+Hodoharaauthor=Y.+Fujiyamaauthor=T.+Maekawa&title=Comparison+of+imatinib%2C+dasatinib%2C+nilotinib+and+INNO-406+in+imatinib-resistant+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines</span></div><div class="casAuthors">Deguchi, Yasuyuki; Kimura, Shinya; Ashihara, Eishi; Niwa, Tomoko; Hodohara, Keiko; Fujiyama, Yoshihide; Maekawa, Taira</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">980-983</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We compared the growth-inhibitory effects and inhibition profile of the SRC family kinases (SFKs) of imatinib, dasatinib, nilotinib and INNO-406.  Dasatinib exhibited the strongest potency against BCR-ABL with little selectivity over SFKs.  Nilotinib exhibited a weaker affinity than the other inhibitors, but was highly specific for ABL and may be useful for the treatment of P-glycoprotein overexpressing leukemic cells.  INNO-406 had an intermediate affinity for BCR-ABL between that of dasatinib and nilotinib, and inhibited only SFKs LCK and LYN among SFKs.  Both nilotinib and INNO-406 were potent inhibitors of the dasatinib-resistant T315A, F317L and F317V BCR-ABL mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBQdgPMo2y7Vg90H21EOLACvtfcHk0liNFsLevpYcBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Slt7Y%253D&md5=cf794bffcdb34ba4556de93069a44a34</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2007.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2007.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DDeguchi%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHodohara%26aufirst%3DK.%26aulast%3DFujiyama%26aufirst%3DY.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DComparison%2520of%2520imatinib%252C%2520dasatinib%252C%2520nilotinib%2520and%2520INNO-406%2520in%2520imatinib-resistant%2520cell%2520lines%26jtitle%3DLeuk.%2520Res.%26date%3D2008%26volume%3D32%26spage%3D980%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostagno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magistroni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marega, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1200%2FJCO.2008.19.8853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19075254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=469-471&author=S.+Redaelliauthor=R.+Piazzaauthor=R.+Rostagnoauthor=V.+Magistroniauthor=P.+Periniauthor=M.+Maregaauthor=C.+Gambacorti-Passeriniauthor=F.+Boschelli&title=Activity+of+bosutinib%2C+dasatinib%2C+and+nilotinib+against+18+imatinib-resistant+BCR%2FABL+mutants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of bosutinib, dusatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Comments</span></div><div class="casAuthors">Redaelli, Sara; Piazza, Rocco; Rostagno, Roberta; Magistroni, Vera; Perini, Pietro; Marega, Manuela; Gambacorti-Passerini, Carlo; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-471</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The treatment of chronic myeloid leukemia (CML) has been radically modified by the discovery, of imatinib, a selective inhibitor of the chimeric protein BCR/ABL that causes the disease.  Patients with Philadelphia-pos. (Ph+) acute lymphoblastic leukemia also benefited from imatinib availability, although to a lesser extent.  In the present study, the activity of the tyrosine kinase inhibitors (TKIs) bosutinib, dasatinib, imatinib, and nilotinib against a panel of 18 mutated forms of BCR/ABL assocd. with imatinib resistance in CML and Ph+ acute lymphoblastic leukemia patients was investigated.  The results revealed differences in the activity spectra of the four TKIs against the 18 BCR/ABL mutations.  The obsd. activity pattern will help physicians develop rational, patient-tailored therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEwo2Cgi3qCLVg90H21EOLACvtfcHk0liNFsLevpYcBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitF2gtrY%253D&md5=e60ba9e376011236e8a548a3334fc8f5</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.8853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.8853%26sid%3Dliteratum%253Aachs%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DRostagno%26aufirst%3DR.%26aulast%3DMagistroni%26aufirst%3DV.%26aulast%3DPerini%26aufirst%3DP.%26aulast%3DMarega%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DActivity%2520of%2520bosutinib%252C%2520dasatinib%252C%2520and%2520nilotinib%2520against%252018%2520imatinib-resistant%2520BCR%252FABL%2520mutants%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D469%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">New BCR-ABL inhibitors in chronic myeloid leukemia: keeping resistance in check</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=865-878&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=New+BCR-ABL+inhibitors+in+chronic+myeloid+leukemia%3A+keeping+resistance+in+check"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNew%2520BCR-ABL%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520keeping%2520resistance%2520in%2520check%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D865%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span> </span><span class="NLM_article-title">ABL tyrosine kinase inhibitors for overriding BCR-ABL/ T315I: from the second to third generation</span> <span class="citation_source-journal">Exp. Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1586%2F14737140.8.9.1387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18759691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1387-1398&author=R.+Tanakaauthor=S.+Kimura&title=ABL+tyrosine+kinase+inhibitors+for+overriding+BCR-ABL%2F+T315I%3A+from+the+second+to+third+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation</span></div><div class="casAuthors">Tanaka, Ruriko; Kimura, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1398</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate.  However, primary and secondary resistance have frequently been reported, particularly in patients with advanced-stage disease.  Point mutations within the Abl kinase domain that interfere with imatinib binding are the most crit. cause of imatinib resistance.  In order to override this resistance, several second generation ATP-competitive Abl TKIs including dasatinib, nilotinib, bosutinib and INNO-406 have been developed.  Despite promising clin. results from these novel Abl TKIs for most mutations, the frequently obsd. mutant T315I is not effectively targeted by any of these agents.  Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks.  In this review, the current status of novel agents for CML treatment is overviewed as follows: pathogenesis and features of CML; imatinib and second-generation Abl TKIs; why Abl TKIs are not effective against T315I; and novel agents that may override the T315I mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHnGTn_O-afbVg90H21EOLACvtfcHk0ljPMO1nQI8ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO&md5=afe3c45934c38478967b259deddd2cb9</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1586%2F14737140.8.9.1387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.8.9.1387%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26atitle%3DABL%2520tyrosine%2520kinase%2520inhibitors%2520for%2520overriding%2520BCR-ABL%252F%2520T315I%253A%2520from%2520the%2520second%2520to%2520third%2520generation%26jtitle%3DExp.%2520Rev.%2520Anticancer%2520Ther.%26date%3D2008%26volume%3D8%26spage%3D1387%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0ljPMO1nQI8ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0ljPMO1nQI8ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of Abl kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+Abl+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0lgUi2fKG40vZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520Abl%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chow, C. P.; Cao, J.; Dneprovskaia, E.; Fine, R. M.; Hanna, E.; Hood, J.; Hwang, L.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Palanki, M. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H.</span><span> </span><span class="NLM_article-title">Design and SAR of thiazole-based inhibitors for the ABL-T315I enzyme</span>. <span class="NLM_conf-name">234th ACS National Meeting</span>, <span class="NLM_conf-loc">Boston, MA</span>, <span class="NLM_conf-date">August 19−23, 2007</span>, Abstract MED-358.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chow%2C+C.+P.%3B+Cao%2C+J.%3B+Dneprovskaia%2C+E.%3B+Fine%2C+R.+M.%3B+Hanna%2C+E.%3B+Hood%2C+J.%3B+Hwang%2C+L.%3B+Kang%2C+X.%3B+Klebansky%2C+B.%3B+Lohse%2C+D.%3B+Mak%2C+C.+C.%3B+McPherson%2C+A.%3B+Noronha%2C+G.%3B+Palanki%2C+M.+S.%3B+Pathak%2C+V.+P.%3B+Renick%2C+J.%3B+Soll%2C+R.%3B+Zeng%2C+B.%3B+Zhu%2C+H.+Design+and+SAR+of+thiazole-based+inhibitors+for+the+ABL-T315I+enzyme.+234th+ACS+National+Meeting%2C+Boston%2C+MA%2C+August+19%E2%88%9223%2C+2007%2C+Abstract+MED-358."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DC.%2BP.%26atitle%3DDesign%2520and%2520SAR%2520of%2520thiazole-based%2520inhibitors%2520for%2520the%2520ABL-T315I%2520enzyme" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gontarewicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balabanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummendorf, T. H.</span><span> </span><span class="NLM_article-title">Simultaneous targeting of Aurora kinases and BCR-ABL kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4355</span><span class="NLM_x">–</span> <span class="NLM_lpage">4364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4355-4364&author=A.+Gontarewiczauthor=S.+Balabanovauthor=G.+Kellerauthor=R.+Colomboauthor=A.+Grazianoauthor=E.+Pesentiauthor=D.+Bentenauthor=C.+Bokemeyerauthor=W.+Fiedlerauthor=J.+Mollauthor=T.+H.+Brummendorf&title=Simultaneous+targeting+of+Aurora+kinases+and+BCR-ABL+kinase+by+the+small+molecule+inhibitor+PHA-739358+is+effective+against+imatinib-resistant+BCR-ABL+mutations+including+T315I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGontarewicz%26aufirst%3DA.%26aulast%3DBalabanov%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DBenten%26aufirst%3DD.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DBrummendorf%26aufirst%3DT.%2BH.%26atitle%3DSimultaneous%2520targeting%2520of%2520Aurora%2520kinases%2520and%2520BCR-ABL%2520kinase%2520by%2520the%2520small%2520molecule%2520inhibitor%2520PHA-739358%2520is%2520effective%2520against%2520imatinib-resistant%2520BCR-ABL%2520mutations%2520including%2520T315I%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4355%26epage%3D4364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multi-kinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multi-kinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multi-kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.-S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as dual Src/ABL kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">4756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-4756&author=W.-S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+dual+Src%2FABL+kinase+inhibitors+targeting+the+inactive+conformation%3A+design%2C+synthesis%2C+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520dual%2520Src%252FABL%2520kinase%2520inhibitors%2520targeting%2520the%2520inactive%2520conformation%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4743%26epage%3D4756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span> </span><span class="NLM_article-title">Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2009.00905.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19895503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=18-28&author=T.+Zhouauthor=L.+Parillonauthor=W.-S.+Huangauthor=Y.+Wangauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeareauthor=T.+Clacksonauthor=X.+Zhuauthor=D.+C.+Dalgarno&title=Structural+analysis+of+DFG-in+and+DFG-out+dual+Src-Abl+inhibitors+sharing+a+common+vinyl+purine+template"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template</span></div><div class="casAuthors">Zhou, Tianjun; Commodore, Lois; Huang, Wei-Sheng; Wang, Yihan; Sawyer, Tomi K.; Shakespeare, William C.; Clackson, Tim; Zhu, Xiaotian; Dalgarno, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-28</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bcr-Abl is the oncogenic protein tyrosine kinase responsible for chronic myeloid leukemia (CML).  Treatment of the disease with imatinib (Gleevec) often results in drug resistance via kinase mutations at the advanced phases of the disease, which has necessitated the development of new mutation-resistant inhibitors, notably against the T315I gatekeeper mutation.  As part of the authors' efforts to discover such mutation resistant Abl inhibitors, the authors have focused on optimizing purine template kinase inhibitors, leading to the discovery of potent DFG-in and DFG-out series of Abl inhibitors that are also potent Src inhibitors.  Here the authors present crystal structures of Abl bound by two such inhibitors, based on a common N9-arenyl purine, and that represent both DFG-in and -out binding modes.  In each structure the purine template is bound deeply in the adenine pocket and the novel vinyl linker forms a non-classical hydrogen bond to the gatekeeper residue, Thr 315.  Specific template substitutions promote either a DFG-in or -out binding mode, with the kinase binding site adjusting to optimize mol. recognition.  Bcr-Abl T315I mutant kinase is resistant to all currently marketed Abl inhibitors, and is the focus of intense drug discovery efforts.  Notably, the authors' DFG-out inhibitor, AP24163, exhibits modest activity against this mutant, illustrating that this kinase mutant can be inhibited by DFG-out class inhibitors.  Furthermore the authors' DFG-out inhibitor exhibits dual Src-Abl activity, absent from the prototypical DFG-out inhibitor, imatinib as well as its analog, nilotinib.  The data presented here provides structural guidance for the further design of novel potent DFG-out class inhibitors against Src, Abl and Abl T315I mutant kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcsXyX0NgLrbVg90H21EOLACvtfcHk0lhs4PcpNyMREQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfP&md5=380bc5982df61ad8402fe0db5ec61d9d</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00905.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00905.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26atitle%3DStructural%2520analysis%2520of%2520DFG-in%2520and%2520DFG-out%2520dual%2520Src-Abl%2520inhibitors%2520sharing%2520a%2520common%2520vinyl%2520purine%2520template%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26spage%3D18%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppress in vitro resistance</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1111%2Fj.1747-0285.2009.00911.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=20028401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=223-227&author=M.+Azamauthor=J.+T.+Powersauthor=W.+Einhornauthor=W.-S.+Huangauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=AP24163+inhibits+the+gatekeeper+mutant+of+BCR-ABL+and+suppress+in+vitro+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">AP24163 inhibits the gatekeeper Mutant of BCR-ABL and suppresses in vitro resistance</span></div><div class="casAuthors">Azam, Mohammad; Powers, John T.; Einhorn, William; Huang, Wei-Sheng; Shakespeare, William C.; Zhu, Xiaotian; Dalgarno, David; Clackson, Tim; Sawyer, Tomi K.; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia.  The second generation BCR/ABL inhibitors nilotinib and dasatinib effectively inhibit most imatinib resistance variants, but are ineffective against the gatekeeper mutant, T315I.  Gatekeeper mutation activates the kinase by stabilizing the hydrophobic spine.  Here, we describe that the rationally designed compd. AP24163 can inhibit native and gatekeeper mutants of the BCR/ABL kinase.  Structural modeling suggests that AP24163 affects the flexibility of the P-loop and destabilizes the active conformation by disrupting the hydrophobic spine.  In vitro screening for drug resistance identified clones with compd. mutations involving both the P-loop and T315I.  Our studies provide structural insights for the design of inhibitors against the gatekeeper mutant and suggest that up-front combination therapy may be required to prevent the emergence of compd.-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxnyZvn4pGQ7Vg90H21EOLACvtfcHk0lhJd5l4CjM9sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovVSguw%253D%253D&md5=4e9674ecae74ed04ae30719899d93507</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00911.x%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DJ.%2BT.%26aulast%3DEinhorn%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DAP24163%2520inhibits%2520the%2520gatekeeper%2520mutant%2520of%2520BCR-ABL%2520and%2520suppress%2520in%2520vitro%2520resistance%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26spage%3D223%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Joshi, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ksebati, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drach, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zemlicka, J.</span><span> </span><span class="NLM_article-title">Synthesis, transformations and biological activity of chloro enamines and ynamines derived from chloroalkenyl- and alkynyl-<i>N</i>-substituted purine and pyrimidine bases of nucleic acids</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=1089-1098&author=R.+V.+Joshiauthor=Z.-Q.+Xuauthor=M.+B.+Ksebatiauthor=D.+Kesselauthor=T.+H.+Corbettauthor=J.+C.+Drachauthor=J.+Zemlicka&title=Synthesis%2C+transformations+and+biological+activity+of+chloro+enamines+and+ynamines+derived+from+chloroalkenyl-+and+alkynyl-N-substituted+purine+and+pyrimidine+bases+of+nucleic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DR.%2BV.%26aulast%3DXu%26aufirst%3DZ.-Q.%26aulast%3DKsebati%26aufirst%3DM.%2BB.%26aulast%3DKessel%26aufirst%3DD.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DDrach%26aufirst%3DJ.%2BC.%26aulast%3DZemlicka%26aufirst%3DJ.%26atitle%3DSynthesis%252C%2520transformations%2520and%2520biological%2520activity%2520of%2520chloro%2520enamines%2520and%2520ynamines%2520derived%2520from%2520chloroalkenyl-%2520and%2520alkynyl-N-substituted%2520purine%2520and%2520pyrimidine%2520bases%2520of%2520nucleic%2520acids%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1994%26spage%3D1089%26epage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Chinchilla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, C.</span><span> </span><span class="NLM_article-title">The Sonogashira reaction: a booming methodology in synthetic organic chemistry</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr050992x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=874-922&author=R.+Chinchillaauthor=C.+Najera&title=The+Sonogashira+reaction%3A+a+booming+methodology+in+synthetic+organic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Sonogashira reaction: a booming methodology in synthetic organic chemistry</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">874-922</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The palladium-catalyzed sp2-sp coupling reaction between aryl or alkenyl halides or triflates and terminal alkynes, with or without the presence of copper(I) cocatalyst, was reviewed.  The mechanism of Sonogashira reaction was discussed, and the catalysts and reaction conditions were explored as well.  In addn., the application of Sonogashira cross-coupling reaction was also introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ8ePd8RdbSrVg90H21EOLACvtfcHk0lhJd5l4CjM9sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWjtbc%253D&md5=91f627efbf940c60809c2acfe597d3b7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcr050992x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr050992x%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DNajera%26aufirst%3DC.%26atitle%3DThe%2520Sonogashira%2520reaction%253A%2520a%2520booming%2520methodology%2520in%2520synthetic%2520organic%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D874%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hand, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smakula, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, W.</span><span> </span><span class="NLM_article-title">Teleamination of the imidazo[1,2-<i>a</i>]pyridine system</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2900</span><span class="NLM_x">–</span> <span class="NLM_lpage">2906</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00408a033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1978&pages=2900-2906&author=E.+Handauthor=P.+Smakulaauthor=W.+William&title=Teleamination+of+the+imidazo%5B1%2C2-a%5Dpyridine+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjo00408a033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00408a033%26sid%3Dliteratum%253Aachs%26aulast%3DHand%26aufirst%3DE.%26aulast%3DSmakula%26aufirst%3DP.%26aulast%3DWilliam%26aufirst%3DW.%26atitle%3DTeleamination%2520of%2520the%2520imidazo%255B1%252C2-a%255Dpyridine%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1978%26volume%3D43%26spage%3D2900%26epage%3D2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">An efficient synthesis of nilotinib (AMN107)</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1055%2Fs-2007-983754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=2121-2124&author=W.-S.+Huangauthor=W.+C.+Shakespeare&title=An+efficient+synthesis+of+nilotinib+%28AMN107%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of nilotinib (AMN107)</span></div><div class="casAuthors">Huang, Wei-Sheng; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2121-2124</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A concise synthesis of AMN107, a compd. currently undergoing several phase II/III clin. trials for chronic myelogenous leukemia, is described.  The new procedure reduces the no. of synthetic steps from eight to four, with an overall yield of 65%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVk1pQeYvBWbVg90H21EOLACvtfcHk0lhNU4Q-wyzYFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D&md5=4ca31907c33acd3510b7dcfa4e70374c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-983754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-983754%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520nilotinib%2520%2528AMN107%2529%26jtitle%3DSynthesis%26date%3D2007%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ding, Q.; Gray, N. S.; Li, B.; Liu, Y.; Sim, T.; Uno, T.; Zhang, G.; Pissot-Soldermann, C.; Breitenstein, W.; Bold, G.; Caravatti, G.; Furet, P.; Guagnano, V.; Lang, M.; Manley, P. W.; Schoepfer, J.; Spanka, C.</span><span> </span><span class="NLM_article-title">Preparation of pyrimidine urea derivatives as kinase inhibitors for use against proliferative diseases</span>. PCT Int. Appl. WO 2006000420,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Q.+Ding&author=N.+S.+Gray&author=B.+Li&author=Y.+Liu&author=T.+Sim&author=T.+Uno&author=G.+Zhang&author=C.+Pissot-Soldermann&author=W.+Breitenstein&author=G.+Bold&author=G.+Caravatti&author=P.+Furet&author=V.+Guagnano&author=M.+Lang&author=P.+W.+Manley&author=J.+Schoepfer&author=C.+Spanka&title=Preparation+of+pyrimidine+urea+derivatives+as+kinase+inhibitors+for+use+against+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520pyrimidine%2520urea%2520derivatives%2520as%2520kinase%2520inhibitors%2520for%2520use%2520against%2520proliferative%2520diseases%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Bold, G.; Caravatti, G.; Floersheimer, A.; Guagnano, V.; Imbach, P.; Masuya, K.; Roesel, J.; Vaupel, A.; Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Diaryl urea derivatives, particularly <i>N</i>-[4-(pyrimidin-4-yloxy)phenyl]-<i>N</i>′-phenylureas, useful in the treatment of protein kinase dependent diseases, especially neoplasm, and their preparation</span>. PCT Int. Appl. WO 2005051366,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+Bold&author=G.+Caravatti&author=A.+Floersheimer&author=V.+Guagnano&author=P.+Imbach&author=K.+Masuya&author=J.+Roesel&author=A.+Vaupel&author=C.+Garcia-Echeverria&title=Diaryl+urea+derivatives%2C+particularly+N-%5B4-%28pyrimidin-4-yloxy%29phenyl%5D-N%E2%80%B2-phenylureas%2C+useful+in+the+treatment+of+protein+kinase+dependent+diseases%2C+especially+neoplasm%2C+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBold%26aufirst%3DG.%26atitle%3DDiaryl%2520urea%2520derivatives%252C%2520particularly%2520N-%255B4-%2528pyrimidin-4-yloxy%2529phenyl%255D-N%25E2%2580%25B2-phenylureas%252C%2520useful%2520in%2520the%2520treatment%2520of%2520protein%2520kinase%2520dependent%2520diseases%252C%2520especially%2520neoplasm%252C%2520and%2520their%2520preparation%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Chaffee, S. C.; Albrecht, B. K.; Hodous, B. L.; Martin, M. W.; McGowan, D. C.; Dimauro, E. F.; Reddy, G.; Cee, V. J.; Olivieri, P. R.; Reed, A.; Romero, K.</span><span> </span><span class="NLM_article-title">Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy</span>. PCT Int. Appl. WO 2006044823,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+C.+Chaffee&author=B.+K.+Albrecht&author=B.+L.+Hodous&author=M.+W.+Martin&author=D.+C.+McGowan&author=E.+F.+Dimauro&author=G.+Reddy&author=V.+J.+Cee&author=P.+R.+Olivieri&author=A.+Reed&author=K.+Romero&title=Heteroaryl-substituted+alkyne+compounds+as+protein+kinase+inhibitors%2C+their+preparation%2C+pharmaceutical+compositions%2C+and+use+in+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26atitle%3DHeteroaryl-substituted%2520alkyne%2520compounds%2520as%2520protein%2520kinase%2520inhibitors%252C%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520in%2520therapy%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I ABL mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+ABL+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520ABL%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0liHTTLjvnSkTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Analysis of the structural basis of specificity of inhibition of the ABL kinase by STI571</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">32214</span><span class="NLM_x">–</span> <span class="NLM_lpage">32219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32214-32219&author=A.+S.+Corbinauthor=E.+Buchdungerauthor=F.+Pascalauthor=B.+J.+Druker&title=Analysis+of+the+structural+basis+of+specificity+of+inhibition+of+the+ABL+kinase+by+STI571"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DPascal%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520basis%2520of%2520specificity%2520of%2520inhibition%2520of%2520the%2520ABL%2520kinase%2520by%2520STI571%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D32214%26epage%3D32219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">–</span> <span class="NLM_lpage">843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1016%2FS0092-8674%2803%2900190-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12654249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=831-843&author=M.+Azamauthor=R.+R.+Latekauthor=G.+Q.+Daley&title=Mechanisms+of+autoinhibition+and+STI-571%2Fimatinib+resistance+revealed+by+mutagenesis+of+BCR-ABL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL</span></div><div class="casAuthors">Azam, Mohammad; Latek, Robert R.; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">831-843</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl fusion protein kinase causes chronic myeloid leukemia and is targeted by the signal transduction inhibitor STI-571/Gleevec/imatinib (STI-571).  Sequencing of the BCR-ABL gene in patients who have relapsed after STI-571 chemotherapy has revealed a limited set of kinase domain mutations that mediate drug resistance.  To obtain a more comprehensive survey of the amino acid substitutions that confer STI-571 resistance, we performed an in vitro screen of randomly mutagenized BCR-ABL and recovered all of the major mutations previously identified in patients and numerous others that illuminate novel mechanisms of acquired drug resistance.  Structural modeling implies that a novel class of variants acts allosterically to destabilize the autoinhibited conformation of the ABL kinase to which STI-571 preferentially binds.  This screening strategy is a paradigm applicable to a growing list of target-directed anti-cancer agents and provides a means of anticipating the drug-resistant amino acid substitutions that are likely to be clin. problematic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkB-4Z31c31bVg90H21EOLACvtfcHk0liHTTLjvnSkTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVWjsbY%253D&md5=eb949f0f59c31b5c821eba8931fcf4ce</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900190-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900190-9%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DMechanisms%2520of%2520autoinhibition%2520and%2520STI-571%252Fimatinib%2520resistance%2520revealed%2520by%2520mutagenesis%2520of%2520BCR-ABL%26jtitle%3DCell%26date%3D2003%26volume%3D112%26spage%3D831%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Facile synthesis of 9-(arenethenyl)purines via Heck reaction of 9-vinylpurines and aryl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7388</span><span class="NLM_x">–</span> <span class="NLM_lpage">7391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7388-7391&author=W.-S.+Huangauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=D.+Wenauthor=S.+Liuauthor=S.+P.+Lentiniauthor=S.+Dasauthor=G.+Bandaauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=Facile+synthesis+of+9-%28arenethenyl%29purines+via+Heck+reaction+of+9-vinylpurines+and+aryl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DFacile%2520synthesis%2520of%25209-%2528arenethenyl%2529purines%2520via%2520Heck%2520reaction%2520of%25209-vinylpurines%2520and%2520aryl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7388%26epage%3D7391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0liHTTLjvnSkTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Horio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2712</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2712-2717&author=T.+Horioauthor=T.+Hamasakiauthor=T.+Inoueauthor=T.+Wakayamaauthor=S.+Itouauthor=H.+Naitoauthor=T.+Asakiauthor=H.+Hayaseauthor=T.+Niwa&title=Structural+factors+contributing+to+the+Abl%2FLyn+dual+inhibitory+activity+of+3-substituted+benzamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DHamasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHayase%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DStructural%2520factors%2520contributing%2520to%2520the%2520Abl%252FLyn%2520dual%2520inhibitory%2520activity%2520of%25203-substituted%2520benzamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2712%26epage%3D2717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_publisher-name">Daylight Chemical Information System, Inc.</span><a href="http://www.daylight.com" class="extLink">http://www.daylight.com</a>. Accessed November 2005.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight+Chemical+Information+System%2C+Inc.http%3A%2F%2Fwww.daylight.com.+Accessed+November+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26pub%3DDaylight%2520Chemical%2520Information%2520System%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+ABL-kinase%3A+phenylaminopyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520ABL-kinase%253A%2520phenylaminopyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Porkka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskenvesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimpilainen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustjoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brethon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccersley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjorth-Hansen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoglund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klamova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brito-Babapulle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span> </span><span class="NLM_article-title">Dasatinib crosses the blood−brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1005-1012&author=K.+Porkkaauthor=P.+Koskenvesaauthor=T.+Lundanauthor=J.+Rimpilainenauthor=S.+Mustjokiauthor=R.+Smyklaauthor=R.+Wildauthor=R.+Luoauthor=M.+Arnanauthor=B.+Brethonauthor=L.+Eccersleyauthor=H.+Hjorth-Hansenauthor=M.+Hoglundauthor=H.+Klamovaauthor=H.+Knutsenauthor=S.+Parikhauthor=E.+Raffouxauthor=F.+Gruberauthor=F.+Brito-Babapulleauthor=H.+Dombretauthor=R.+F.+Duarteauthor=E.+Elonenauthor=R.+Paquetteauthor=C.+M.+Zwaanauthor=F.+Y.+F.+Lee&title=Dasatinib+crosses+the+blood%E2%88%92brain+barrier+and+is+an+efficient+therapy+for+central+nervous+system+Philadelphia+chromosome-positive+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DKoskenvesa%26aufirst%3DP.%26aulast%3DLundan%26aufirst%3DT.%26aulast%3DRimpilainen%26aufirst%3DJ.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DSmykla%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DArnan%26aufirst%3DM.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DEccersley%26aufirst%3DL.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DHoglund%26aufirst%3DM.%26aulast%3DKlamova%26aufirst%3DH.%26aulast%3DKnutsen%26aufirst%3DH.%26aulast%3DParikh%26aufirst%3DS.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DF.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DElonen%26aufirst%3DE.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DZwaan%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26atitle%3DDasatinib%2520crosses%2520the%2520blood%25E2%2588%2592brain%2520barrier%2520and%2520is%2520an%2520efficient%2520therapy%2520for%2520central%2520nervous%2520system%2520Philadelphia%2520chromosome-positive%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1005%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruthardt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=306-314&author=A.+Yokotaauthor=S.+Kimuraauthor=S.+Masudaauthor=E.+Ashiharaauthor=J.+Kurodaauthor=K.+Satoauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=Y.+Deguchiauthor=Y.+Urasakiauthor=Y.+Teruiauthor=M.+Ruthardtauthor=T.+Uedaauthor=K.+Hatakeauthor=K.-i.+Inuiauthor=T.+Maekawa&title=INNO-406%2C+a+novel+BCR-ABL%2FLyn+dual+tyrosine+kinase+inhibitor%2C+suppresses+the+growth+of+Ph%2B+leukemia+cells+in+the+central+nervous+system%2C+and+cyclosporine+A+augments+its+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DDeguchi%26aufirst%3DY.%26aulast%3DUrasaki%26aufirst%3DY.%26aulast%3DTerui%26aufirst%3DY.%26aulast%3DRuthardt%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DHatake%26aufirst%3DK.%26aulast%3DInui%26aufirst%3DK.-i.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DINNO-406%252C%2520a%2520novel%2520BCR-ABL%252FLyn%2520dual%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520Ph%252B%2520leukemia%2520cells%2520in%2520the%2520central%2520nervous%2520system%252C%2520and%2520cyclosporine%2520A%2520augments%2520its%2520in%2520vivo%2520activity%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D306%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beppu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erben, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span> </span><span class="NLM_article-title">Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4204</span><span class="NLM_x">–</span> <span class="NLM_lpage">4210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm100395q&amp;key=10.1200%2FJCO.2009.21.8230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm100395q&amp;key=19652056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4204-4210&author=T.+Hughesauthor=G.+Saglioauthor=S.+Branfordauthor=S.+Soveriniauthor=D.-W.+Kimauthor=M.+C.+Mullerauthor=G.+Martinelliauthor=J.+Cortesauthor=L.+Beppuauthor=E.+Gottardiauthor=D.+Kimauthor=P.+Erbenauthor=Y.+Shouauthor=A.+Haqueauthor=N.+Gallagherauthor=J.+Radichauthor=A.+Hochhaus&title=Impact+of+baseline+BCR-ABL+mutations+on+response+to+nilotinib+in+patients+with+chronic+myeloid+leukemia+in+chronic+phase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase</span></div><div class="casAuthors">Hughes, Timothy; Saglio, Giuseppe; Branford, Susan; Soverini, Simona; Kim, Dong-Wook; Muller, Martin C.; Martinelli, Giovanni; Cortes, Jorge; Beppu, Lan; Gottardi, Enrico; Kim, Dongho; Erben, Philipp; Shou, Yaping; Haque, Ariful; Gallagher, Neil; Radich, Jerald; Hochhaus, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4204-4210</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy.  In this subanal. of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed.  Patients and Methods: Baseline mutation data were assessed in 281 (88%) of 321 patients with CML-CP in the phase II nilotinib registration trial.  Results: Among imatinib-resistant patients, the frequency of mutations at baseline was 55%.  After 12 mo of therapy, major cytogenetic response (MCyR) was achieved in 60%, complete cytogenetic response (CCyR) in 40%, and major mol. response (MMR) in 29% of patients without baseline mutations vs. 49% (P = .145), 32% (P = .285), and 22% (P = .366), resp., of patients with mutations.  Responses in patients who harbored mutations with high in vitro sensitivity to nilotinib (50% inhibitory concn. [IC50] ≤ 150 nM) or mutations with unknown nilotinib sensitivity were equiv. to those responses for patients without mutations (not significant).  Patients with mutations that were less sensitive to nilotinib in vitro (IC50 > 150 nM; Y253H, E255V/K, F359V/C) had less favorable responses, as 13%, 43%, and 9% of patients with each of these mutations, resp., achieved MCyR; none achieved CCyR.  Conclusion: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response.  However, mutational status at baseline may influence response.  Less sensitive mutations that occurred at three residues defined in this study, as well as the T315I mutation, may be assocd. with less favorable responses to nilotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6idp3ScsGrVg90H21EOLACvtfcHk0lhmpyWh88uYxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2jtLrF&md5=dcffe456f1084d39ad2941fc9b683e69</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.21.8230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.21.8230%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBeppu%26aufirst%3DL.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DErben%26aufirst%3DP.%26aulast%3DShou%26aufirst%3DY.%26aulast%3DHaque%26aufirst%3DA.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DRadich%26aufirst%3DJ.%26aulast%3DHochhaus%26aufirst%3DA.%26atitle%3DImpact%2520of%2520baseline%2520BCR-ABL%2520mutations%2520on%2520response%2520to%2520nilotinib%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520in%2520chronic%2520phase%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4204%26epage%3D4210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">For other examples using the acetylene linker in kinase inhibitor design:</p></div><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bready, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caenepeel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polverino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span> </span><span class="NLM_article-title">Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061112p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=627-640&author=V.+J.+Ceeauthor=B.+K.+Albrechtauthor=S.+Geuns-Meyerauthor=P.+Hughesauthor=S.+Bellonauthor=J.+Breadyauthor=S.+Caenepeelauthor=S.+C.+Chaffeeauthor=A.+Coxonauthor=M.+Emeryauthor=J.+Fretlandauthor=P.+Gallantauthor=Y.+Guauthor=B.+L.+Hodousauthor=D.+Hoffmanauthor=R.+E.+Johnsonauthor=R.+Kendallauthor=J.+L.+Kimauthor=A.+M.+Longauthor=D.+McGowanauthor=M.+Morrisonauthor=P.+R.+Olivieriauthor=V.+F.+Patelauthor=A.+Polverinoauthor=D.+Powersauthor=P.+Roseauthor=L.+Wangauthor=H.+Zhao&title=Alkynylpyrimidine+amide+derivatives+as+potent%2C+selective%2C+and+orally+active+inhibitors+of+Tie-2+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1021%2Fjm061112p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061112p%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DP.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DBready%26aufirst%3DJ.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DEmery%26aufirst%3DM.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BE.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DP.%2BR.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPolverino%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DAlkynylpyrimidine%2520amide%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520inhibitors%2520of%2520Tie-2%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D627%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hartung, I.; Bothe, U.; Kettschau, G.; Luecking, U.; Mengel, A.; Krueger, M.; Thierauch, K. H.; Lienau, P; Boemer, U.</span><span> </span><span class="NLM_article-title">Alkynylpyrimidines as Tie2 kinase inhibitors</span>. PCT Int. Appl. WO 2008155140,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Hartung&author=U.+Bothe&author=G.+Kettschau&author=U.+Luecking&author=A.+Mengel&author=M.+Krueger&author=K.+H.+Thierauch&author=P+Lienau&author=U.+Boemer&title=Alkynylpyrimidines+as+Tie2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHartung%26aufirst%3DI.%26atitle%3DAlkynylpyrimidines%2520as%2520Tie2%2520kinase%2520inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jones, C. D.; Luke, R. W. A.; Mccoull, W.</span><span> </span><span class="NLM_article-title">Preparation of ethynylpyrimidine derivatives as Tie2 receptor tyrosine kinase inhibitors for the treatment of cancer</span>. PCT Int. Appl. WO 2006103449,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+D.+Jones&author=R.+W.+A.+Luke&author=W.+Mccoull&title=Preparation+of+ethynylpyrimidine+derivatives+as+Tie2+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26atitle%3DPreparation%2520of%2520ethynylpyrimidine%2520derivatives%2520as%2520Tie2%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Askew, B. C.; Brugger, N.; Lan, R.; Sutton, A.</span><span> </span><span class="NLM_article-title">Pyrrolopyridine and thienopyrimidine derivatives as protein kinase inhibitors useful in the treatment of various diseases and their preparation</span>. PCT Int. Appl. WO 2009094123,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+C.+Askew&author=N.+Brugger&author=R.+Lan&author=A.+Sutton&title=Pyrrolopyridine+and+thienopyrimidine+derivatives+as+protein+kinase+inhibitors+useful+in+the+treatment+of+various+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAskew%26aufirst%3DB.%2BC.%26atitle%3DPyrrolopyridine%2520and%2520thienopyrimidine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%2520useful%2520in%2520the%2520treatment%2520of%2520various%2520diseases%2520and%2520their%2520preparation%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Vaisburg, A.; Moradei, O.; Frechette, S.; Saavedra, O.; Isakovic, L.; Raeppel, S.; Gaudette, F.</span><span> </span><span class="NLM_article-title">Preparation of inhibitors of kinase activity with 1,2-di-cyclyl substituted alkynes</span>. PCT Int. Appl. WO 2009100536,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Vaisburg&author=O.+Moradei&author=S.+Frechette&author=O.+Saavedra&author=L.+Isakovic&author=S.+Raeppel&author=F.+Gaudette&title=Preparation+of+inhibitors+of+kinase+activity+with+1%2C2-di-cyclyl+substituted+alkynes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVaisburg%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520inhibitors%2520of%2520kinase%2520activity%2520with%25201%252C2-di-cyclyl%2520substituted%2520alkynes%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span>NCT00660920, <a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>. Accessed January 2010.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT00660920%2C+http%3A%2F%2Fwww.clinicaltrials.gov.+Accessed+January+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span>Reaction Biology Corporation, <a href="http://www.reactionbiology.com" class="extLink">http://www.reactionbiology.com</a>. Accessed August 2009.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Reaction+Biology+Corporation%2C+http%3A%2F%2Fwww.reactionbiology.com.+Accessed+August+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teleha, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span> </span><span class="NLM_article-title">Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1729</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0497949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1729-1744&author=M.+L.+Quanauthor=P.+Y.+S.+Lamauthor=Q.+Hanauthor=D.+J.+P.+Pintoauthor=M.+Y.+Heauthor=R.+Liauthor=C.+D.+Ellisauthor=C.+G.+Clarkauthor=C.+A.+Telehaauthor=J.-H.+Sunauthor=R.+S.+Alexanderauthor=S.+Baiauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=P.+C.+Wongauthor=R.+R.+Wexler&title=Discovery+of+1-%283%E2%80%B2-Aminobenzisoxazol-5%E2%80%B2-yl%29-3-trifluoromethyl-N-%5B2-fluoro-4-+%5B%282%E2%80%B2-dimethylaminomethyl%29imidazol-1-yl%5Dphenyl%5D-1H-pyrazole-5-carboxyamide+Hydrochloride+%28Razaxaban%29%2C+a+Highly+Potent%2C+Selective%2C+and+Orally+Bioavailable+Factor+Xa+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</span></div><div class="casAuthors">Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1729-1744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein.  Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding.  The SAR and pharmacokinetic profile of this series of compds. is described.  These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa.  On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compd. was selected for clin. development as razaxaban (DPC 906, BMS-561389).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSs9m3fldmGbVg90H21EOLACvtfcHk0liDXGAzNs_Z9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Kqsbk%253D&md5=c16a8d1ca98191a873f2e53cb0c5678c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0497949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497949%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%2BP.%26aulast%3DHe%26aufirst%3DM.%2BY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DC.%2BD.%26aulast%3DClark%26aufirst%3DC.%2BG.%26aulast%3DTeleha%26aufirst%3DC.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26atitle%3DDiscovery%2520of%25201-%25283%25E2%2580%25B2-Aminobenzisoxazol-5%25E2%2580%25B2-yl%2529-3-trifluoromethyl-N-%255B2-fluoro-4-%2520%255B%25282%25E2%2580%25B2-dimethylaminomethyl%2529imidazol-1-yl%255Dphenyl%255D-1H-pyrazole-5-carboxyamide%2520Hydrochloride%2520%2528Razaxaban%2529%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Factor%2520Xa%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1729%26epage%3D1744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm100395q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0liDXGAzNs_Z9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E2B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E2B','PDB','2E2B'); return false;">PDB: 2E2B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3','PDB','3IK3'); return false;">PDB: 3IK3</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm100395q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-12%3Barticle%3Aarticle%3A10.1021%2Fjm100395q" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm100395q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677affc20f4a3c52","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
